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RESUMO DA TESE 
Introdução: A nova geração de vacinas são, na maioria dos casos, resultado dos 
rápidos avanços que se têm verificado nos últimos anos na área da biologia molecular e 
da imunologia, permitindo o uso da biotecnologia na produção de proteínas 
recombinantes com acção imunológica protectora. A vacina contra o vírus da hepatite B 
é disso o melhor exemplo. Esta vacina foi licenciada pela primeira vez em 1981, sendo 
nesta altura um produto derivado do plasma de portadores crónicos da hepatite B. Só 
mais tarde, em 1986, o mesmo antigénio, uma proteína de superfície do vírus da 
hepatite B, começou a ser produzido em sistemas de cultura celular. A vacina da 
hepatite B foi a primeira vacina recombinante a ser licenciada e a sua concepção tem 
servido de modelo ao desenvolvimento de novas vacinas, nomeadamente em doenças 
provocadas por vírus. Por outro lado, tem sido constatado pela comunidade científica 
que estas vacinas recombinantes são em geral antigénios fracos e por isso necessitam 
de ser administrados conjuntamente com substâncias que ampliem o seu efeito, os 
adjuvantes. Assim, paralelamente ao crescente desenvolvimento, que se tem verificado 
nos últimos anos, da tecnologia para o desenvolvimento e produção de novas vacinas, 
assiste-se também a uma crescente investigação na descoberta de adjuvantes mais 
seguros e potentes que tornem essas vacinas mais eficazes e estáveis. 
O termo “adjuvante” vem do termo latim adjuvare que significa ajuda. 
Recentemente, num livro editado por Virgil Schijns e Derek O’Hagan, dois de entre os 
maiores especialistas na área das vacinas e adjuvantes, o termo adjuvante é definido 
tendo em conta o seu efeito biológico. Estes investigadores classificam-nos em duas 
categorias principais: os adjuvantes cuja função principal é o controlo da 
biodisponibilidade da vacina nos tecidos linfoides (“delivery mechanism”) e os 
imunopotenciadores que têm uma acção directa sobre componentes da resposta imune 
inata. 
O presente trabalho teve por objectivo desenvolver um sistema nanoparticular 
(“delivery mechanism”), com potencial para a encapsulação de vacinas resultantes da 
tecnologia recombinante, com a finalidade de transportar e controlar a apresentação do 
antigénio nos tecidos linfóides. 
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Tem sido referido por alguns investigadores que o sistema de libertação de 
vacinas ideal deve ter em conta o fenómeno de maturação da afinidade, que ocorre 
durante uma resposta imune. Quando a concentração de um antigénio é reduzida, as 
células com elevada afinidade para os receptores são estimuladas selectivamente. De 
acordo com este modelo, o padrão do sistema ideal deve imitar os perfis de 
concentração de antigénios que são observados no decurso de uma infecção natural: 
elevadas doses de antigénios, nos primeiros dias da administração, seguidos por um 
período em que há decréscimo da quantidade de antigénios. A biodisponibilidade inicial 
dos antigénios irá influenciar a extensão da formação da memória das células T, 
enquanto a subsequente diminuição dos antigénios irá beneficiar o desenvolvimento da 
maturação da afinidade dos anticorpos. 
Por outro lado, será útil fazer uma reflexão sobre qual a via de administração 
mais indicada para a administração de vacinas. Visto que as mucosas, nomeadamente 
a oral, a nasal, a pulmonar e genitourinária, são os locais por onde entram a maior parte 
dos microorganismos patogénicos, então a protecção contra esses microorganismos 
será mais eficiente pela presença de anticorpos nas secreções locais do que no soro. 
Alguns autores referem mesmo que a imunoglobulina A secretória (sIgA) local previne 
de forma mais eficiente, não só a colonização dos tecidos das mucosas, mas também a 
entrada de microorganismos na corrente sanguínea, quando comparada com a acção 
dos anticorpos sistémicos. Por outro lado, a indução de anticorpos nas mucosas não 
parece ser possível através da administração subcutânea ou intramuscular, usadas 
vulgarmente nos esquemas de vacinação. As evidências científicas, até hoje reunidas, 
indicam que, para haver indução de anticorpos (sIgA) nas mucosas, a administração do 
antigénio deve ser feita através das mucosas que se encontram revestidas por tecido 
linfoíde. Por esta razão, parece desejável que a próxima geração de vacinas, 
particularmente para os microorganismos patogénicos que invadem o organismo 
através das superfícies das mucosas, deve ser desenvolvida ou optimizada tendo em 
atenção a potencial indução de uma resposta imune nas mucosas. 
Para além da importante vantagem apresentada anteriormente, a administração 
através das mucosas, particularmente a administração oral, tem sido apontada como a 
via mais natural para introdução de fármacos no organismo, a de mais fácil acesso e 
sem os inconvenientes de outras vias de administração, como sejam os riscos de 
infecção por utilização de agulhas contaminadas, riscos de efeitos hemolíticos ou 
possível dor durante a administração. Para além disso, a via oral é sem dúvida a melhor 
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aceite, nomeadamente pelas crianças que são a população alvo da maioria das vacinas. 
Acresce ainda referir que a vacinação em larga escala, num curto espaço de tempo, 
seria muito facilitada se tivéssemos vacinas orais em que, para a sua administração, 
não fossem necessários técnicos especializados. É o caso de situações de 
bioterrorismo, de ameaças de surtos infecciosos ou, simplesmente, o caso de países 
não industrializados que, por escassez de recursos humanos e também financeiros, 
continuam a ter taxas elevadas de prevalência de doenças para as quais já existem 
vacinas eficazes, como por exemplo de hepatite B. 
A administração oral de macromoléculas como o DNA, as proteínas e os 
peptídeos tem-se mostrado ineficaz, conduzindo a que, em alternativa, esta classe de 
fármacos seja administrado por uma das vias parentéricas. A limitada biodisponibilidade 
oral deve-se fundamentalmente a três ordens de razões. Por um lado ao extensivo 
metabolismo pré-sistémico a que estão sujeitos, devido à degradação enzimática que 
sofrem antes e durante os processos de absorção, não só ao nível do lúmen, como da 
mucosa gastrointestinal. A segunda barreira encontrada, prende-se com as fracas 
características de absorção destes fármacos e, por último, a terceira razão terá a ver 
com o efeito da primeira passagem pelo fígado (hepatic first pass effect). Consciente 
destas dificuldades, a comunidade Científica tem procurado novos sistemas 
terapêuticos, que permitam contornar ou minimizar as condições adversas do meio que 
impedem a administração oral destas moléculas. Neste contexto, os sistemas de 
transporte mais estudados, para a encapsulação destas macromoléculas, são as 
nanopartículas poliméricas e dentro destas são preferidos os sistemas biodegradáveis. 
A encapsulação irá proteger o antigénio do meio ácido e rico em enzimas 
proteolíticas como é o tubo digestivo. Para além das vantagens apontadas, acresce 
ainda referir que um sistema de transporte polimérico permite uma cedência gradual das 
moléculas activas, prolongando o seu efeito no organismo e contribuindo assim para a 
simplificação dos esquemas posológicos. Por outro lado, estes sistemas contribuem 
igualmente para a simplificação da logística de produção, armazenamento e distribuição 
de vacinas. Um dos sistemas que tem sido estudado é o de bioadesivos de libertação 
de fármacos (BDDS- bioadhesive drug delivery system). Os Tecnologistas estão 
confiantes que este novo conceito poderá contornar as dificuldades relacionadas com a 
libertação oral de peptídeos e análogos de peptídeos. Os BDDS são produzidos com a 
finalidade de se fixarem ao revestimento mucoso do tracto gastrointestinal. Desta forma, 
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este sistema deverá exercer uma influência positiva na absorção dos fármacos que 
transportam. Essa influência deverá fazer-se por vários mecanismos: 
- prolongamento do tempo de residência no local de absorção do fármaco, com 
vista à redução da frequência de administração. 
- Intensificação do contacto com a barreira epitelial da mucosa subjacente, com 
vista ao incremento do transporte através do epitélio. 
- Pensa-se que alguns polímeros mucoadesivos têm a capacidade de modular a 
permeabilidade dos tecidos epiteliais, actuando ao nível das junções das células do 
epitélio (tight  junctions). 
- Pensa-se igualmente, que alguns polímeros mucoadesivos podem actuar como 
inibidores de enzimas proteolíticas.  
 
Objectivo: Este trabalho teve como objectivo desenvolver e avaliar in vitro e in vivo um 
sistema nanoparticular, com potencial para a encapsulação de vacinas resultantes da 
tecnologia recombinante, com a finalidade de permitir a sua administração através das 
mucosas, nomeadamente a mucosa oral e nasal.  
Com este propósito foram desenvolvidas nanopartículas de quitosano às quais, 
numa primeira fase, foi adsorvida a vacina e, subsequentemente, efectuado um 
revestimento com o alginato de sódio. O alginato de sódio, ao contrário do quitosano, é 
um polímero aniónico, característica que teoricamente facilitaria o revestimento. Por 
outro lado, tem a particularidade de ser insolúvel em meio ácido e, portanto, 
teoricamente poder conferir às nanopartículas resistência ao pH baixo do estômago. 
Finalmente, as suas propriedades mucoadesivas, em teoria, terão um papel importante 
para o aumento do tempo de retenção das nanopartículas no tubo digestivo. 
O quitosano é um polímero derivado da quitina, um polissacarídeo presente na 
natureza em crustácios (p. ex. no camarão) e em algumas espécies de fungos. Este 
polímero é obtido por desacetilação da quitina, podendo aparecer no mercado com 
diversos graus de desacetilação, assim como com diversos pesos moleculares. 
Estruturalmente, o quitosano é um poli(2-amino 2-deoxi D-glucopyranose), no qual as 
unidades de repetição estão ligadas por ligações β 1-4. Possui grupos hidroxil e grupos 
amino reactivos, que por modificação química nos permitem a obtenção de derivados 
com propriedades diferentes, possibilitando diversas aplicações. O polímero é 
largamente usado, não só na indústria farmacêutica (excipiente, composição de 
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produtos para emagrecimento), como na indústria Alimentar, na Agricultura, na indústria 
de cosméticos, tratamento de águas, etc. 
O interesse por este polímero tem sido crescente nos últimos anos, 
principalmente pela sua abundância na natureza, pelas suas propriedades físico-
químicas, por ser biodegradável e por não apresentar toxicidade. Diversos estudos 
evidenciam as suas propriedades mucoadesivas, a sua capacidade de aumentar a 
permeabilidade das membranas e de inibir a acção de algumas enzimas, tornando-o um 
forte candidato à produção de microsferas mucoadesivas. 
Deve no entanto realçar-se que o quitosano é pouco solúvel a pH 6,5, 
condicionando a sua actividade de promotor de absorção, em especial, nas mucosas 
com este pH de que é exemplo uma parte significativa do intestino. 
 
Primeiro Capítulo: No primeiro capítulo são apresentados os resultados do 
desenvolvimento e optimização das nanopartículas de quitosano revestidas com 
alginato. Na literatura, encontram-se alguns trabalhos que descrevem a produção de 
sistemas multiparticulares. Estes consistem basicamente na encapsulação em 
microsferas de alginato, de partículas de quitosano, com vista à protecção destas 
partículas durante a sua passagem pelo estômago. Estes sistemas, normalmente com 
tamanhos unitários superiores a 10 µm, destinam-se a libertar a proteína no intestino 
para que esta seja depois absorvida. O presente trabalho teve como objectivo o 
desenvolvimento de um sistema constituído por nanoparticulas transportadoras de 
antigénios destinadas a ser internalizadas pelas células M das placas de Peyer do 
intestino e não a libertar a vacina na mucosa gástrica, onde esta poderia ser facilmente 
destruída pelas enzimas ai presentes. É frequentemente descrito na literatura que estes 
sistemas nanoparticulares devem ser constituídos por partículas inferiores a 10 µm, 
para que possam ser internalizados pelas células M. Por conseguinte, e dado que com 
estas características nada havia descrito na literatura, foi necessário, na primeira fase 
do trabalho, fazer o desenvolvimento do método que permitisse a obtenção das 
referidas nanopartículas, com tamanho inferior a 10 µm.  
O método de obtenção das nanopartículas de quitosano consiste na precipitação 
do quitosano, após a adição de uma solução de sulfato de sódio, sob agitação e sob o 
efeito de ultrasons. Nesta fase do trabalho foram optimizadas a concentração de 
quitosano em solução e o volume de solução de sulfato de sódio a adicionar. O 
resultado deste estudo permite concluir que soluções com 0,25% de quitosano 
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conduzem à formação de partículas, quando são adicionados 3,5 ml de uma solução de 
sulfato de sodio a 10%. As nanopartículas preparadas deste modo apresentaram um 
tamanho médio de 643 ± 171 nm e um potêncial zeta de +37 ± 4 mV (zetasizer 3000 
HSA). 
Após a liofilização das nanopartículas, estas são posteriormente re-suspendidas 
numa solução tampão fosfato e incubadas com a solução de uma vacina modelo, a 
ovalbumina, à temperatura ambiente (20º C) e sob agitação moderada. Foram 
experimentadas diferentes concentrações de ovalbumina e de suspensão de partículas, 
tendo-se verificado que 0,5% de ovalbumina e 1% de partículas de quitosano produziam 
os melhores resultados de eficiência de encapsulação e de capacidade de 
encapsulação para estas partículas. Verificou-se ainda que a adsorção é imediata e os 
períodos de incubação até 120 minutos não resultaram num aumento da eficiência e da 
capacidade de encapsulação destas partículas, quando comparados com o momento 
inicial da adição da ovoalbumina às nanopartículas. 
O quitosano é um polímero solúvel em soluções ácidas, nomeadamente em 
ácido acético e em ácido clorídrico. As partículas de quitosano, obtidas por precipitação 
do polímero com sulfato de sódio, são pouco resistentes em meio ácido, particularmente 
a 37ºC. Por esta razão, foi decidido revestir estas nanopartículas já com a ovoalbumina 
adsorvida, tendo-se escolhido o alginato de sódio. Dado que as partículas de quitosano 
são carregadas positivamente e o alginato tem uma carga predominantemente negativa, 
a hipótese para o desenvolvimento de um método foi esperar que o revestimento se 
concretizasse por interacção electrostática. Com esta finalidade foram experimentadas 
diferentes composições de sistemas (solução de alginato/suspensão de partículas de 
quitosano). Na maioria dos sistemas verificou-se uma imediata agregação das 
partículas, tendo-se observado que os sistemas mais estáveis tinham na sua 
composição 0,5% de alginato e 0,2% de partículas de quitosano. Estes sistemas foram 
mantidos 20 minutos sob agitação moderada e, no final, o alginato que não reagiu foi 
eliminado, centrifugando a suspensão das nanopartículas revestidas. As nanopartículas 
foram posteriormente ressuspendidas numa solução de cloreto de cálcio. 
As imagens obtidas por microscopia electrónica de varrimento permitiram 
concluir que, para além do tamanho médio anteriormente registado e avaliado com 
recurso ao zetasizer, existe igualmente um número elevado de nanopartículas com um 
tamanho médio de cerca de 100 nm, antes do revestimento. A maior parte, porém, 
apresentou um tamanho entre os 300 e os 600 nm, após o revestimento. 
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Consequentemente, as nanopartículas revestidas terão um tamanho adequado para ser 
internalizadas pelas células M das placas de Peyer no intestino. 
Dado que a vacina modelo se encontrava predominantemente adsorvida à 
superfície das partículas, foi necessário, durante o processo de revestimento, 
monotorizar a sua libertação a partir das nanopartículas de quitosano. Verificou-se que a 
capacidade de encapsulação das nanopartículas revestidas diminuiu ligeiramente, 
quando comparada com as partículas não revestidas, resultando numa capacidade de 
encapsulacão de 35% (w/w). 
A confirmação da presença do revestimento de alginato de sódio foi feita através 
da análise das nanopartículas por calorimetria diferencial de varrimento (DSC) e por 
espectrofotometria de infravermelho (FTIR). A inversão dos valores de + 37 mV, 
encontrados para o potencial zeta das nanopartículas antes de serem revestidas, para -
34.9 mV, após o processo de revestimento com o alginato de sódio, veio reforçar o 
pressuposto da presença do alginato à superfície das nanopartículas. Por último, neste 
capítulo é ainda apresentado e discutido o resultado dos primeiros estudos de 
libertação, feitos em fluido intestinal simulado (USP XXIV), usando uma proteína modelo 
(albumina do ovo), a partir de suspensões de partículas revestidas e de partículas não 
revestidas. O perfil de libertação da proteína foi alterado após o revestimento, tendo-se 
verificado que o revestimento permitiu evitar a sua dessorpção rápida nos primeiros 
minutos do ensaio. Por conseguinte, este ensaio veio mais uma vez confirmar não só a 
presença do referido revestimento, mas também realçar a utilidade do revestimento no 
controlo da libertação da proteína a partir das nanopartículas. 
 
Segundo Capítulo: No segundo capítulo são apresentados os resultados de uma série 
de experiências que tiveram como objectivo principal um conhecimento mais 
aprofundado das nanopartículas desenvolvidas. Paralelamente, faz-se uma avaliação do 
potencial destas nanopartículas para poderem vir a ser usadas em estudos in vivo. 
Assim, foram feitos estudos adicionais de libertação da proteína-modelo, a partir das 
nanopartículas em diversos meios, como o de tampão fosfato pH=7,4; pH=6,8 e pH=5,5, 
em fluido gástrico simulado, em água e em tampão HEPES pH=7,4. 
Os resultados são significativamente diferentes para partículas revestidas e para 
partículas não revestidas, tendo-se ainda verificado que as partículas não revestidas 
são instáveis em determinados valores de pH do meio, libertando imediatamente toda a 
proteína. De uma forma geral, o revestimento retardou a libertação da albumina e, 
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particularmente nos ensaios feitos em água e em tampão HEPES, só 5% da proteína 
tinha sido libertada ao fim de 3,5 horas. Também a força iónica do meio (tampão) 
parece ter influência na cinética de libertação da substância activa a partir das 
nanopartículas revestidas com alginato. 
Ainda neste capítulo são apresentados e discutidos os estudos de citotoxicidade 
das nanopartículas revestidas. Neste estudo foram usadas culturas primárias de células 
do baço de ratinhos Balb/c. Foram testados, individualmente, os polímeros quitosano e 
alginato de sódio, assim como as partículas revestidas. A avaliação da morte celular foi 
feita por dois métodos diferentes: num, usando o iodeto de propídio para marcação das 
células mortas e fazendo a contagem das células viáveis e das células mortas por 
citometria de fluxo; no segundo, as células mortas foram coradas com o azul tripano e 
observadas ao microscópio. O ensaio efectuado com MTT (tetrazolium assay) permitiu 
avaliar o estado metabólico das células. Verificou-se que, por qualquer um dos métodos, 
tanto o quitosano como o alginato, como ainda as nanopartículas revestidas, nas 
concentrações estudadas, não apresentam toxicidade para as células. 
Finalmente, ainda no segundo capítulo, foram descritos e discutidos os estudos 
de internalização das nanopartículas de quitosano revestidas com alginato, nas células 
M e placas de Peyer do intestino do rato (Wistar). 
Na literatura, estão descritos vários trabalhos fazendo referência à capacidade 
de partículas hidrófobas e partículas positivamente carregadas poderem ser 
internalizadas pelas células M do intestino. No caso presente, das nanopartículas 
revestidas com alginato, existem partículas carregadas negativamente, por isso é 
importante verificar se também estas terão aquela capacidade. Para o efeito, foram 
realizados estudos no rato, através de uma pequena cirurgia que permitiu a colocação 
da suspensão das nanopartículas directamente no duodeno. As partículas 
permaneceram no intestino durante duas horas e no final os ratos foram sacrificados. O 
intestino delgado foi removido e lavado com tampão fosfato salino (pH 7.5), as placas de 
Peyer foram posteriormente removidas e preparadas para poderem ser observadas no 
microscópio confocal. Verificou-se que as nanopartículas revestidas foram capazes de 
ser internalisadas nas placas de Peyer. Este resultado, embora qualitativo, mostrou que 
a utilização destas nanopartículas in vivo poderia ser promissora. 
 
Terceiro Capítulo: No terceiro capítulo são apresentados os resultados de estudos in 
vitro efectuados com culturas primárias de células extraídas do baço do ratinho com o 
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objectivo de determinar se a presença do quitosano ou do alginato na cultura celular, 
induziria algum tipo de estimulação nos linfócitos. 
Paralelamente e funcionando como controles positivos foram ainda ensaiados 
nas mesmas condições a “concanavalin A” e o “CpG ODN”. A activação das células foi 
avaliada pela expressão do marcador CD69 e pela maior ou menor capacidade das 
células proliferarem na presença dos compostos. O CD69 é um receptor que é expresso 
à superfície dos linfócitos quando estes são estimulados. Este receptor tem a 
particularidade de poder ser expresso após 2 horas de exposição a um mitogénio e 
atingir o pico entre as 18 e as 24 horas de exposição. Foi mostrado, neste trabalho, pela 
primeira vez, que a presença do quitosano ou do alginato induz à expressão do CD69 
nos linfócitos B numa percentagem elevada e um pouco inferior nos linfócitos T do tipo 
CD4+, sendo o alginato, dos dois polímeros, o que mostrou o menor efeito. 
Relativamente aos linfócitos T do tipo CD8+, apenas o quitosano mostrou capacidade 
para induzir a expressão deste receptor. A indução do receptor CD69+, tendo sido 
generalizada nos linfócitos, não foi no entanto acompanhada pela proliferação dos 
mesmos. Paralelamente, com este estudo foi confirmado que o CpG ODN (1826), usado 
como adjuvante nos estudos in vivo a seguir apresentados, é essencialmente um 
activador de linfócitos B.  
Nos capítulos quarto, quinto e sexto são apresentados e discutidos os estudos, in 
vivo, de immunização no ratinho Balb/c, usando a vacina da hepatite B. Nestes 
capítulos, as nanopartículas revestidas são avaliadas quanto à sua capacidade para 
poderem funcionar como adjuvantes da vacina da hepatite B recombinante. 
Paralelamente é avaliada a associação de um outro adjuvante, o CpG ODN. 
As nanopartículas foram usadas para a encapsulação da vacina da Hepatite B e 
para a encapsulação do CpGODN. A eficiência de encapsulação para o antigénio de 
superfície do vírus da hepatite B foi 85.9 ± 4.7% e para o CpG ODN foi 98.8% ± 4.7%. 
 
Quarto Capítulo: No quarto capítulo são apresentados e discutidos os resultados da 
resposta imune, observada após a administração oral da vacina encapsulada. A vacina 
foi administrada em solução (grupo de referência) ou encapsulada nas partículas 
revestidas, associada ou não com o imunopotenciador CpG ODN. Este, por sua vez, foi 
administrado encapsulado a alguns grupos e noutros foi dado em solução. A primeira 
imunização com 10 µg da vacina foi seguida de um reforço, 3 semanas depois com a 
mesma dose da vacina. Os ratinhos foram sacrificados 10 dias depois do reforço. 
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Apenas o grupo vacinado com a suspensão das nanopartículas carregadas com o 
antigénio (grupo I) e o grupo vacinado com uma mistura de nanopartículas, umas 
carregadas com o antigénio e outras carregadas com o CpG (grupo VI), apresentaram 
valores de parâmetros imunológicos diferentes dos verificados no grupo de ratinhos não 
imunizados. Ambos os grupos mostraram valores significativamente maiores de 
expressão do CD69+ em linfócitos CD4+ e CD8+ e, paralelamente, valores de CD69+ 
significativamente inferiores em linfócitos B. Os mesmos grupos apresentaram os 
valores mais elevados de proliferação de linfócitos do baço colocados em cultura na 
presença da concanavalina A. Finalmente, foi nos mesmos grupos, muito embora com a 
presença dentro dos grupos de ratinhos que não responderam à vacina, que se 
observou a produção de anticorpos específicos contra o antigénio de superfície do vírus 
da hepatite B, no sangue (IgG e isotipos) e na mucosa do intestino (sIgA) dos ratinhos. 
No entanto, de entre os dois grupos, o VI foi o que apresentou um número maior de 
ratinhos que responderam e caracterizou-se por apresentar uma resposta imune do tipo 
Th1, desejável no caso do vírus da hepatite B. 
 
Quinto Capítulo: No capítulo quinto são apresentados e discutidos os resultados da 
resposta imune, observada após a administração nasal da vacina encapsulada. A 
vacina foi administrada em solução (grupo de referência) ou encapsulada nas partículas 
revestidas, associada ou não com o imunopotenciador CpG ODN. Este, por sua vez, foi 
administrado encapsulado a alguns grupos, e noutros foi dado em solução. A primeira 
imunização com 10 µg (15 µl) da vacina foi seguida de mais dois reforços, com 3 
semanas de intervalo entre as imunizações, com a mesma dose da vacina. Os ratinhos 
foram sacrificados 4 semanas depois do último reforço. Comparando a resposta imune 
observada nos ratinhos dos grupos, imunizado com uma solução nasal contendo o 
antigénio ou vacinado com a formulação comercial pela via subcutânea, com a resposta 
imune obtida com a suspensão nasal das nanopartículas revestidas, contendo o 
antigénio da hepatite B, verificou-se que o último grupo, ao contrário dos primeiros, 
apresentou, nas secreções nasais e vaginais, quantidades detectáveis da 
imunoglobulina A secretora, específica do antigénio de superfície do vírus da hepatite B. 
Esta observação vem comprovar o que já se sabia relativamente à vacina comercial, 
administrada subcutaneamente, dado que esta não induz a produção de anticorpos nas 
mucosas. Por outro lado, para que se verifique a indução de anticorpos nas mucosas 
não basta que o antigénio seja aplicado directamente na mucosa, a presença de um 
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adjuvante será sempre necessária para a vacina da hepatite B. Com este estudo, foi 
igualmente observado que a vacina encapsulada nas partículas revestidas mostrou ser 
eficiente na indução de anticorpos nas mucosas. A presença de anticorpos específicos 
(IgG) no soro dos ratinhos só foi observada quando às formulações foi adicionado um 
imunopotenciador o CpG ODN.  
 
Sexto Capítulo: No capítulo sexto são apresentados e discutidos os resultados da 
resposta imune, observada após a administração subcutânea da vacina encapsulada 
nas nanopartículas revestidas. Com este estudo pretendeu-se avaliar se as 
nanopartículas revestidas teriam ou não um efeito adjuvante, quando administradas com 
o antigénio de superfície do vírus da hepatite B pela via subcutânea. Nomeadamente, 
pretendeu-se avaliar a concentração de anticorpos específicos no soro, visto que uma 
resposta imune nas mucosas era pouco provável após uma administração parentérica. 
A vacina foi administrada em solução (grupo de referência) ou encapsulada nas 
nanopartículas revestidas, associada ou não com o imunopotenciador CpG ODN. Este, 
por sua vez, foi administrado encapsulado no grupo III e em solução no grupo II. A 
primeira imunização com 10 µg da vacina foi seguida, três semanas depois, por um 
reforço com uma dose igual. Os ratinhos foram sacrificados quatro semanas após o 
reforço. O grupo de ratinhos vacinados, em que o antigénio tinha sido encapsulado nas 
nanopartículas revestidas (Grupo I), apresentou uma concentração média elevada de 
IgG, específica no soro, com uma clara predominância de anticorpos específicos, típicos 
de uma resposta do tipo Th2. Esta concentração foi aproximadamente 5 vezes superior 
à concentração média calculada no grupo de ratinhos vacinados com a solução do 
antigénio sem adjuvante. Relativamente à resposta imune celular, nomeadamente à 
concentração da IL-4 e do IFN-γ, secretados pelos linfócitos do baço do ratinho 
colocados em cultura, os valores médios não apresentaram diferenças entre estes dois 
grupos. Foi depois investigada a resposta imune induzida após a administração de uma 
suspensão contendo o antigénio encapsulado nas nanopartículas e o adjuvante CpG 
ODN em solução (grupo II). Muito embora, neste último grupo, o valor médio dos 
anticorpos específicos não tenha sido estatisticamente diferente do valor do grupo I 
(Grupo com o antigénio encapsulado nas nanopartículas), o tipo de resposta imune foi 
diferente. Observou-se um aumento de anticorpos do tipo IgG2a e uma diminuição dos 
anticorpos do tipo IgG1, resultando uma resposta imune mista Th1/Th2. Fazendo ainda 
a comparação destes mesmos grupos (Grupos I e II), em que a vacina foi administrada 
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encapsulada, observou-se um aumento da produção de IFN-γ no grupo que continha o 
CpG ODN em solução (Grupo II). Finalmente, foi ainda constituído um terceiro grupo de 
ratinhos aos quais foi administrada uma formulação mais simples que consistiu numa 
suspensão de nanopartículas de quitosano não revestidas às quais foram previamente 
adsorvidos o CpG ODN e o antigénio de superfície do vírus da hepatite B. Os resultados 
apresentados não demonstraram uma clara superioridade desta formulação, tendo-se 
verificado que a resposta imune foi, neste caso, do tipo Th2, apesar da presença nesta 
formulação do CpG ODN. 
 
Considerações finais: neste trabalho foi apresentado um novo sistema de libertação 
constituído por nanopartículas poliméricas. As nanopartículas são constituídas por um 
núcleo de quitosano onde foi posteriormente adsorvido o antigénio e finalmente 
revestido com alginato de sódio. O método desenvolvido permite encapsular, com 
elevada eficiência, antigénios do tipo proteico em condições reconhecidamente não 
agressivas, minimizando assim a possibilidade de perda de acção biológica por parte da 
vacina. 
As nanopartículas revestidas mostraram ter um efeito adjuvante relativamente à 
vacina da hepatite B quando administradas pela via subcutânea. A adição do 
imunopotenciador CpG ODN à suspensão das nanopartículas, contendo o antigénio da 
hepatite, permitiu modificar o tipo de resposta imune de Th2 para uma resposta mista 
Th1/Th2, mais adequada no caso do vírus da hepatite B.  
A administração, através das mucosas oral e nasal, da vacina da hepatite B 
encapsulada nas nanopartículas de quitosano revestidas permitiu confirmar a opinião de 
muitos especialistas na área da vacinologia, que defendem que não será suficiente a 
inclusão do antigénio em sistemas de libertação de nanopartículas, principalmente 
quando se trata de um antigénio fraco. Para se obter uma resposta imunológica 
adequada, para além da encapsulação do antigénio, vai ser ainda necessário adicionar 
um imunopotenciador. De facto, os melhores resultados foram obtidos com formulações 
que continham na sua composição o CpG ODN. Para finalizar, o sistema nanoparticular 
desenvolvido mostrou ser igualmente útil para a encapsulação do imunopotenciador em 
formulações orais. Em contraste, na mucosa nasal, o imunopotenciador produziu 
melhores resultados quando foi administrado em solução, pelo que a futura utilização 
destas nanopartículas para a encapsulação de moléculas que demonstrem uma elevada 
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afinidade para o quitosano, como o caso do CpGODN, estará condicionada a uma 
optimização conveniente destas nanopartículas. 
As nanopartículas de quitosano, revestidas com alginato provaram ter um efeito 
adjuvante com o antigénio da hepatite B pela via subcutânea. Por conseguinte, os 
próximos estudos serão feitos com o objectivo de avaliar se o sistema nanopartícular 
poderá substituir, com vantagem, o actual adjuvante (compostos de alumínio), da vacina 
da hepatite B. Para finalizar, o efeito adjuvante, observado para a vacina da hepatite B, 
deverá ser avaliado com outras vacinas, de preferência mais fortes, não só pela via 
subcutânea mas também através das mucosas oral e nasal. 
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THESIS ABSTRACT 
It has been long known that protection against pathogens invading the organism via 
mucosal surfaces correlates better with the presence of specific antibodies in local 
secretions than with serum antibodies. The most effective way to induce mucosal 
immunity is to administer vaccine directly to the mucosal surface. The development of 
vaccines for mucosal application requires antigen delivery systems and 
immunopotentiators that efficiently facilitate the presentation of the antigen to the 
mucosal immune system. 
In the more recent years, several polymeric delivery systems have been 
investigated to deliver vaccines to the mucosa, while protecting them from adverse 
conditions that could affect their bioactivity. There are also indications that these delivery 
systems act as adjuvants, increasing the immunogenicity of poor immune response 
antigens. One of the problems in vaccine formulation is the structural and/or 
conformational change of antigens during preparation or storage. Therefore, the 
preservation of antigen stability during encapsulation and release is essential for the 
development of successful controlled release vaccine delivery systems.  
Taking this into consideration, the main aim of this thesis was to develop a 
multiparticulate delivery system, appropriate to protect the antigen from the adverse 
conditions on the mucosal surfaces, particularly in the gastrointestinal tract. 
Simultaneously, these particles should be taken up by M- cells of Peyer’s patches in the 
gut, and M-cells from the nose-associated lymphoid tissue (NALT).  
Chitosan and sodium alginate are biodegradable and biocompatible natural 
polysaccharide polymers with a good safety profile. Both materials are polyelectrolyte 
polymers and they are of opposite charges. Furthermore, these polymers allow the 
absence of organic solvent during the particles preparation. This aspect is particularly 
important for the encapsulation of vaccines, which might be denatured even by limited 
exposure to organic solvents.  
The adsorption of the antigen to previously manufactured empty chitosan 
microspheres has been shown to be a very mild process since it can be done in 
phosphate buffered saline. For vaccines it seems to be the more appropriate method. 
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However when the particles are non porous, like in this case the antigen will be linked at 
the surface. This is probably one of the major drawback of the adsorption method 
because the antigen will be exposed to enzymes of mucosal surfaces. This problem is 
believed to be overcome by coating the particles with a polymer resistant to those 
adverse conditions. Therefore, the developed delivery system is composed of a chitosan 
core, to which the antigen was adsorbed, being both subsequently coated with sodium 
alginate. The majority of these coated nanoparticles have a diameter between 300 and 
600 nm and a negative charge.  
In this work, the capability of these coated nanoparticles for being internalized in 
rat Peyer’s patches as well as their cytotoxicity were evaluated. With the help of a 
surgery, the alginate coated particles loaded with ovalbumin fluorescein were placed 
directly into the duodenum and two hours later the rats were sacrificed, the small 
intestine removed and the Peyer’s patches isolated for CLSM analysis. The confocal 
images of the Peyer’s patches undoubtedly showed the presence of coated particles in 
this specific secondary lymphatic tissue. Additionally, cytotoxicity studies performed with 
spleen cells have confirmed the non-toxicity of these polymers as well as the non-toxicity 
of the coated and uncoated chitosan nanoparticles.  
The suitability of the alginate coated chitosan nanoparticles for the encapsulation 
of the surface hepatitis B antigen, a recombinant protein and the immunopotentiator, the 
CpG ODN was also investigated in this work. In order to optimize the encapsulation 
conditions, different ratios of hepatitis B vaccine to chitosan nanoparticles and CpG ODN 
to chitosan nanoparticles were investigated. The systems with the highest loading 
efficacy were used for further studies. It was found that hepatitis B antigen (HBsAg) and 
CpG ODN were efficiently associated with alginate coated chitosan nanoparticles. The 
loading efficacy of hepatitis B vaccine on coated nanoparticles was 84.1 ± 3.0 % (mean 
± STDEV) and the mean of the loading capacity was 83.9 µg of HBsAg/ mg of dry 
chitosan nanoparticles ± 2.77 (mean ± STDEV). The loading efficacy of CpG was 97.0 ± 
1.3% and the loading capacity was 97.0 ± 0.03 (µg of CpG ODN/ mg of dry chitosan 
nanoparticles). Furthermore, SDS-PAGE and blotting of the released antigen from the 
particles in buffer phosphate (37ºC) demonstrated that no important modifications in the 
structure of the antigen were produced during the entrapment process. 
The role of the alginate coated chitosan nanoparticles, as adjuvant for hepatitis B 
vaccine was investigated by oral, intranasal and subcutaneous administration routes.   
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Subcutaneously vaccinated mice with the antigen associated with the 
nanoparticles showed a high anti-HBsAg IgG titer, with the majority of antibodies being 
Th2 profile. This immune response was 5.3-fold higher than the mean value found for the 
reference group immunized with the saline solution of the antigen.  However, concerning 
cellular immune response, no important differences were observed concerning the 
antigen-specific splenocyte proliferation or the secretion of Th1 (IFN-γ) and Th2 type 
cytokines (IL-4) between both groups, the group vaccinated with the antigen associated 
with the nanoparticles and reference group. Moreover, in the same study it was proven 
the usefulness of adding together in the same formulation the antigen associated with 
coated nanoparticles with the immunopotentiator CpG ODN in solution. The redirection 
of the Th2 profile for a mixed Th1/Th2 immune response was observed, which make this 
formulation promising for further studies not only with HBsAg but also with other 
antigens. 
Mucosal vaccination studies were conducted with similar formulations, however 
different results were obtained. The oral vaccination with coated nanoparticles containing 
HBsAg and coated nanoparticles containing CpG ODN has shown to be able not only to 
induce anti-HBsAg sIgA in the gut, but also systemic specific antibodies. Although the 
seroconversion rate had not been excessively high, it was, however, higher than the 
seroconversion rate observed in mice group vaccinated just with the antigen associated 
with nanoparticles. Moreover, the intranasal vaccination just with the antigen associated 
with the nanoparticles induced mucosal antibodies, but a systemic immune response 
was not observed. A systemic immune response was induced only in mice intranasally 
vaccinated with formulations containing the immunopotentiator, CpG ODN.  
Therefore, these results showed that alginate coated chitosan nanoparticles have 
an adjuvant effect for the hepatitis B antigen when administered subcutaneously, 
however for the mucosal routes the association of an immunopotentiator is required. As 
future prospects, the evaluation of the adjuvant effect of this new delivery system will be 
performed with different antigens. 
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ABSTRACT 
The aim of this thesis is to design a new nanoparticulate mucosal vaccine delivery 
system that protects the loaded subunit vaccine during its passage through the 
gastrointestinal and nasal mucosa and facilitates the internalization of the vaccine into 
the mucosal-associated lymphoid tissue. 
This introductory chapter provides an overview of the events within mucosal 
tissues that lead to protective mucosal immune responses. The understanding of those 
biological mechanisms together with knowledge of the technology of vaccines and 
adjuvants provides guidance on the technical aspects of mucosal vaccine design. 
Therefore, this chapter also provides some technical information related to modern 
adjuvants. This is not an exhaustive review since the objective of this chapter is to make 
information available related to the biomaterials and adjuvants used in this thesis in order 
to enable a clear understanding of the work. Moreover a small introduction is provided in 
each of the following chapters in order to bring the area under discussion into focus. 
1.1 A BRIEF HISTORY OF VACCINES AND ADJUVANTS 
The Scientific era of vaccinology started in the early eighteenth century, with the 
introduction in Europe of an ancestral Chinese practise of preventing severe natural 
smallpox by inoculating pus from smallpox patients. This procedure was introduced to 
England for the first time by a farmer named Benjamin Justy who inoculated his family 
with cowpox pus to prevent smallpox, and the first clinical investigations were eventually 
conducted in 1796 by the English practitioner Edward Jenner [1]. During the fifteenth 
century in China, healthy people acquired immunity to smallpox by sniffing powdered 
smallpox pustules, by inserting them into small cuts in the skin (a technique called 
variolation) [2], or finally by the oral administration of fleas from cows with cowpox. 
These are the first reports of a mucosal vaccination practice [3].  
A great expansion of biomedical sciences and vaccinology occurred in the 19th 
century with the enormous contribution by Louis Pasteur of the first attenuated vaccine 
(vaccine = vacca; latin for cow), and with the achievements of Robert Koch, Emil von 
Behring, the first recipient of the Medicine Nobel Prize, and Paul Ehrlich. Between World 
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Wars I and II, many studies were carried out which led to the description of most kinds of 
humoral immunologic phenomena [1]. Although that period also had many financial 
restrictions since resources were principally used for military purposes, this early period 
led to the appearance of the first vaccines against typhoid fever, shigellosis, tuberculosis, 
plague, diphtheria and tetanus.  
The modern era of vaccine science began in about 1950 with the bacterial 
capsular polysaccharide vaccines such as pneumococcus, meningococcus and 
Haemophilus influenzae. Moreover, the Sabin oral polio vaccine in the early 1960s had 
an important role in the programme for the global eradication of polio and brought 
mucosal immunization to prominence [3]. The appearance of viral vaccines such as the 
inactivated poliovaccines and live vaccines for preventing pediatric diseases, measles, 
mumps, rubella and varicella vaccine also played important roles in the history of 
vaccines. More recently, the discovery of vaccines against hepatitis in the early 1960s 
was initiated with the purpose of discovering the etiological agent causing hepatitis A and 
B. Blumberg and colleagues in 1965 discovered the surface antigen of the hepatitis B 
virus present in the blood of human carriers of the infection [1]. This discovery opened 
the door to a hepatitis B vaccine, which has been considered among the most 
remarkable scientific achievements of the 20th century [4]. According to Hilleman [1], 
hepatitis vaccines represent the world’s first subunit vaccine, the world’s first licensed 
vaccine against human cancer and the world’s first recombinantly expressed vaccine.  
Detailed reviews focusing on the history of the hepatitis B vaccine can be found in 
the scientific literature [1, 4-7]. In brief, the plasma-derived hepatitis B vaccine was 
licensed in 1981, 16 years after Blumberg’s discovery. The main reason for this delay 
was the inability to propagate HBV in tissue culture systems. The pioneering work of 
Krugman and colleagues [8] made feasible the production of a vaccine containing 
hepatitis B surface antigen obtained by purification of the serum of asymptomatic chronic 
HBV carriers and characterized elsewhere [9-12], which was decisive for the 
development of the vaccine.  
The hepatitis plasma derived vaccines successfully immunized several million 
individuals world-wide over almost a decade. However, because these vaccines had a 
poor acceptance rate due to concerns regarding the safety of the plasma derived 
products and because the supplies of acceptable human carrier plasma were inadequate 
to meet market needs, recombinant DNA techniques were investigated as an alternative 
production method. Therefore, a yeast-derived hepatitis B vaccine based on recombinant 
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DNA technology was licensed in 1986, and its properties have been reviewed elsewhere 
[13-15]. 
According to Hilleman [1], contemporary vaccinology research is very complex, at 
least for viral vaccines, and is largely dedicated to the subunit vaccine approach. 
Moreover, subunit vaccines are built on the same base and may be considered to be an 
extension of recombinant subunit hepatitis B technology, one example being the 
investigation of a vaccine against AIDS. The discovery of new vaccines to control more 
than 20 diseases, especially malaria, tuberculosis, hepatitis C and AIDS, rely on the 
identification of appropriate antigens and epitopes, and progress towards this goal will 
benefit from the expansion of knowledge in the fields of immunology and molecular 
biology.  
The major questions for current vaccine research seem to be “what to present to 
the immune system” and “how to present it” [1]. The answer to the last question will 
depend on the parallel development of new, safe and efficient adjuvants.  
1.2 MUCOSAL VACCINATION 
Mucosal vaccination has been the common generic name attributed to the oral, 
intranasal, pulmonary, rectal and vaginal routes of vaccine administration. However, the 
mucous membranes do not only cover the aerodigestive and urogenital tracts, but also 
the eye conjuntiva, the inner ear and the ducts of all exocrine glands, which have been 
less explored as routes of vaccine administration.  
Mucosal surfaces, with a combined surface area of about 400 m2 [2], are 
undoubtedly the major site of entry for most pathogens. Therefore, these vulnerable 
surfaces are associated with a large and highly specialized innate and adaptive mucosal 
immune system that protects the surfaces and the body against potential destructive 
agents and harmless substances from the environment. In a healthy human adult, this 
local immune system contributes almost 80% of all immune cells [16]. These immune 
cells accumulate in a particular mucosa or circulate between various mucosa-associated 
lymphoid tissues (MALT), which together form the largest mammalian lymphoid organ 
system [2]. 
Chapter 1 
           
- 6 - 
In theory, mucosal surfaces seem to be the more accessible lymphoid organ for 
the induction of an immune response such as that required for immunization. 
Nevertheless, one of the more important reasons for the development of mucosal 
vaccines is the increasing evidence that local mucosal immune responses are important 
for protection against disease, principally for diseases which start on mucosal surfaces 
such as the respiratory, gastrointestinal or urogenital mucosae. On the other hand, 
mucosal immune responses are most efficiently induced by the administration of 
vaccines onto mucosal surfaces, while injected vaccines are generally poor inducers of 
mucosal immunity and are therefore less effective against infection at mucosal surfaces 
[17]. However, even with the many attractive features of mucosal vaccination described 
below (see 2.1), it has often proven difficult (see 2.2) in practice to stimulate strong sIgA 
immune responses and protection by mucosal antigen administration [16]. As a 
consequence, no more than half a dozen mucosal vaccines are currently approved for 
human use (Table 1), and no subunit vaccines are listed among those approved. 
 
Table 1 – Licensed mucosal vaccines (adapted from ref [16]) 
Infection Vaccine  Route 
Polio Live attenuated vaccine (OPV) Oral 
Cholera Cholera toxin B subunit + inactivated V. cholerae O1; whole cells Oral 
Cholera CVD 103.HgR live attenuated V. cholerae 01 strain Oral 
Typhoid Ty21a live attenuated vaccine Oral 
Rotavirus Live attenuated monovalent human rotavirus strain Oral 
Influenza Live attenuated cold-adapted influenza virus reassortant strains Nasal 
1.2.1 Additional advantages of oral and nasal vaccination  
Oral and/or nasal vaccination has several attractive features that can be summarized as 
follows: 
 
- Both vaccination routes do not require injection and are therefore less painful. 
- Oral administration has a high patient compliance among infants and adults. 
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- Both vaccination routes do not require trained medical personnel for delivery and are 
thus more appropriate for mass vaccination programmes, especially in under developed 
countries. Moreover, this would be also a benefit in pandemic and bioterrorism 
situations. 
- Oral administration is a more natural route of administration. 
- Oral formulations can in theory allow vaccines with a higher stability. 
- Both vaccination routes can generate mucosal antibodies. 
- Nasal administration is the most effective route to elicit optimal protective immunity in 
both mucosal and systemic immune compartments. 
- Nasal administration can avoid the degradation of the vaccine antigen caused by 
digestive enzymes, so it requires a smaller antigen dose than oral immunization. 
- Nasal vaccination can generate cross-protective immunity in the gut through the 
common mucosal immune system. 
1.2.2 Challenges in mucosal vaccine design:  
Thorough knowledge of the principal obstacles to mucosal vaccination is essential to 
design vaccine delivery systems, and can be summarised in this way: 
 
- Nasal vaccination may leads to a possible deposition of antigen in the central nervous 
system through the olfactory bulbs and olfactory nerves (this feature requires further 
investigation however should not be excluded). 
- There is a low ability for the antigens to be taken up by the mucosal immune system.  
- Gastrointestinal deactivation of the vaccines can occur, so high doses of the vaccine 
are required for oral vaccination. 
- Oral vaccination has been associated with a high variability of the response and mixed 
clinical data. 
- High clearance in the nasal mucosa is a cause of low absorption of biomacromolecules.  
- Nasal tissue has significant enzymatic activity. 
- Nasal administration has limited applicability in patients with upper respiratory-tract 
infections. 
- Induction of Immunological tolerance can occur (this subject will be discussed below).  
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1.3 UNDERSTANDING THE ANATOMOPHYSIOLOGY OF THE MUCOSAL 
IMMUNE SYSTEM 
Mucosal-associated lymphoid tissue (MALT) includes the gut-associated lymphoid tissue 
(GALT), bronchus-associated lymphoid tissue (BALT), nasopharynx-associated lymphoid 
tissue (NALT), the mammary and salivary glands and the urogenital organs. The 
common mucosal immune system (CMIS) acts as an integrated pathway that establishes 
communication between the organized mucosa-associated lymphoid tissues (inductive 
sites) and the diffuse mucosal tissues (effector sites). However, there is some evidence 
supporting the theory that this CMIS is compartmentalized. For instance, stimulation at 
one mucosal site in MALT can induce an immune response at remote mucosal effector 
sites [18, 19]. However, the extent of the immune response at the effector sites depends 
on where the induction occurred [20]. Holmgrenn & Czerkinsky [16] recently summarized 
this phenomenon in this way: “Oral immunization may induce substantial antibody 
responses in the small intestine (strongest in the proximal segment), ascending colon 
and mammary and salivary glands and it is relatively inefficient at evoking an IgA 
antibody response in the distal segments of the large intestines, tonsils or female genital 
tract mucosa. Conversely, intranasal immunization in humans results in antibody 
responses in the upper airway and cervicovaginal mucosa, and regional secretions 
(saliva, nasal secretions) without inducing an immune response in the gut”. Kiyono [21] 
recently referred to important evidence that may explain, at least in part, the dependence 
of the mucosal site where the IgA is generated on the route of antigen administration. He 
cited a study [22] which showed that nasal immunization induces the expression of high 
levels of chemokine receptor 10 (CCR10) and α4β1–integrin by IgA-committed B cells, 
allowing them to efficiently traffic to the respiratory and genito-urinary tracts, which 
express the corresponding ligands, chemokine ligand 28 (CCL28) and vascular cell 
adhesion molecule 1 (VCAM1). In contrast, orally induced IgA-committed B cells express 
CCR9 and CCR10 as well as α4β7 and α4β1-integrins, so the cells migrate to sites such 
as the small intestine, which express CCL25 and/or CCL28 together with mucosal 
addressin cell-adhesion molecule -1 (MADCAM1) and/or vascular cell adhesion 
molecule-1 (VCAM1). Therefore, despite the fact that NALT and Peyer’s patches are 
apparently colonized by similar immune cells, subtle differences like the example 
referred to above indicate that these two lymphoid structures may have somewhat 
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different biological functions which are most probably related to their anatomically and 
environmentally distinct locations [21].  
This work will focus on the GALT and NALT. In particular, we will focus on 
Peyer’s patches and NALT as the inductive sites, and the effector sites will be briefly 
described as well. Effector sites include the lamina propria of the intestinal and 
respiratory tracts responsible for the generation of antigen-specific T helper 2 (Th2)-cell-
dependent IgA responses and Th1-cell and cytotoxic T lymphocyte (CTL)-dependent 
immune responses, which function as the first line of defence at mucosal surfaces. 
1.3.1 Gut-associated lymphoid tissue (GALT)  
The gut-associated lymphoid tissue described elsewhere [2] lines the digestive system 
and has two organizational levels to its structure: one with little organization, 
characterized by loose clusters of lymphoid cells in the lamina propria of the intestinal 
villi, and the other with a high level of organization called Peyer’s patches.  
The so-called intraepithelial lymphocytes (IELs) can be found in the outer 
mucosal epithelial layer, and the majority of these cells are CD8+ T-lymphocytes. Due to 
its localization, it is thought that this population of T cells may function to encounter 
antigens that enter through the intestinal mucous epithelium. Under the epithelial layer is 
the lamina propria, which contains large numbers of B cells, plasma cells, activated TH 
cells and macrophages in loose clusters. It is interesting to note that in healthy children, 
histological sections of the lamina propria have revealed more than 15,000 lymphoid 
follicles in total (described in [2]).  
Peyer’s patches, located in the submucosal layer underneath the lamina propria, 
contain 30-40 lymphoid follicles organized as macroscopic nodules or aggregates. In a 
similar way to what happens with lymphoid follicles in other sites, those from mature 
Peyer’s patches can develop into secondary follicles with germinal centers, supported or 
connected by follicular dendritic cells.  
Parafollicular T-lymphocyte zones located between the large B-cell follicles 
present a large number of high endothelium venules, allowing cellular migration and 
lymphocytes recirculation.  
Between the follicle-associated epithelium (FAE) and the organized lymphoid 
follicle aggregates, there is a more diffuse area known as the subepithelial dome (SED).  
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The FAE is the name given to the mucous membrane overlying the organized 
lymphoid follicles. The FAE is a small region characterized by the presence of 
specialized flattened epithelial cells called M-cells. Together, the FAE, lymphoid follicles 
and associated structures form the antigen sampling and inductive sites of the mucosal 
immune system [23]. 
The function and structural characteristics of microfold epithelial cells (M cells) 
have been described in several recent reviews [2, 23, 24]. It has been widely accepted 
that M cells are probably play a key role in mucosal infection and immunity. It is thought 
that the main role of M-cells is the sampling of antigens to transport them across 
mucosal epithelia to the underlying lymphoid tissues where protective immune 
responses are generated. In addition, M-cells are a common, if not the only, route for 
complex antigens and pathogen invasion, for examples several invasive Salmonella 
species, Vibrio cholerae, Yersinia species, Escherichia coli and the polio virus [24].  
M-cells have been identified in the epithelia of a variety of mucosal tissues and 
within the FAE of a wide variety of animal species, including laboratory animals (mice, 
rats, rabbits), domestic pets and man. In mice and men, M-cells reside in about 10% of 
the FAE in contrast with 50% in the rabbit. In the gut, M-cells are easily recognized by 
the lack of surface microvilli and the normal thick layer of mucus that characterizes the 
rest of the epithelial cells. Additionally, M-cells contain a deep invagination similar to a 
pocket in the basolateral cytoplasmic membrane that contains one or more lymphocytes 
and occasional macrophages [23]. The epithelium of the gut intestine provides an 
effective barrier to the entrance of most pathogens and particulates due to strong 
connections between epithelial cells called tight junctions. In contrast, the M-cells can be 
exploited by microorganisms as the port of entrance for two reasons; the organisms can 
adhere with less difficulty to the apical cell membrane, and after that these agents need 
only be transported a short distance before reaching the M cell pocket, where by 
interaction with lymphocytes, the antigens or the particulates gain rapid access to the 
organized MALT inductive site. 
1.3.2 Nasopharynx-associated lymphoid tissue (NALT) 
In rodents, NALT is found on both sides of the nasopharyngeal duct, dorsal to the 
cartilaginous soft palate, and it is considered to be analogous to Waldeyer’s ring in 
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humans (Pharyngeal lymphoid tissue that includes adenoid, tubal tonsil, palatine tonsil, 
lingual tonsil) [25]. In the rat, lymphoid aggregates are situated at the nasal entrance to 
the pharyngeal duct [26]. Detailed reviews of NALT and nasal vaccination can be found 
elsewhere [26-28]. NALT is a well organised structure consisting of B- and T-cell-
enriched areas which are covered by an epithelial layer containing microfold M-cells, the 
so-called follicle-associated epithelium (FAE). The function of these antigen-sampling M 
cells seems to be similar to those found on the FAE of Peyer’s patches [21]. Although 
NALT and Peyer’s patches share certain similarities, the two differ markedly in 
morphology, lymphoid migration patterns and the binding properties of the [high] 
endothelial venules [25]. Additionally, intraepithelial lymphocytes and antigen-presenting 
cells including dendritic cells (DCs) and macrophages can also be found in NALT [29]. 
Therefore, according to Kiyono [21], NALT contains all of the lymphoid cells that are 
required for the induction and regulation of mucosal immune responses to antigens 
delivered to the nasal cavity. 
1.4 NALT- AND PEYER’S-PATCH-INITIATED IMMUNE RESPONSES 
Several evidences converge on the insight that the organized MALT plays an important 
role in antigen sampling and generation of lymphocytes, including specific IgA effector B 
cells, memory B cells and T cells. This implicates active lymphocyte proliferative activity, 
local production of cytokines and continuous cellular trafficking [30].  
In stratified and pseudostratified epithelia (which lack tight junctions), antigen-
processing dendritic cells move into the epithelium, internalise antigens from the lumen 
and migrate back to local or distant organized tissues. In the intestinal and airway 
epithelia, whose mucosal epithelial cells are sealed by tight junctions, antigen transport 
is carried out by the M cells. Luminal antigens are endocytosed into vesicles that are 
transported from the luminal membrane to the underlying M-cell pocket membrane. 
Vesicles and the pocket membrane experience fusion, and the antigens are delivered to 
the clusters of lymphocytes present within the pocket. It is not known whether M cells 
participate in antigen processing and presentation nor if they express MHC class II 
molecules [30, 31]. Simultaneously, it is believed that the intact antigens are processed 
by professional APCs such as macrophages and dendritic cells, either in the epithelium 
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or in the underlying dome region immediately below M cells which is thus ideally located 
to sample transported antigens. Moreover, chemokines secreted by the FAE result in an 
additional attraction of DCs to the FAE, resulting in a high density of phagocytic cells at 
sites of entry of foreign antigens and pathogens [17]. Phenotypically immature DCs are 
subsequently moved to the T-cell areas, where they upregulate the expression of 
maturation markers and MHC molecules [17].  
In the follicle, B cells undergo immunoglobulin class switching from expression of 
IgM to IgA under the influence of several local factors, including transforming growth 
factor (TGF-β), IL-10 and cellular signals delivered by dendritic cells and T cells [31]. 
Furthermore, it is thought that because dendritic cells are migratory cells, they can 
transport microbes to the mesenteric lymph nodes and to the spleen for the induction of 
systemic responses [32]. Therefore, these cells also possibly transport antigens, 
especially those sampled directly from the luminal contents.  
The lymphocytes primed in the Peyer’s patches move through the draining 
lymphatics to the mesenteric lymph nodes (MLN) where they can reside for an undefined 
period for further differentiation before they migrate again to the mucosa. According to 
Kiyono [33], Peyer’s patches contain all the cellular and microarchitectural environments 
(e.g., a B cell follicle including germinal centers, a dendritic cell network and an 
interfollicular T cell area) needed for the generation of IgA-committed B cells. Therefore, 
B cells primed in the Peyer’s patches or in NALT and transported to the MLN migrate 
again to the diffuse mucosal effector tissues such as the lamina propria of the upper 
respiratory and intestinal tract where full maturation is achieved under the influence of 
IgA-enhancing cytokines IL-5, IL-6 and IL-10, and are transformed into immunoglobulin-
secreting active plasma or blast cells [21, 33]. 
How the lymphocytes know where to return is an interesting and important aspect 
of the mucosal immune response. It seems to be well established already that following 
activation in organized mucosal lymphoid tissues, B and T cells are able to upregulate 
the expression of tissue-specific adhesion molecules and chemokine receptors that 
function as “homing receptors” to guide the lymphocytes back to the mucosa through the 
recognition of endothelial counter-receptors in the mucosal vasculature [17, 22, 34]. For 
example, the exit of the lymphocytes into the mucosa occurs because lymphocytes that 
are primed by antigen in the GALT lose expression of L-selectin and selectively 
upregulate the expression of α1β7 integrin. This guides the emigration of lymphocytes 
from the bloodstream by interacting with mucosal addressin cell-adhesion molecule 1 
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(MADCAM1) [31]. Another example refers to the expression of the chemokine receptor-9 
(CCR9), induced by gut-derived T cells that respond to the chemokine ligand-25 
(CCL25), also known as TECK (thymus-expressed chemokine), which is expressed 
selectively by small bowel epithelial cells. On the contrary, T cells primed in peripheral 
lymphoid organs cannot migrate to mucosal surfaces because they do not express the 
same molecules. 
IgA-secreting B cells that are activated in MALT express CCR10, the receptor for 
CCL28. Therefore, CCR10+IgA+ B cells can be attracted by all tissues containing 
CCL28-secretor epithelial cells, which include the small and large intestines, salivary 
glands, tonsils, respiractory tract and lactating mammary glands [22]. This mechanism 
explains why mucosal immunization at one site can result in the secretion of specific IgA 
antibodies in other mucosal or glandular tissues. On the other hand, there are also some 
receptor-mediated recognition systems that have a more selective function. For example, 
IgA+ B cells that are generated in the intestinal inductive sites express the homing 
receptor α4β7-integrin that interacts strongly with MADCAM1, an addressin that is 
expressed by venules in the small and large intestines and in lactating mammary glands, 
but not in other mucosal tissues [22]. The reason that IgA+ B cells which are activated in 
the peripheral lymph nodes following systemic immunization do not migrate to mucosal 
sites seems to be related to their inability to express the CCR10, α4β7-integrin and other 
mucosal “homing receptors”.  
Mucosal antigen delivery can either up-regulate or down-regulate systemic 
immune responses. Therefore, the understanding of both mechanisms will provide better 
guidance on the technical aspects for mucosal vaccine design. 
1.4.1 Production of immunoglobulin A (IgA) 
Although IgA constitutes only 10%-15% of the total immunoglobulin in serum, it is the 
predominant immunoglobulin class in external secretions such as breast milk, saliva, 
tears and mucus of the bronchial, genitourinary and digestive tracts [2]. In humans, more 
IgA is produced than all other immunoglobulin isotypes combined, and IgA is 
concentrated over 1 mg /ml in secretions associated with the mucosal surfaces [35]. The 
IgA of external secretions, called secretory IgA (sIgA), consists of a dimer or tetramer, a 
j-chain polypeptide and a polypeptide chain called the secretory component [2, 36]. This 
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sIgA is resistant to degradation in the protease-rich external environment of mucosal 
surfaces. The resistance is due to its dimerization and high degree of glycosylation 
during its synthesis in mucosal plasma cells, and by its association with a glycosylated 
fragment (the secretory component) [17]. 
The secretory immunoglobulin A has several functions in mucosal defence 
described elsewhere [16, 17, 21] . So-called “immune exclusion” is a mechanism that 
consists of the entrapment of antigens or microorganisms by the sIgA in mucus, 
preventing direct contact of the antigen with the mucosal surface [17, 37]. Additionally, 
specific sIgA might block or sterically hinder the microbial surface molecules that 
mediate epithelial attachment [38].  
1.4.2 Immunological tolerance  
Epithelial cells are active participants in the mucosal defence. They have been described 
as functioning as sensors detecting dangerous signals like microbial components 
through pattern recognition receptors such as Toll-like receptors (TLRs) [17]. The 
epithelial cells respond to the dangerous signals by producing cytokine and chemokine 
signals to underlying mucosal cells, such as dendritic cells (DCs) and macrophages, to 
trigger innate, non-specific defences and promote adaptive immune responses [17, 39].  
In the intestine, the environment is extraordinarily rich in food antigens and 
microorganisms that constitute the normal flora. For this reason, there are mechanisms 
that reduce and modulate the cytokine and chemokine signals to avoid undesirable 
responses (reviewed in [40-42]) such as mucosal inflammation. The mucosal surfaces 
are in a permanent state of alert, but they adapt to the presence of foreign 
microorganisms. As a consequence, vaccines that produce a strong immune response if 
injected in sterile tissues such as muscle could be ignored when administered through 
mucosal surfaces [17]. This state of unresponsiveness or so-called immunological 
tolerance is dependent on the route of administration of the vaccine (see table 2) and 
has been appointed as one of the bigger challenges for mucosal vaccine development. 
Therefore, intended mucosal vaccination strategies should overcome mucosal tolerance 
mechanisms, and will require a more detailed understanding of the underlying 
mechanisms behind the phenomenon.  
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Table 2 – Route of antigen administration affects immunological response (adapted from ref. 
[43])  
Route of antigen administration Usual outcome 
 
Subcutaneous 
 
Immunization 
Intramuscular Immunization 
Injury Immunization 
Intravenous Tolerance 
Mucosal (Oral, nasal and pulmonary) Tolerance 
Portal vein Tolerance 
Anterior chamber of the eye Tolerance 
 
Although the phenomenon of oral tolerance has been known for almost a century, 
the mechanistic basis is still not fully understood. For instance, the molecular mechanism 
by which the innate immune system distinguishes commensal from pathogenic bacteria 
is a topic of great interest which is so far not understood. Answers to this and others 
questions will provide vital information for the development of effective oral vaccines. 
Some review articles about the state of the art of this knowledge have been published 
recently [31, 43], therefore only a short summary concerning immunological tolerance is 
presented here. 
Increasing evidence has shown that the induction of mucosal tolerance is related 
to the path for antigen internalization. One important pathway for tolerance might involve 
passing through intestinal epithelial cells, escaping capture by lamina-propria 
phagocytes and transport through blood capillaries to the liver [43]. Another important 
pathway for the entrance of the antigens from the lumen are via dendritic cells, which 
can intercalate between epithelial cells and sample antigens directly from the intestinal 
lumen [44]. It was recently demonstrated that the expansion of dendritic-cell populations 
mediates the enhancement of oral tolerance [45]. Moreover, these unprocessed antigens 
are carried through the lymphatics to the mesenteric lymph nodes, which have been 
implicated in oral tolerance [43, 46]. On the contrary, as demonstrated in more recent 
studies, Peyer’s patches appear not to have an important role in the induction of 
tolerance [47-49], although the uptake of antigens via Peyer’s patches is essential for the 
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induction of an immune response and determines the profile of the induced immune 
response when using particles as oral antigen carriers [50].  
Another important approach for the induction of immunological tolerance is the 
administration of a single high dose of the antigen or a repeated exposure to lower 
doses. These two forms of tolerance, now the so-called high- and low-dose tolerance, 
are mediated by distinct mechanisms as described recently [43]. It is thought that T cells 
are the major cell type involved in the induction of mucosal tolerance. It is generally 
agreed that the status of oral tolerance can be explained by clonal anergy, clonal 
deletion of T cells or by active suppression by T regulatory cells through the secretion of 
inhibitory cytokines. The most controversial issue is how and where the antigen-specific 
T cells in the MLNs first encounter antigen, and Mowat [31] has reviewed several studies 
addressing this question. According to the same author, however, it seems more 
probable that presentation of the antigen to naïve T cells occurs in the MLNs themselves 
due to unprocessed antigen brought there by APCs that traffic to the MLNs after being 
loaded with antigen in the mucosa or Peyer’s patches [31].  
1.5 CHALLENGES IN ORAL AND NASAL VACCINE DESIGN: 
Vaccines administered mucosally encounter the same host defence barriers as do 
microbial pathogens and other foreign macromolecules: they are diluted in mucosal 
secretions, detained in mucus gels, attacked by proteases and nucleases and barred by 
epithelial barriers [17]. Therefore, it is estimated that large doses of antigen would be 
required. Moreover, soluble non-adherent antigens are taken up at low levels if at all, 
and in the intestine, such antigens generally induce immune tolerance [43].  
To circumvent or minimize these difficulties, vaccine formulations and delivery 
strategies have to be carefully designed in order to efficiently stimulate the innate and 
adaptive immune response appropriate for the target pathogen [17]. Following this idea, 
delivery strategies are likely to be most promising when they mimic pathogens. 
Therefore, particulate delivery systems that adhere to mucosal surfaces or even better 
that would be able to selectively target M-cells are likely to be the most effective [17]. 
Moreover, to be distinguished from commensal microorganisms, the vaccine 
formulations should also carry substances that activate innate signalling pathways in the 
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epithelial cells and/or in the underlying antigen-presenting cells. These substances which 
are included in vaccine formulations with the aim of enhancing its immunogenicity are 
termed adjuvants (adjuvare; latin, to help). Presently, there is no optimal adjuvant 
classification. Although the complete working mechanism of many adjuvants is not 
entirely known at the moment, classification based on their mode of action has been 
suggested [51, 52]. Increasing evidence has demonstrated that most non-particulate 
mucosal adjuvants act by binding to specific receptors, and this adjuvant-class is 
frequently named immunopotentiators. Particulate adjuvants mainly function to 
concentrate vaccine components and to target vaccines towards antigen presenting cells 
(APCs) or carry out a depot action (see table 3). Therefore, this section will briefly review 
existing mucosal adjuvants, mainly dealing with those which have been used in the 
present experimental work of this thesis. So, chitosan based particulate delivery systems 
and CpG oligodeoxynucleotides, described in the following chapters.  
 
Table 3 – Classification of vaccine adjuvants (adapted from [52]) 
Antigen delivery systems Immunopotentiators 
Alum MPL and synthetic derivatives 
Calcium phosphate MDP and derivatives 
Tyrosine CpG oligos 
Liposomes Alternative PAMPS - flagellin 
Virosomes Lipopeptides 
Emulsions Saponins 
Microparticles DsRNA 
Iscoms Small-molecule immunopotentiators 
Virus-like particles  
 
1.5.1 Micro- and nanoparticles as polymeric vaccine delivery systems 
The category of particulate carriers includes different particles which have been widely 
reviewed in the recent scientific literature, including microemulsions (such as MF59) [52, 
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53], iscoms [54, 55], liposomes [54], virosomes [56], virus-like particles and polymeric 
microparticles [52, 57-61]. These particles have a common feature, which is that their 
size should be similar to the size of a pathogen in order to be taken up by APCs [62, 63] 
and subsequently deliver the associated antigen into these cells. Therefore, the main 
role of the delivery systems is to concentrate the antigen in the lymphoid tissues 
responsible for immune response induction. However, the potency of these delivery 
systems can be significantly improved by the association of an immunopotentiator (see 
5.2) [64]. This aspect is of particular importance for recombinant vaccines and other 
weak antigens.  
Therefore, there is a huge amount of information about the interaction of immune 
cells with different compounds (immunopotentiators) and particulate delivery systems, 
which allow for vast combination possibilities to be used in adjuvant formulations. 
According to O’Hagan [52], we are entering an exciting and dynamic time in vaccine 
research in which the principles leading to the successful induction of potent and 
protective immune responses are becoming better understood. This explosion of 
knowledge is not only for the traditional parenteral routes of vaccine administration but 
also for mucosal vaccination. Regarding oral and nasal vaccination, the entrapment of 
vaccine antigens in delivery systems has two main purposes. The first goal is to protect 
the antigen against degradation on mucosal surfaces, and the other is the enhancement 
of their uptake in MALT. The most successful work in achieving these two goals has 
been done with nano- and microparticles. The interaction between particulates and the 
GALT has been a subject of several reviews [65-68], and a deep understanding of this 
interaction would be key in the design of successful nanoparticles. The uptake of inert 
particles has been shown to take place transcellularly through normal enterocytes and 
specialized M-cells, or to a lesser extent across paracellular pathways through the tight 
junctions between cells [66]. Although transport by the paracellular route has been 
shown for example with polyalkylcyanoacrylate nanocapsules in the jejunal mucosa of 
the rat [69], the probability of its incidence does not seem to be high since the opening 
diameter of the gap junctions between the cells is between 7 and 20 nm in diameter [66].  
Regarding the transcellular transport, its occurrence via M-cells appears to be a 
very natural mechanism since M-cells are specialised for endocytosis and subsequently 
transport the particulates to the adjacent lymphoid tissue (Peyer’s patches in the gut). 
Therefore, after the particle binds to the M-cell apical membranes, the particulates are 
rapidly internalized and offered to the continuous lymphoid tissue. Depending on their 
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size, the particles can be retained within the lymphoid tissue (>3µm) [65], or they can be 
internalized by phagocytic cells and subsequently transported to another lymphoid tissue 
through the lymphatic vessels that innervate the PP dome area. There is a broad 
consensus that M-cells, associated with Peyer’s patches are the main target for 
vaccination purposes. However, several questions have arisen regarding this issue. One 
issue is related to the number of Peyer’s patches in the gut and therefore the total area 
covered with M-cells. Mice and rats have between 6 and 10 discrete Peyer’s patches, 
while a human being has many hundreds [70]. In this respect, the differences between 
mice and men mean that one must take extreme caution when extrapolating from animal 
models to humans. On the other hand, these uptake studies have been performed in a 
small target area in the animal models. Another question is related to the factors that 
may influence the particle uptake across the gastrointestinal tract epithelium. Some 
examples reviewed in [65, 71] are the particle size, polymer composition, particle 
hydrophobicity, particle surface charge, particle dose, administration vehicle, animal 
species and age, feeding state of the animals, use of penetration enhancers and use of 
targeting agents.  
A number of polymeric delivery systems have been evaluated by mucosal routes, 
however most of the work in this area has focused on poly(lactide-co-glycolide) (PLGs) 
polymers (some examples in ref. [72-78]). These polymers are biodegradable and 
biocompatible, and there is already a long experience of their use in humans as a suture 
material [71]. Moreover, they have appropriate release characteristics for use in single-
dose vaccines [79]. One of the limitations of this polymer is its insolubility in water, which 
makes the use of organic solvents necessary in particle preparation. Additionally, the 
antigen may also be exposed during the manufacturing process of the particles to high 
shear stress, aqueous/organic interfaces and elevated temperatures, which have been 
considered extreme conditions for working with proteins and antigens. More recently, a 
different approach was adopted with these nanoparticles as the antigen was adsorbed 
onto the cationic modified surface of PLG nanoparticles after their preparation [80, 81]. 
Although PLG have been successfully used for the entrapment of several 
antigens, the investigation of new polymeric delivery systems produced in a harmless 
environment has emerged over the last years. Some examples include the preparation of 
alginate microspheres for the entrapment of rotavirus [82], polyacryl starch for the 
entrapment of salmonella [83] and chitosan nanoparticles for the entrapment of 
diphtheria [84]. 
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1.5.1.1 Chitosan 
The term chitosan is applied to a family of deacetylated chitins and is the only largely 
available cationic polysaccharide. Chitosan is a copolymer of glucosamine and N-acetyl 
glucosamine linked by β-(1-4) linkages. It has been considered a non toxic, 
biodegradable and biocompatible polymer, so a lot of research has been directed toward 
its use in medical applications such as drug delivery. The properties of chitosan and its 
biomedical applications have been recently reviewed [85-91]. One major advantage of 
this polymer is its ability to easily produce nanoparticles under harmless conditions. This 
has been one of the main reasons for its wide applicability to the encapsulation of 
macromolecules such as DNA, proteins, vaccines and peptides. Additionally, the loading 
efficacy for these macromolecules is generally very high. 
Another important issue is the finding of the capability of chitosan nanoparticles to 
be internalized in tissues or in cells. Recent studies using in vitro cell culture models 
demonstrated the uptake of chitosan nanoparticles by a number of different cell lines [92-
97]. These studies emphasised that the polycationic, mucoadhesive chitosan 
nanoparticles association more strongly with mucus-secreting cells (MTX-E12) than with 
Caco-2 cell monolayers [92]. Moreover, an intense electrostatic interaction between 
positively charged chitosan nanoparticles and negatively charged mucins is regarded as 
the cause for the strong interaction of chitosan with mucus [92, 98].  
Those nanoparticle formulations have been used as delivery platforms for 
different vaccines such as meningococcal C conjugate [99], diphtheria [84] and tetanus 
toxoid [100, 101]. Chitosan has also been used without any modification, suspending the 
bulk powder in a solution of the meningococcal C conjugate vaccine [102], using a 
soluble chitosan derivative with the influenza vaccine [103, 104] or finally by using 
chitosan to surface-modify PLGA microspheres containing hepatitis B vaccine for 
intranasal immunization [105]. 
1.5.2 Immunopotentiators 
Non-microbial particles, macromolecules and protein-subunit antigens generally induce 
weak or undetectable adaptive immune responses when applied mucosally. The 
encapsulation of the antigen in a particulate delivery system can direct the antigen to the 
inductive site, ideally to the Peyer’s patches, but may not be sufficient to evoke an 
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appropriate immune response, because it may not be recognized as a harmful 
particulate. To be distinguished from harmless substances and nutrients, therefore, 
mucosal vaccines should raise alarms in the mucosa by including substances that 
activate innate signalling pathways [17]. 
The best-known mucosal immunopotentiators are the secreted enterotoxins of V. 
cholerae and E. coli, cholera toxin (CT) and E. coli heat-labile enterotoxin (LT). However, 
this kind of adjuvants has been shown to be toxic for humans. Therefore, several 
genetically modified forms have been engineered to reduce or eliminate the toxicity 
associated with the enzymatic A subunits of these toxins [106, 107]. Furthermore, many 
live attenuated mucosal vaccine vectors, including poliovirus, adenovirus and enteric 
bacteria are currently under development and have been extensively reviewed [108, 
109]. Although the superiority of these live attenuated pathogens as mucosal vaccines 
and vaccine vectors is due in part to their ability to activate multiple innate immune 
responses, some safety and acceptability issues will delay their use in humans. 
Meanwhile, with the recent progress in this area, a number of immunopotentiators 
have become available for inclusion in vaccines (see table 3), which have been 
extensively reviewed elsewhere [52, 64, 110]. Moreover, in more recent years, new 
information about the functions of immunomodulatory cytokines and the discovery of 
Toll-like receptors (TLRs) have provided promising new alternatives. It has also been 
demonstrated that the vertebrate innate immune system uses pattern recognition 
receptors, including TLRs, specifically to detect pathogen-associated molecular patterns 
(PAMPs) present in infectious agents [111]. To date, at least ten different human TLRs 
have been identified, as well as a number of naturally occurring TLR ligands (some 
examples are described in table 4). For example, various TLR ligands including CpG-
containing oligonucleotides [111], flagellin [112] and bacterial porins [113] have shown 
adjuvant activity when administered mucosally together with antigens. However, 
synthetic TLR ligands have also been identified, including imidazoquinoline compounds 
such as Imiquimod and Resiquimod (R-848), which activate human TLR7 and TLR8 
[111] as well. 
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Table 4 - Toll-like receptors and naturally occurring ligands 
Receptor Ligand References 
 
TLR2 Lipoproteins and peptidoglycans [114, 115] 
TLR3 Double-stranded RNA of viral origin [116] 
TLR4 Lipopolysaccharide (LPS) from Gram-negative bacteria and lipoteichoic 
acid from gram-positive bacteria 
[117-120] 
TLR5 Flagellin, a protein found in bacterial flagella [121, 122] 
TLR7/ 8 Single-stranded viral RNA [123] 
TLR 9 Unmethylated CpG motifs found in bacterial DNA [124-126] 
 
1.5.2.1 CpG ODNs 
According to a definition of Krieg [127], CpG motifs are DNA oligodeoxynucleotide 
sequences that include an unmethylated cytosine-guanosine sequence and certain 
flanking nucleotides, which have been found to induce innate immune responses through 
interaction with the Toll-like receptor 9. The three major classes of CpG ODN that are 
structurally and phenotypically distinct are comprehensively described (A, B, C-class) 
elsewhere [111, 127-130]. B-class CpG ODN has been frequently used in animal studies 
due to their strong B cell activation and capacity to induce potent Th1-type immune 
response. The same B-class CpG have also been shown to be safe and efficacious 
vaccine adjuvants in humans [131, 132].  
Although most cell types have the capacity to internalize CpG ODN via 
endocytosis [130], only those cells that express the TLR9 are activated. In humans, only 
B cells and plasmacytoid dendritic cells (pDCs) are able to express the TLR9, whereas in 
mice, TLR9 is also found on myeloid dendritic cells (mDCs), macrophages and 
monocytes [111]. Within minutes after exposure to CpG ODN, these cells take up the 
CpG ODN into an endosomal compartment where interaction with the TLR9 occurs 
[133]. This leads to the activation of cell signalling pathways comprehensively described 
by McCluskie [111].  
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CpG ODN has been shown to be an effective mucosal adjuvant after 
administration to different mucosal surfaces such as the respiratory tract [134-136], the 
genitourinary tract [137] and the gastrointestinal tract [138, 139] in combination with 
different antigens including the hepatitis B antigen [135, 140].  
The combination of CpG with other adjuvants has been considered to be useful 
regarding several issues. One issue is CpG ODN, a strong Th1 profile inducer which has 
been shown to be able to dominate the Th2 bias associated with adjuvants such as alum 
or Freund’s incomplete adjuvant (FIA) [135, 141]. Another important advantage is the 
depot effect offered by several adjuvants that may result in an extended release period 
during which both antigen and CpG ODN are available. Finally and not less important is 
the fact that the association of CpG ODN with nanoparticles may protect the CpG ODN 
from degradation on mucosal surfaces, particularly the ODN synthesized with the native 
phosphodiester (PO) backbone, which rapidly degrades in vivo. 
1.6 THE PRESENT INVESTIGATION 
Most pathogens gain access to their hosts through mucosal surfaces. The induction of 
helpful specific antigen mucosal antibodies is feasible only when the antigen is 
administered by one of the mucosal routes. On the other hand, a number of obstacles 
must be overcome in order to efficiently stimulate innate responses and evoke adaptive 
immune responses without disturbing mucosal homeostasis. This is why fewer mucosal 
vaccines have been developed. Therefore, the investigation of novel non-toxic adjuvants 
is urgently required. This thesis has as its main objective the development of a new 
nanoparticulate delivery system to be used as a mucosal adjuvant, and it will therefore 
contribute to the area of modern adjuvants.  
1.6.1 Aim of the thesis: 
The aim of this thesis is the design of a chitosan based nanoparticulate system as a 
novel antigen delivery system for mucosal surfaces. This delivery system is composed of 
a chitosan core with adsorbed antigen and a sodium alginate coating.  
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Coated nanoparticles should have an appropriate size (< 10µm) for internalization 
by M-Cells. Therefore, an appropriate coating method must be developed. Moreover, the 
use of polymers with mucoadhesive properties such as chitosan and alginate would 
confer optimized surface properties on the delivery system in order to have lower 
clearance rates in the NALT and in the GALT. A complete characterization of the delivery 
system was performed after the optimization of the preparation conditions. 
The principal mode of action of this delivery system is to promote the 
internalization of the antigen into the Peyer’s patches via M-cells of the FAE, and 
subsequently antigen uptake into APCs. Therefore, uptake studies in rat Peyer’s patches 
were performed and are shown in chapter 3. Additionally, cytotoxicity and ovalbumin 
release studies from the particles are also shown in the same chapter. 
The adjuvant capacity of the coated chitosan nanoparticles was evaluated using 
the recombinant hepatitis B antigen (HBsAg).  
Hepatitis B vaccine represents the world’s first subunit vaccine and the world’s 
first recombinantly expressed vaccine, therefore the recombinant antigen was used as a 
model vaccine to evaluate the adjuvant properties of alginate coated chitosan 
nanoparticles. A second adjuvant was used, the CpG ODN 1826, with the goal of 
evaluating synergistic effects between the systems. At same time, the suitability of the 
new delivery system to encapsulate the CpG ODN was also evaluated. Therefore, 
several formulations have been tested. Chapters five, six and seven present the results 
of the in vivo studies with Balb/c mice for the oral, intranasal and subcutaneous routes of 
administration, respectively. Additionally, the mucosal adjuvants used with the hepatitis B 
antigen for each of the routes are reviewed in the introduction of each chapter. 
Finally, although it is not a main concern in this thesis, the immunostimulatory 
properties of the polymers used in the construction of the present delivery system were 
evaluated. More precisely, mice spleen cells were cultured together with the polymers, 
and their stimulation status was estimated. Chapter four presents these results and 
performs a bibliographic review of the immunostimulatory properties of chitosan and 
alginate. 
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ABSTRACT 
It has been found that the adsorption of antigens onto chitosan particles is an easy and 
unique mild loading process suitable to be used with vaccines. In order to increase the 
stability of this particles and to prevent an immediate desorption in gastrointestinal fluids, 
a coating process with sodium alginate was developed. One of the challenges of this 
developing process was to keep the particles in the nanosized range in order to be taken 
up by M-cells of the Peyer’s patches. The observed inversion of the particles’ zeta 
potential values after coating suggested the presence of an alginate coating layer. These 
results were confirmed by FTIR and DSC techniques. Additionally, in vitro release 
studies showed that the presence of the alginate layer around the particles was able to 
prevent a burst release of loaded ovalbumin and to improve the stability of the 
nanoparticles in simulated intestinal fluid at 37ºC. The optimisation of the coating 
process resulted in 35% (w/w) for the loading capacity of the coated particles. SEM 
investigations confirmed a suitable size of the coated nanoparticles   for the uptake by M-
cells. 
2.1 INTRODUCTION 
In recent years, mucosal vaccination is being considered as a subject of great interest 
due to its advantages above the i.m. or s.c. application. The presence of specific 
antibodies in mucosal surfaces has long been recognized as the first barrier against 
pathogens entrance. The most effective way to induce mucosal immunity (i.e., secretory 
IgA) is to administer a vaccine directly to the mucosal surface. Additionally, the existence 
of a common mucosal immune system allows successful targeting of vaccines to 
inductive compartments within mucosa-associated lymphoid tissues, inducing local 
humoral responses in lymphoid tissues at distant mucosal loci [1]. Both intranasal and 
oral routes have been used in several studies to achieve this goal. Particularly, the oral 
administration permits targeting of a suitable vaccine loaded delivery system to the ports 
of entry (so-called M-cells) of the largest inductive lymphoid tissue in the body, the 
intestine. The oral route is well accepted and easily allows the vaccination of large 
populations. However, the acidic environment of the stomach and the presence of 
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enzymes make the oral delivery of vaccines a challenge where is difficult to achieve high 
and reproducible effects. In order to solve these difficulties, a considerable number of 
polymeric microparticulate systems are under investigation to deliver vaccines to the 
intestine while protecting them from adverse conditions that could affect their bioactivity 
[2]. Another important aspect is that these delivery systems could act as imunostimulants 
or adjuvants, increasing the immunogenicity of poor immune response antigens [3, 4]. 
Nevertheless, from a pharmaceutical perspective, it became evident that further 
advances in the formulation of delivery platforms needs to be introduced in order to 
increase both the stability of the antigens in the gastro-intestinal tract and the uptake of 
antigen-containing particles by the M-cells. One of the parameters that should be 
addressed is the size of the particles. It is well known that the size of the particles should 
be below 10 m in order to be taken up by M-cells of the Peyer’s patches in the gut [5, 
6]. Moreover, the preservation of antigen stability during encapsulation is also essential 
for the development of a successful controlled release vaccine delivery platform.  
Chitosan microparticles as an oral and intranasal vaccine delivery system were 
already used in our group showing promising capabilities [7-9]. In these studies the 
vaccine was loaded by a mild and simple but effective adsorption method. By this 
method, deleterious preparation conditions, like elevated temperatures, high shear rates 
or the presence of organic solvents were avoided. This method has also been described 
by other groups that reported good adsorption capacities for different substances [10, 
11]. In the case that the chitosan particles are not very porous, the antigen will be 
preferentially adsorbed to the particle surface. This can cause stability problems because 
processes like desorption or the attack of the antigens by enzymes or acidic substances 
from the body fluids may occur. These obstacles may be overcome by coating those 
particles with an acid resistant polymer, like sodium alginate. 
The two chosen polymers chitosan and sodium alginate, for this novel delivery 
platform are naturally occurring polysaccharides. They are polyelectrolyte polymers of 
opposite charges, biocompatible and biodegradable, and show a good safety profile. 
Furthermore they have been reported as pharmaceutical excipients (PhEur 2002). 
Chitosan is the deacetylated form of chitin comprising copolymers of glucosamine and N-
acetyl glucosamine linked by -(1-4) linkages. The primary amino groups lead to special 
properties that make chitosan very interesting for pharmaceutical applications. Sodium 
alginate is also a hydrophilic polymer and comprises D-mannuronic (M) and L-guluronic 
acid (G) residues joined linearly by 1,4-glycosidic linkages [12]. The wide pharmaceutical 
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applicability of alginates is, to a large extent, associated with their gel-forming capacity. 
Di- or polyvalent cations (calcium being the most widely studied example) can induce the 
gelation by cross-linking of the guluronic acid units [12, 13]. Sodium alginate has been 
used for preparing nanoparticles [13, 14], microspheres [15-20], microcapsules [21] and 
beads [15], for oral delivery. In particularly the use of alginate microparticles as an 
antigen delivery system has been described in several publications and there are some 
indications that they are able to induce a mucosal and systemic immune response in a 
variety of animal species by both oral and intranasal administration [22-24]. 
Over the last years, sodium alginate has also been used as a coating material for 
cells with some advantages. It seems that the coating acts as a barrier to microbial 
contamination and thus improved survival prospects of the coated cells [25]. In another 
study the coating is performed to protect donor mammalian cells against antibodies and 
cytotoxic cells of the host immune system, allowing the transplantation of cells in the 
absence of immunosuppression [26].  
This manuscript describes the development of a true nanocoating procedure, 
whereas other publications describing the entrapment of cells, liposomes [27] or 
microspheres [10, 28] in an alginate gel matrix. This is, as far as we know, the first time 
that the construction of a nanosized alginate coated chitosan delivery system is 
described with the particularly aspect that the antigen is adsorbed to the chitosan 
particles surface. 
2.2  MATERIALS AND METHODS  
2.2.1 Materials 
Chitosan was purchased from Primex BioChemicals AS (ChitoClearTM, Avaldsnes, 
Norway). According to the provider’s specifications, the degree of deacetylation is 95% 
(titration method) and the viscosity is 8 cP (1% solutions in 1% acetic acid). Low viscosity 
sodium alginate was kindly donated by ISP Technologies Inc (MANUCOL LB, Surrey, 
UK). Ovalbumin (grade V; minimum 98%) was purchased from Sigma Chemicals (St. 
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Louis, USA) and all the others reagents used were of analytical grade. All solutions were 
prepared in Millipore water. 
2.2.2 Preparation of chitosan particles  
Chitosan particles were prepared by the precipitation/coacervation method described 
previously [29]. Shortly, chitosan was dissolved at a concentration of 0.25% w/v in a 
solution with 2% (v/v) of acetic acid and 1% (w/v) of Tween 80. The formation of the 
particles was achieved after the addition of 3.5 ml of sodium sulfate solution (10% w/v) to 
200 ml of the chitosan solution. The addition was made at a rate of 1 ml/minute under 
mild agitation (< 50 rpm) and continuous sonication (vibracell sonicator; 600-Watt model 
(output control “1”); Sonics & Materials, INC, Danbury; USA).  Sonication was maintained 
for additional 15 minutes and the agitation for 60 minutes at room temperature (RT). The 
suspension was centrifuged for 30 minutes at 3500 rpm (2800 x g) and the supernatant 
was discarded. The particles were re-suspended twice in Millipore water, centrifuged 
again for 30 minutes and the supernatants were discarded. The particles were frozen in 
liquid nitrogen and freeze-dried overnight using a Christ freeze-dryer (Osterode am Harz, 
Germany). The dry powder was kept frozen until further use. 
2.2.3 Loading of the particles with ovalbumin  
The first step of the loading procedure was the suspension of the freeze dried particles in 
a phosphate buffer (pH =7.4) placed in an ultrasound bath for 30 minutes in order to 
disaggregate the particles. The loading was done by incubating a solution of ovalbumin 
with chitosan particles under mild agitation at room temperature. The various 
concentrations used are presented in table 1. 
The loading efficacy and the loading capacity of the uncoated particles were 
calculated by an indirect way, quantifying the protein that remained in solution. After 
incubation, an aliquot of the particle suspension was centrifuged at 14,000 rpm for 30 
minutes and the protein in supernatant was quantified by BCA-protein assay (PIERCE, 
Rockford, USA) using a microplate reader with a 590 nm filter (BIO-RAD model 550, 
Veenendaal, The Netherlands). The absorbance reading value was corrected subtracting 
the average absorbance reading obtained in the BCA-protein assay from that one of the 
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supernatants of unloaded nanoparticles prepared exactly in the same conditions. The 
corrected OD value was then used to calculate the concentration using the standard 
curve prepared at same time from individual ovoalbumin standards. 
The drug loading capacity (LC) and loading efficacy (LE) were calculated from the 
following equations: 
LC (%w/w) = (total amount of ovalbumin – non-bound ovalbumin)/weight of the particles 
*100 
LE (%) = (total amount of ovalbumin – non-bound ovalbumin)/total amount of ovalbumin 
*100 
 
Table1 - Composition of the different systems used for the development of the alginate coating 
method of the chitosan nanoparticles. 
 A B C D E 
Loading 
1% particles 
0.5% ovalbumin 
(PB; pH=7.4) 
 
0.5% particles 
0.25% ovalbumin 
(PB; pH=7.4) 
 
0.375% particles 
0.19% ovalbumin 
(PB; pH=7.4) 
0.4% particles 
0.25% ovalbumin 
(PB; pH=7.4) 
0.5% particles 
0.25% ovalbumin 
(PB; pH=7.4) 
Coating No 
0.125% particles 
0.5% alginate 
(water) 
 
0.188 % particles 
0.5% alginate 
(phosphate 
buffer pH=7.4) 
 
0.2 % particles 
0.5% alginate 
(phosphate 
buffer pH=7.4) 
0.25 % particles 
1% alginate 
(phosphate 
buffer pH=7.4) 
 
 
2.2.4 Coating of the nanoparticles with alginate  
Various amounts of the ovalbumin loaded particle suspension were added under 
agitation to various solutions of sodium alginate (table 1). The suspension of the particles 
was maintained under agitation with a magnetic stirrer for 20 minutes at RT. The 
suspension was then centrifuged for 10 minutes at 1600 rpm and the supernatant was 
discarded. To chemically cross-link the alginate at the particle’s surface, the particles 
were re-suspended in 0.524 mM CaCl2 solution and kept under agitation for another 10 
minutes. For the characterization of the nanoparticles (section 2.5.) the optimised 
formulation batch was used as given in table 1 (system D).  
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2.2.5 Evaluation of the desorption during the coating procedure  
During the incubation of the particles with sodium alginate, aliquots of the particles 
suspension were collected, centrifuged at 14,000 rpm for 30 minutes and the protein in 
the supernatant was assayed with a BCA-protein assay as described in section 2.3.  
Statistical methods used in this section include descriptive statistics (arithmetic 
mean and standard deviation) and Student’s t-test. 
2.2.6 Characterization of  the nanoparticles  
2.2.6.1 Morphology  
The morphology and surface appearance of the particles were examined by scanning 
electron microscopy (SEM). One drop of the particles suspension was placed on a gold-
coated plate and maintained at least 12 hours at room temperature in a desiccator for 
complete dryness of the sample. The dry samples were coated with a thin gold layer 
using Emitech K650X large sample coater (Emitech, Kent, UK) and observed with a Jeol 
JSM-6700F field emission scanning electron microscope (JEOL BV, Schiphol-Rijk, The 
Netherlands).  
2.2.6.2 Size and zeta potential measurments 
The particle size and zeta potential were evaluated by a dynamic light scattering 
technique with a Zetasizer 3000HSA (Malvern Instruments, Bergen op Zoom, The 
Netherlands). Zeta potential determinations were based on electrophoretic mobility of the 
nanoparticles in diluted aqueous suspensions. These measurements were performed at 
least in triplicate with independent particle batches.   
2.2.6.3 FT/IR studies  
The coated particles were washed with Millipore water, centrifuged and the sediment 
was freeze-dried overnight (Labconco, Kansas City, USA). The coated and uncoated 
particles were kept in desiccator at room temperature until analysis. The IR spectra of 
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the samples were recorded using a Fourier-transformed infrared spectrophotometer 
instrument FT/IR – 420 Jasco (Jasco Inc, Tokyo, Japan) with attenuated total reflection 
(ATR).  
2.2.6.4 Differential scanning calorimetry (DSC) 
DSC scans were recorded using a differential scanning calorimeter (DSC-50, Shimadzu 
Co, Kyoto, Japan). Two to 4 mg of the dry particles were accurately weighed into 
aluminium pans without seals and heated from 25 to 350ºC at a heating rate of 10ºC/min 
under a nitrogen flow of 20 ml/min.  
2.2.6.5 Invitro release studies  
The ovalbumin release from the coated and uncoated particles was performed in 
simulated intestinal fluid (SIF) as described in USP XXIV. The nanoparticles suspensions 
were added (1:4) to individual tubes containing the release medium previously 
equilibrated at 37ºC and placed in a shaker bath adjusted to 50 rpm. At appropriate time 
intervals, samples from each tube were filtered with a low protein-binding filter 
(MILLEX®GV - 0.22 µm; durapore PVDF membrane; MILLIPORE, Malsheim, France) 
followed by centrifugation for 20 minutes at 14,000 rpm and the ovalbumin in 
supernatant assayed with a BCA-protein assay. Simultaneously coated and uncoated 
blank nanoparticles suspensions were submitted to the same conditions and the filtered 
samples were used as blanks for correction of the BCA-protein assay as described in 
section 2.3. 
For the determination of the total protein content, 0.5 ml of the suspensions of the 
coated and uncoated particles were incubated with 1.5 ml of 0.085N hydrochloric acid 
solution (pH=1.2) in an ultrasound bath for 30 minutes, followed by 3 hours in a water 
bath at 37ºC. The samples were filtered and the protein was assayed by the BCA-protein 
assay. Suspensions of unloaded particles were analysed under the same conditions and 
were used as a blank for the correction of the OD value of the samples analysed with 
BCA-protein assay as described in section 2.3. Additionally, the unbound ovalbumin in 
the particle’s suspension was also determined in order to calculate the amount of the 
ovalbumin encapsulated in the beginning of the assay.  
All experiments were performed at least in triplicate. 
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2.2.6.6 SDS-polyacrylamide gel electrophoretic (PAGE) analysis of released ovalbumin 
(OVA) 
Samples from the loading and coating particle suspensions were centrifuged at 14000 
r.p.m, the supernatants were collected and the concentration was adjusted in order to 
have the same theoretical concentration (i.e. assumption of 0% of loading efficiency) of 
the protein. Alginate coated chitosan nanoparticles loaded with ovalbumin were diluted 
(1:5) in buffer phosphate pH= 7.5 at 37ºC and incubated overnight at 50 r.p.m. An aliquot 
was collected and centrifuged. The ovoalbumin samples were then suspended in the 
loading buffer and heated for 5 min at 100ºC just before the run.  
The SDS-PAGE was performed with gels composed of 12% acrylamide, cast and 
run in tris-glycine buffer. Gels were stained with 0.1% Coomassie Brilliant blue in 10% of 
acetic acid in a solution of methanol:water (1:1).   
2.3 RESULTS AND DISCUSSION 
2.3.1 Preparation of the vaccine delivery system  
The preparation of the delivery system contains three main steps, the manufacturing of 
the chitosan particles, their ovalbumin loading by adsorption and finally the coating with 
sodium alginate. The formation of the chitosan particles by a precipitation process with 
sodium sulphate has been described by several authors [29-31]. They all describe an 
existing correlation between the necessary amount of sulphate ions, the molecular 
weight and deacetylation degree of the polymer. 
The loading of the cationic particles with the protein is a very mild process, which 
can be achieved by suspending the particles in a solution of the protein in an appropriate 
buffer. The adsorption of the protein onto chitosan particles is mainly caused by ionic 
interaction of the chitosan amino groups with the carboxyl groups of protein substrate in 
a buffer phosphate solution of pH = 7.4 with high buffer capacity. According to previous 
work done in our laboratory [30], the loading capacity of ovalbumin at a chitosan particles 
concentration of 1% (w/v) is not substantially influenced in the range of 0.5% to 2% (w/v) 
ovalbumin. Therefore, an ovalbumin concentration of 0.5% (w/v) was used as loading 
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solution resulting in a sufficient high loading capacity. For instance, for the system A, as 
shown in figures 1and 2 the loading capacity and the loading efficacy were about 40% 
and 80%, respectively. It was also found from the measurements of the unbound protein 
at different time points during the loading process that the adsorption equilibrium is 
rapidly reached. This means that the protein is bound to the surface of the particles and 
that the adsorption process of the ovalbumin to the particles surface occurs immediately 
after the addition of the protein solution to the particle suspension. Better loading 
capacity results (p<0.00001) of the uncoated particles were found when the ratio 
particles/ovalbumin in the loading suspension was decreased from 2 (system A, B and 
E) to 1.6 (system D) while the loading efficacy (uncoated particles) was not different 
(p=0.15) between the systems. 
The third step of the preparation was the coating of the chitosan nanoparticles 
with alginate solution. To our knowledge this coating process has not been described in 
literature earlier. Consequently, the first part of this work is focused on the selection of 
the appropriate conditions and experimental methodology for the coating process with 
sodium alginate. For that purpose several systems with different ratios sodium 
alginate/chitosan particles have been investigated with the main objective to obtain a 
stable particle suspension. In the majority of the first trials an immediate flocculation was 
observed, particularly in systems with higher particles concentration. The formation of 
these agglomerates was easily observed because of the formation of a precipitate and a 
clear supernatant. Systems with a ratio alginate/particles > 2 have shown to be stable. 
Thus, in the following optimization steps of the coating methodology always ratios higher 
than 2 were used. 
Another important parameter studied was the desorption of ovalbumin from the 
particles during the coating process. The addition of the sodium alginate solution to the 
suspension of the loaded particles resulted in a new adsorption equilibrium characterized 
by the different concentration of protein and by the presence of alginate polymer that can 
compete with the interaction of the charges at the particle’s surface. A significant 
decrease of the loading capacity of the coated particles was observed in all the systems 
(p< 0.05 for systems B, C, D, E). Furthermore, we have observed that modifications in 
the pH of the coating medium can also modify the adsorption equilibrium of the protein. 
In our first experiments, the coating process was carried out at pH 5.5. This pH value 
seems to be the most favourable for the interaction between chitosan and alginate as the 
pKa of the chitosan is around 6.5 and the pKa of the sodium alginate is between 3.4 and 
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4.4. However at this pH value we have observed more than 60% of ovalbumin 
desorption (data not shown). For that reason a pH =7.4 was adopted as it was observed 
to have the better compromised between loading capacity and efficiency of the coating 
process.  
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FIGURE 1. Loading capacity of the particles during the different stages of the coated particles 
preparation. Results for the different systems (A, B, C, D, and E) 
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FIGURE 2 Loading efficacy of the particles during the different stages of the alginate coated 
particles preparation. Results for the different systems (A, B, C, D, and E) 
The highest loading capacity for the alginate coated nanoparticles was achieved 
with system D (p=0.086 when comparing with system B and p=0.032 comparing with 
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system E). On the other hand the comparison with system B (p=0.001) and E (p=0.004) 
showed, that this option (system D) was achieved on the expenses of a slight decrease 
of the loading efficacy (figure 2). 
2.3.2 Characterization of the nanoparticles  
2.3.2.1 Morphology, size and zeta potential measurements  
The precipitation of chitosan with sodium sulphate using ultrasounds for homogenisation 
led to the formation of particles in the nanoscale size (table 2). One of the major currently 
described drawbacks of this technique is the high polydispersity of the obtained 
nanoparticles [32]. Sizes between 100 nm and 1000 nm were found by SEM technique. 
The mean hydrodynamic diameter of the obtained particles after the precipitation 
process was 684 nm and the size increased after the freeze-drying process (table 2). 
This is a direct consequence of particle aggregation during the drying process. To 
overcome particle aggregation the use of trehalose as a lyoprotectant was tried at 
concentrations of 3.3%, 5% and 7% (w/v).  
A complete redispersibility of the freeze-dried nanoparticles in all trehalose 
concentrations and the maintenance of the particle size could be observed by light 
microscopy and dynamic light scattering technique. However, we optimised the duration 
of the freeze-drying process in order to avoid the use of cryo-protectants as they would 
interfere with the coating process. 
Table 2 - Size of the chitosan nanoparticles in different stages of the preparation process. 
 
Cumulant Z Ave (nm)  
Mean ±  STDEV 
Polydispersity)  
Mean ±  STDEV 
After the precipitation 
process 
643.2 ± 171.7 
(16 batches) 
0.379 ± 0.168 
(16 batches) 
After lyophilization process 955.6 ± 161.0 
(3 batches) 
0.387 ± 0.129 
(3 batches) 
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SEM observations (figure 3) indicated that the size range of the particles 
remained unchanged. This result indicates the feasibility of coating of ovalbumin loaded 
chitosan nanoparticles with a thin layer of alginate.  SEM images (figure 3) show in first 
picture some small particles (< 100 nm) and a particle’s agglomerate. However it is not 
clear if this is a consequence of the freeze-dry process or if it is a consequence of the 
sample preparation (particle’s concentration of the sample) for the SEM  (figure 3b). 
The stability of many colloidal systems is directly related to the magnitude of their 
zeta potential. In general, if the value of the particle zeta potential is large, the colloidal 
system will be stable. Conversely, if the particle zeta potential is relatively small, the 
colloid system will agglomerate. The surface charge of the particles is of substantial 
importance in all the production steps of these coated particles because the efficiency of 
the different steps is directly related to the establishment of electrostatic interactions. 
Chitosan particles showed a positive value of about 37 mV, which explains the stability of 
the particle suspensions in water and in several buffer systems. After adsorption of 
ovalbumin, the particles are still positively charged with values higher than 30 mV. 
During the coating procedure an inversion of the surface charge of the particles to 
negative values was observed. This zeta potential inversion explains the difficulties that 
were found in preventing the formation of particles agglomerates during the coating 
process. After complete adsorption of the alginate to the particles, a surface charge of 
the particles of about –35 mV was found (table 3). This zeta potential inversion is a 
strong indication of the presence of an alginate coating on the surface of the particles. 
      
FIGURE 3. Scanning electron micrographs of chitosan nanoparticles. A) After freeze-dry and 
ressuspending in water. B) After the coating procedure with sodium alginate. 
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Table 3 - Zeta () potential of unloaded, ovalbumin loaded chitosan nanoparticles and alginate 
coated chitosan nanoparticles. 
  
Empty chitosan 
nanoparticles 
 
Ovalbumin loaded 
chitosan particles 
 
Alginate coated chitosan 
particles 
 
Zeta potential (mV)  
mean average ±  STDEV 
 
+ 37.0 ± 3.6 
(7 batches) 
 
+ 41.3 ± 6.4  
 (5 batches) 
 
- 34.9 ± 8.3 
(5 batches) 
 
 
 
2.3.2.2 Differential scanning calorimetry  
As shown in Figure 4, the DSC scans of the chitosan polymer exhibited an endothermic 
peak at about 66ºC that has been attributed to the evaporation of absorbed water. The 
exothermic baseline deviation beginning around 250 ºC indicates the onset of chitosan 
degradation [33]. The analysis of the DSC curves for chitosan particles showed two 
additional endothermic peaks at about 237ºC and 275ºC. The peak at 237ºC is probably 
related to the breakdown of weak unspecific electrostatic interactions. The second peak 
is probably related to the cleavage of the electrostatic interactions between the polymer 
and the sulphate ions.  
After the coating process with sodium alginate, the particles exhibited a 
completely different behaviour as shown in figure 5, which means that an alteration 
occurred in the composition of the particles. In the DSC scans the two endothermic 
peaks disappeared and no endothermic peak was found in the temperature range 
studied. In fact, a gradual appearance of an exothermic behaviour was detected starting 
around 200ºC that coincides with the exothermic behaviour of the sodium alginate as 
referred to in several publications [34] as the decomposition of the polymer.  
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FIGURE 4. Differential scanning calorimetry curves of chitosan, unloaded chitosan particles and 
sodium sulphate 
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FIGURE 5. Differential scanning calorimetry curves of sodium alginate, uncoated chitosan 
particles and alginate coated particles. The DSC investigation was conducted using the 
unloaded particles. 
These observations strongly support the presence of alginate molecules linked to 
the surface of the chitosan particles: when the temperature of the sample reaches values 
around 200ºC, the two phenomena, the exothermic contribution from the alginate and 
the endothermic contribution from the chitosan particles determine the shape of the 
curve.  
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2.3.2.3 FTIR characterization 
The FTIR spectra of chitosan and the chitosan particles, sodium alginate, and the coated 
particles are shown in Figure 6 and 7, respectively. 
In the chitosan spectra the strong and broad peaks in the 3400-3200 cm-1 ranges 
correspond to combined peaks of O-H stretching and intermolecular hydrogen bonding. 
The N-H stretching from primary amines are overlapped in the same region. The C=O 
stretching (amide) peak near 1633 cm-1 and N-H bending (amide and amine) peak near 
1542 cm-1 was observed as well. The intense peak at 1414 cm-1 belongs to the N-H 
stretching of the amide and ether bonds give the peaks in the fingerprint region of the 
spectra, where the symmetric stretch of C-O-C is found around wave numbers of 1065-
1027 cm-1. In the chitosan particles the peak of 1558 cm-1 is shifted to 1535 cm–1 and 
the relative intensity of this peak is reduced. In addition the peak related with C-N stretch 
(1414 cm–1) has almost disappeared in the chitosan particles. Similar observations are 
reported for chitosan particles prepared with tripolyphosphate [35]. These observations 
are in agreement with the fact that the sulphate ions interact with the primary amino 
groups of the chitosan, resulting in the formation of crosslinked chitosan particles 
(reticulation process). 
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FIGURE 6. FTIR spectra of chitosan and unloaded chitosan particles 
Sodium alginate as a carboxylate salt showed a strong asymmetric stretch at 
1605 cm-1. The frequency of carbonyl absorption is lowered compared to the value 
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found for the parent carboxylic acid due to a resonance phenomenon. The carboxyl and 
carboxylate groups are present at wave number of about 1000-1400 cm-1. From the 
FTIR analysis spectra of the coated particles we were able to distinguish the presence of 
these three peaks that are different from those of the chitosan uncoated particles. As 
conclusion of these findings, the results clearly show the existence of alginate coating 
layer around the chitosan particles. 
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FIGURE 7. FTIR spectra of sodium alginate, uncoated chitosan particles and alginate coated 
chitosan particles. The FTIR investigation was conducted using the unloaded chitosan particles. 
2.3.3 Release studies 
In a preliminary study we observed that the temperature is an important 
determinant for the integrity of the chitosan particles placed in different pH buffers. The 
particle integrity was monitored by turbidity transmission measurements at 500 nm. In 
fact at room temperature we were able to obtain stable suspensions of the particles in 
simulated gastric fluid (SGF) and in simulated intestinal fluid (SIF). In contrast when the 
chitosan particles were added to the same solutions (SGF and SIF) at 37ºC, a loss of 
integrity was observed translated with high values of transmission measurements. Thus, 
the complete release of the ovalbumin from the chitosan particles in SIF at 37ºC (Fig. 8)  
is directly related to the loss of integrity of the particles and less with a simple desorption 
phenomenon. In contrast, the coating of the particles with alginate increased the stability 
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of the particles (lower values of transmission measurements) in SIF at 37ºC resulting in a 
slower release rate of ovalbumin. After 7 hours more than 60% of ovalbumin was still 
found in the alginate coated particles. These release studies also suggest that the 
formation of an alginate layer increases the stability of the chitosan particles and reduces 
the release of the adsorbed protein from these particles. 
0
20
40
60
80
100
0 100 200 300 400 500 600 700
Time (minutes)
%
 
re
le
as
ed
coated particles
uncoated particles
 
FIGURE 8. Release behaviour of ovalbumin from alginate coated and uncoated chitosan 
particles in SIF at 37ºC. Individual points represent the mean averages from 3 assays 
2.3.4 SDS-PAGE 
The main task of this work was the development of an appropriate method for the 
adsorption of antigens to an optimised delivery platform. With this method the protein 
antigen was never exposed to potentially harsh conditions, such as contact with organic 
solvents or mechanical agitation or sonication. The SDS-PAGE (figure 9) of the released 
ovoalbumin from the particles showed identical bands for the entrapped (lane 4, 5 and 6) 
and native ovoalbumin (lane 1) and there were no additional bands to indicate the 
presence of molecular weight aggregates or fragments greater or less than 45K (the 
molecular weight of ovalbumin). Hence, the data suggest that the structural integrity of 
ovalbumin was not significantly affected by the entrapment procedure. 
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FIGURE 9. Electrophoretic analysis on SDS-12% PAGE with Coomassie brilliant blue staining. 
Shown are solution of ovalbumin before conjugation to the nanoparticles (lane1), ovoalbumin 
from the supernatant remaining after the conjugation (lane 2), ovoalbumin from the supernatant 
remaining after the coating with alginate (lane 3), ovoalbumin released from alginate coated 
chitosan nanoparticles (lanes 4, 5 and 6). 
2.4 CONCLUSION  
This work describes a new nano-sized mucosal vaccine delivery system, consisting of 
chitosan particles that are prepared by crosslinking with sodium sulphate. The chitosan 
nanoparticles are loaded under very mild conditions with a model antigen (ovalbumin), 
which was negatively charged in the used buffer systems. The validity of an easy and 
economic loading process was shown. In order to increase the stability of the loaded 
chitosan particles at physiological temperature in SGF and SIF a coating process with 
sodium alginate was developed. This coating process was optimized in such ways that 
only small amounts of ovalbumin were desorbed during the coating process and the 
antigen release from the coated nanopaticles was strongly reduced in comparison to the 
uncoated chitosan nanoparticles. Hence a nano-sized delivery platform is described with 
improved features of antigen stability in simulated gastrointestinal fluids. In vivo studies 
are under way to show the efficacy of these systems  for mucosal vaccination. 
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ABSTRACT 
The design of particulate vaccine delivery systems, particularly for mucosal surfaces, has 
been a focus of interest in recent years. In this context, we have previously described the 
development and the characterization of a new nanosized delivery system, consisting of 
a model antigen adsorbed to chitosan particles and coated with sodium alginate. In the 
present work the ovalbumin release profiles from these coated nanoparticles in different 
pH buffers were investigated and compared to those of the uncoated particles. 
Cytotoxicity of the polymers and nanoparticles was assessed using the MTT assay. 
Finally, particle uptake studies in rat Peyer’s patches were performed. It was 
demonstrated that the coating of the nanoparticles with sodium alginate not only avoided 
a burst release observed with uncoated particles but also increased the stability of the 
particles at pH 6.8 and 7.4 at 37ºC. At neutral pH, the release was lower than 5% after 
3.5 hours incubation in a low ionic strength buffer. For both, chitosan and alginate 
polymers, and for the nanoparticles, comparable cell viability data close to 100%, were 
obtained. Additionally, based on confocal laser scanning microscopy observations, it was 
shown that alginate coated nanoparticles were able to be taken up by rat Peyer’s 
patches, rendering them suitable carriers for intestinal mucosal vaccination. 
3.1 INTRODUCTION 
The primary reason for using the mucosal route of vaccination is that it is the most 
effective route to induce a local protective immune response, resulting in the release of 
sIgA, against infections originating at a mucosal surfaces [1, 2]. However, only few 
vaccines currently approved for human use are administered mucosally, most of which 
are live-attenuated ones. Mucosal vaccines, comprising soluble protein antigens, in 
general yielded rather disappointing results. Many factors have been described causing 
this problem [2] and different strategies have been applied to meet this challenge [2, 3]. 
One such strategy is the development of polymeric nanoparticulate delivery systems. In 
general, these systems are thought to promote entrapment and retention of antigens in 
local lymph nodes [4]. On the other hand, they might protect the antigens from the 
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adverse environment in the presence of hydrolytic enzymes or low pH at the 
gastrointestinal mucosal surface.  
In a recent publication we have described the development and the 
characterization of a new nanosized delivery system, consisting of chitosan 
nanoparticles with ovalbumin adsorbed at the surface and coated with sodium alginate 
[5]. These particles were designed for crossing mucosal barriers and releasing the 
antigen into lymphoid tissue, in particular in the ileal Peyer’s patches. In the present 
manuscript, successive studies related to this new delivery system are presented. 
One of the objectives of the present study was to assess the model vaccine 
release profiles from coated nanoparticles in order to examine the nature of the 
interactions between the chitosan core and the alginate coating. Furthermore, these 
studies were performed to obtain information about the in vivo antigen released from the 
particles.  
The second objective was to evaluate the potential of these coated particles for 
being taken up by Peyer’s patches. Mucosal uptake of microparticulates has been a 
matter of several reviews [6, 7]. Particularly, a number of studies, not only in rodent 
animal models [8, 9] but also in porcine gut [10] showed the uptake of chitosan 
nanoparticles by Peyer’s patches [8, 9] or by gut villous cells [10]. Likewise, studies 
using in vitro cell culture models demonstrated the uptake of chitosan nanoparticles by a 
number of different cell lines [9, 11-15] and it was emphasised that the polycationic, 
mucoadhesive chitosan nanoparticles revealed a stronger association with mucus-
secreting cells MTX-E12 than with Caco-2 cell monolayers [9]. An intense electrostatic 
interaction between positively charged chitosan nanoparticles and negatively charged 
mucins is regarded as the cause for the strong interaction of chitosan with mucus [9, 16]. 
In one of our own recent studies the coating of the chitosan nanoparticles with sodium 
alginate has inverted the surface charge of the particles from positive to negative values 
[5], however, the hydrophilicity of these mucoadhesive [17] nanoparticles remained 
unaltered. The present coated nanoparticles presumably have the same surface 
properties as alginate nanoparticles and recent studies [18-20] have shown that alginate 
particles, despite of their negative surface charge, are also able to be taken up by 
Peyer’s patches. Thus, we examined the internalization of these coated particles by 
Peyer’s patches. 
Finally, the third objective was to evaluate the cytotoxicity of the coated and 
uncoated nanoparticles in comparison to the polymers used to prepare these particles. 
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The in vitro evaluation of the cytotoxicity of chitosan has been performed in a number of 
previous studies [11, 21-24] with different cell lines and its low cytotoxicity has already 
been demonstrated. However, different results were found in the literature, which may 
possibly be related to the presence of impurities on the different sources of bulk polymer. 
On the other hand, the differences observed can also be associated with the 
concentration of the polymer in the cell culture or to different incubation times of the 
polymer with the cells or finally to the cell line used. For instance for A549 cells, a cell 
viability near 100% (MTT assay) was demonstrated [11] with concentrations lower than 
0.74 mg/ml, and a mean IC50 value of 1.1 mg/ml and 1.2 mg/ml for chitosan and chitosan 
nanoparticles, respectively. With Calu-3 cells a concentration of 1.5% of chitosan in 
culture medium decreased the cell viability to 30% [23]. Similarly, sodium alginate has 
been widely used because of its biodegradability, biocompatibility [25] and low toxicity 
[26]. Examples of its utilization include the immobilization of living cells [27] and the 
production of antigen delivery systems [28].  
The MTT assay is considered an easy and rapid test for the evaluation of 
cytotoxicity and was used in this work to assess the cytotoxicity of the polymers, chitosan 
or sodium alginate and the alginate coated or uncoated chitosan nanoparticles in mice 
spleen cells.  
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
3.2.1.1 Polymers 
Chitosan (ChitoClearTM) was purchased from Primex BioChemicals AS (Avaldsnes, 
Norway). According to the provider’s specifications, the degree of deacetylation was 95% 
(titration method) and the viscosity was 8 cP (measured in 1% solutions in 1% acetic 
acid). Sodium alginate (MANUCOL LB) was kindly donated by ISP Technologies Inc. 
(Surrey, UK).  
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3.2.1.2 Reagents 
Ovalbumin (grade V; minimum 98%), [3-(4,5-dimethylthiazol-2-yl)] 2,5-diphenyl 
tetrazolium bromide (MTT), trypan blue and concanavalin A (con A) were purchased 
from Sigma Chemicals (St. Louis, USA), certified fetal bovine serum (fbs), L-glutamine 
(200 mM) and gentamicin were from Gibco (Invitrogen Co, Paisley, Scotland, UK), 1M 
HEPES buffer (0.85% NaCl) and RPMI 1640 without L-glutamine were from Biowhitaker 
(Cambrex Bio Science, Verviers, Belgium), ovalbumin fluorescein conjugate (3.9 moles 
dye/mole protein) and BODIPY® 665/676 from Molecular Probes (Leiden, The 
Netherlands). All other reagents used were of analytical grade. All solutions were 
prepared in Millipore water. 
3.2.2 Preparation of alginate coated chitosan nanoparticles  
Alginate coated chitosan nanoparticles were prepared by the method described 
previously [5]. Chitosan was dissolved at a concentration of 0.25% (w/v) in an acetic acid 
solution and the formation of the particles was achieved after the addition of 3.5 ml of 
sodium sulfate solution (10% w/v) to 200 ml of the chitosan solution. The resultant 
suspension of particles was centrifuged for 30 minutes at 3500 rpm (2800 x g) and the 
supernatant was discarded. The particles were suspended in Millipore water and 
centrifuged twice more and then were frozen in liquid nitrogen and freeze-dried overnight 
using a Christ freeze-dryer (Osterode am Harz, Germany). The dry powder was kept 
frozen until further use. 
The loading with ovalbumin was performed by incubating a solution of ovalbumin 
with a suspension of chitosan particles at pH 7.4 (phosphate buffer) under mild agitation 
at room temperature during 120 minutes. The resulting suspension of 0.25% (w/v) 
ovalbumin and 0.4% (w/v) nanoparticles was used in successive release studies as 
uncoated loaded nanoparticles and was used in the subsequent coating step. Alginate 
coated nanoparticles were obtained by mixing of equal volumes of nanoparticles 
suspension and a buffer phosphate solution of sodium alginate (1% w/v) under magnetic 
stirring. The agitation was maintained during a 20 minute period. The suspension was 
then centrifuged for 10 minutes at 1600 rpm and the supernatant was discarded. The 
particles were re-suspended in 0.524 mM CaCl2 in 50 mM HEPES buffer solution and 
kept under agitation for another 10 minutes. 
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3.2.3  In vitro release studies 
Ovalbumin release from the coated and uncoated particles was performed by incubation 
in several buffers: 8 mM phosphate buffer pH 7.4, 100 mM phosphate buffer pH 5.5, 5 
mM HEPES buffer pH 7.4, simulated intestinal fluid (SIF) and in simulated gastric fluid 
(SGF), as described in USP XXIV. The nanoparticle suspensions were added (1:4) to 
individual tubes containing the release medium previously equilibrated at 37ºC and 
placed in a shaker bath adjusted to 50 rpm. At appropriate time intervals, samples were 
taken from each tube and filtered through a low protein-binding filter (MILLEX®GV - 0.22 
µm; Durapore PVDF membrane; MILLIPORE, Molsheim, France) followed by 
centrifugation for 20 minutes at 14,000 rpm. The concentration of ovalbumin in the 
supernatant was assayed by BCA-protein assay. Simultaneously coated and uncoated 
blank (without ovalbumin) nanoparticle suspensions were subjected to the same 
conditions and the filtered samples were used as blanks in the BCA-protein assay. For 
the determination of the total protein content in the particle suspension, 0.5 ml of the 
suspensions of the coated and uncoated particles were incubated with 1.5 ml of 0.085N 
hydrochloric acid solution (pH=1.2) in an ultrasound bath for 30 minutes, followed by 3 
hours in a water bath at 37ºC. The samples were filtered and the protein was assayed by 
BCA-protein assay. Suspensions of unloaded particles were analysed under the same 
conditions and were used as a blank for the correction of the OD value of the samples 
analyzed with BCA-protein assay. In order to calculate the amount of the ovalbumin 
encapsulated, the concentration of unbound ovalbumin in the supernatant of particle 
suspensions was also determined and subtracted from the total concentration of the 
ovalbumin in suspension. All experiments were performed at least in triplicate.  
The data of ovalbumin release from the coated nanoparticles in the phosphate 
buffers at different pH’s (5.5, 6.8 and 7.4), were analyzed according to zero-order 
kinetics, first-order kinetics, Higuchi, Korsmeyer-Peppas, Hopfenberg and Weibull as 
described in [29]. All kinetic models were fit to the release date (graph Mt/M0 versus time) 
using the SigmaPlot software (version 8.0, SPSS Inc.)  
The drug loading capacity (LC) and loading efficacy (LE) of the nanoparticles 
were calculated using the following equations: 
Eq. 1: LC (w/w) = (total amount of ovalbumin – non-bound ovalbumin)/weight of 
the nanoparticles  
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Eq. 2: LE (%) = (total amount of ovalbumin – non-bound ovalbumin)/total amount 
of ovalbumin *100 
3.2.4  Cytotoxicity studies 
3.2.4.1 Preparation of single cell suspensions of spleen cells 
Three 8-week old female BALB/c mice (Harlan Iberica, Barcelona, Spain) were sacrificed 
by cervical dislocation and their spleens were aseptically removed. Individual spleen cell 
suspensions were prepared in a Petri dish using curved needles and washed twice with 
RPMI 1640. The final suspension was adjusted to a final concentration of 1x107 cells per 
ml in complete RPMI 1640 medium (supplemented with 10% (v/v) fetal bovine serum, 
1% (v/v) glutamine, 1% (v/v) gentamicin and 2% (v/v) 1M HEPES buffer). 
3.2.4.2 Solutions of the polymers 
The 0.25% chitosan test solution was prepared with complete RPMI and the 0.25% 
sodium alginate was prepared in 50 mM HEPES buffer (pH=7.4). The solutions were 
heated and sonicated in order to completely dissolve the polymers. Immediately prior to 
incubation with the cells, the solutions were aseptically filtered 
3.2.4.3 In vitro stimulation of spleen cells with polymer solutions and nanoparticle 
suspensions and MTT assay 
Using sterile 96-well tissue culture plates (TPP, Switzerland), 25 µl of splenocyte 
suspension from three mice were plated individually, in triplicate along with 20 µl of a 
concanavalin A solution (50 µg/ml in complete RPMI solution) and 135 µl of a complete 
RPMI solution of the polymer or suspension of the nanoparticles and incubated (95% 
relative humidity, 5% CO2) for 20 h. Assayed were 138.8 µg/ml and 208.3 µg/ml of the 
polymers (chitosan and sodium alginate), respectively, and 277.6 µg/ml and 416.6 µg/ml 
of the coated and uncoated nanoparticles, respectively.  
The solvents used for the preparation of the polymer solutions (see 2.4.2) were 
also assayed as a control of the experiment. In the same way, the solutions of the 
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polymers and the suspension of the particles were assayed without cells in order to 
evaluate possible interferences of the polymers or the particles in the MTT assay. 
Cytotoxicity was evaluated by measuring the reduction of MTT by the 
mitochondrial dehydrogenase of living cells as an indication of cell viability. 18 µl of MTT 
solution (5 mg/ml in a phosphate buffered saline pH 7.4) were added to each well 
following 2.5 hours of additional incubation at 37ºC. To ensure solubilization of the 
formazan crystals, 100 µl of 0.1N isopropanol-HCl was added to each well and the 
optical density values were measured at 570 nm using a microplate reader. The relative 
cell viability (%) related to control wells containing spleen cells in culture medium without 
polymer was calculated by equation:  
Eq. 3: % cell viability = [A] test/ [A] control x 100. 
In order to analyse and compare the results for the control group with the polymer 
and nanoparticle groups, a one-way ANOVA analysis followed by Dunnett’s post test 
was performed using the GraphPad Prism 4 software. Significant differences were 
considered for p<0.05. 
3.2.4.4 Trypan blue and propidium iodide stain 
The viability of the splenocytes was also evaluated by the capability of these cells with 
uncompromised membrane integrity to exclude the dye. The in vitro stimulation of the 
cells with the polymers or the nanoparticles was done as described above in the 
absence of concanavalin A and for a period of 15 hours. Three samples of the same 
animal were mixed with the a PBS solution of trypan blue and the resultant suspensions 
(0.2% trypan blue) were visualized using a standard light microscope. Stained and 
unstained cells were counted manually using a hemocytometer. Additionally, the pooled 
culture cells from the same animal and the same formulation test were also stained with 
propidium iodide (PI)(0.25 µg/ml) and the fluorescence immediately measured with a 
fluorescence activated cell sorter (FACS Calibur) (BD, Biosciences, Madrid, Spain). Data 
were analysed by Cell Quest software (BD, Biosciences, Madrid, Spain). 
Data were presented as means ± S.E.M. for three experiments and statistical 
significance was assessed using repeated measured one-way ANOVA followed by 
Dunnett’s post test using the GraphPad Prism 4 software. Significant differences were 
considered for p<0.05. 
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3.2.5 Uptake studies in Rat Peyer’s patches 
The studies with Wistar rats (Charles River, Someren, The Netherlands) were performed 
according to the guidelines of the Ethical Committee of Leiden University. Male rats 
weighing 250-340 g were housed for acclimatization one week before the experiments 
with free access to food and water with 12h light/dark cycle. On the day before the 
experiment they were starved overnight, allowing only free access to water. 
The rats were anaesthetized by IM administration of 0.5 ml/kg of Hypnorm® 
(fentanyl citrate 0,315 mg/ml and fluanisone 10 mg/ml) and 0.5 ml/kg of Dormicum® 
(midazolam 5 mg/lm). The animals remained anaesthetized throughout the experiment 
and were placed on electrical heating mats. A small incision in the lower stomach was 
made and a teflon tube (Ø: 0.5 mm I.D. x 1.0 mm O.D.) was introduced through the 
pylorus approximately 3 to 5 cm into the duodenum. The coated particle suspensions 
loaded with FITC-ovalbumin or the 0.05% FITC-ovalbumin PBS solutions were 
administered (500 µl) and the incision was closed after the removal of the tube from the 
stomach. The rats were sacrificed after 2 hours by cervical dislocation. The whole 
intestine was removed and flushed with 20 ml of phosphate buffered saline. Between 4 
and 5 Peyer’s patches were excised from each intestine and fixed with 2% 
paraformaldehyde, rinsed again with PBS (4ºC) and the tissue was permeabilized by 
immersion in 0.1% Triton X-100 (PBS) for 20 minutes. The tissue was rinsed again and 
stained with a 0.0617% solution of BODIPY 665/676 (Pierce, Leiden, The Netherlands) 
in methanol for 60 minutes. Finally, the Peyer’s patches were mounted on glass slides 
and observed using a confocal laser scanning microscope (CLSM) (Bio-Rad, Alphen a/d 
Rijn, The Netherlands). The confocal images were obtained by scanning the tissue 
samples in the x,y plane with a z-step of 500 nm. 
Fluorescein label (FITC) coated nanoparticles were prepared according to the 
procedure described above, using a 0.05% FITC-ovalbumin solution in phosphate 
buffered saline.  
Three rats for the group control (solution of the FITC-ovalbumin) and four rats for 
the group treated with the suspension of the FITC-coated nanoparticles were included in 
this study. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Characterization of the nanoparticles 
In a recent publication [5] of our group, the development of alginate coated chitosan 
nanoparticles was described and the characterization of this new delivery system 
reported. Before coating with sodium alginate, chitosan nanoparticles had a mean 
diameter of 643 nm (dynamic light scattering technique) and were positively charged 
(+37 mV). Scanning electron microscopy (SEM) images of uncoated particles also 
revealed the presence of small nanoparticles (around 100 nm). After the coating 
process, however, SEM micrographs allowed us to verify that most of the particles were 
in a range between 300 and 600 nm. The presence of the alginate coating layer was 
confirmed by FTIR and DSC studies and by the observation of the inversion of the zeta 
potential (-34 mV) of coated nanoparticles. The loading of the nanoparticles was done by 
an adsorption process based on electrostatic interaction [30-32] between the negatively 
charged ovalbumin at pH 7.4 and the positively charged chitosan nanoparticles. The 
excellent properties of the chitosan delivery systems to adsorb at its surface proteins [33, 
34] and vaccines [30, 35], renders them a promising carrier systems. In the present 
work, the ovalbumin loading efficacy (see eq. 2) of uncoated particles prepared under 
the conditions described before was 75%, and the loading capacity (see eq. 1) was 0.49 
mg ovalbumin/mg of nanoparticles which are close to those results found in literature 
[34]. Smaller values of those quantities, of loading efficacy and loading capacity, 57% 
and 0.39 mg ovalb./mg particles respectively, were observed for the alginate coated 
particles. 
Moreover, physical degradation, including aggregation of the ovalbumin, released 
from the coated nanoparticles, was not observed as was previously demonstrated by 
SDS-PAGE [5]. This result was not a surprise because the ovalbumin loading process, 
as well as the following step, the coating of the nanoparticles with sodium alginate, were 
performed using a phosphate buffer (pH 7.4), considered as mild entrapment process, 
having no deleterious effect on the conformation of the protein [36]. 
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3.3.2 In vitro release studies 
3.3.2.1 Ovalbumin release profiles from chitosan nanoparticles 
In vitro release studies in various aqueous media were performed in order to evaluate 
the differences of ovalbumin release profiles from uncoated and coated nanoparticles 
and as an attempt to understand the physicochemical structure of these two delivery 
systems. The results are illustrated in figure 1 for the uncoated chitosan nanoparticles 
and in figure 2 for the alginate coated chitosan nanoparticles.  
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Figure 1 - In vitro release profiles of ovalbumin from uncoated chitosan nanoparticles into 
various aqueous dissolution media at 37ºC. Mean ± standard deviation, n=3 
An almost complete ovalbumin desorption from uncoated particles was observed 
immediately after the addition of the suspension of the particles to the equilibrated 
release medium at pH 1.2 (simulated gastric fluid) and pH 5.5 (100 mM buffer 
phosphate). At low pH values, chitosan nanoparticles displayed probably the highest 
positive surface charge due to the protonation of the free amine groups of chitosan. 
Additionally, ovalbumin has also predominantly positive charges below its isoelectric 
point (ovalbumin isoforms: pI between 4.8 and 5.0) [37], resulting from the protonation of 
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the amine group. The combination of these two factors can explain the immediate 
desorption of ovalbumin. Such behaviour, the burst release, also allowed us to suggest 
that ovalbumin was mostly adsorbed to the surface of the particles and not inside the 
pores.  
 
  
Alginate coated chitosan nanoparticles
  
0,0  
10,0  
20,0  
30,0  
40,0  
50,0  
60,0  
70,0  
80,0  
90,0  
100,0  
0  120  240  360  480  600  720  840  960  1080 
Time (minutes)  
  
pH=1.2  buffer phosphate pH=5.5  buffer phosphate pH=6.8  
buffer phosphate pH=7.4  hepes buffer pH=7.4   water  
 %
 
c
u
m
u
la
tiv
e
 
re
le
a
s
e
d 
Coated particles (pH=7.4)
Time (minutes)
0 50 100 150 200
M
t/M
0
0,0
0,1
0,2
0,3
0,4
0,5
0,6
Mt/M0=a*(1-exp(-b*t)
a=0.5448±0.0067
b=0.0318 ±0.0016
R2=0.9828
M
t/M
0
M
t/M
0
 
Coated particles (pH=6.8)
Time (minutes)
0 50 100 150 200
M
t/M
0
0,05
0,10
0,15
0,20
0,25
0,30
0,35
0,40
0,45
Mt/M0=a*(1-exp(-b*t)
a=0.3361±0.0106
b=0.0296 ±0.0036
R2=0.91193
M
t/M
0
M
t/M
0
 
  
Coated particles (pH=5.5)
Time (minutes)
0 50 100 150 200
M
t/M
0
0,05
0,10
0,15
0,20
0,25
0,30
0,35
0,40
0,45
Mt/M0=a*(1-exp(-b*t)
a=0.3508±0.0069
b=0.0392 ±0.0034
R2=0.94074
M
t/M
0
M
t/M
0
 
 
Figure 2 – a) In vitro release profiles of ovalbumin from alginate coated chitosan nanoparticles 
into various aqueous dissolution media at 37ºC. Mean ± standard deviation, n=3; b, c and d) 
Release-time profile (Mt/M0 versus time) from alginate coated particles up to 180 minutes with 
the first order mass balance function. Mt/M0 is the fraction of drug released under time t.  
On the other hand, when the release studies of uncoated particles were 
conducted at pH 7.4 (phosphate buffer), the initial white colour of the nanoparticle 
suspension disappeared, immediately after its addition to the release medium, 
reappearing, in a progressive way after a few seconds. This phenomenon was believed 
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to be related to the destruction of the initial structure of the nanoparticles as a 
consequence of its instability at 37º C in phosphate buffer (pH 7.4), followed by the 
formation of new nanoparticles (precipitates), indicated by turbidity [32] examined by 
transmission measurements at 500 nm (data non shown). As a consequence, in the first 
moment after the addition of the particles suspension to the release medium, an 
immediate desorption of the ovalbumin from the particles occurred, to which followed a 
progressive re-association of the protein to the recently formed particles and the 
establishment of a new adsorption equilibrium. This new equilibrium was then stable, 
under the given conditions of buffer strength and pH. This occurrence was reflected by 
the atypical release profile shown in figure 1. Similar results were observed when the 
study was repeated at 37º C with HEPES buffer (pH 7.4) (figure 1). Once the ovalbumin 
loading of the particles was conducted with the same buffer (phosphate buffer) at room 
temperature, it was assumed that the observed intermediate instability of the particles 
was probably related, not only to the pH of the release medium, but also to the 
temperature. Furthermore, the small size of the particles is also an important factor 
contributing to the instability of the delivery system and consequently to the initial fast 
release [38] of ovalbumin. This instability was also described in our own previous studies 
[5] in simulated intestinal fluid (SIF). However, this behaviour was not observed by others 
which could mean that despite of the apparently similar formulation and preparation 
procedures, a diversity of characteristics of the chitosan particles exist [33, 34, 39-43]. 
The cause of different release behaviours from chitosan nanoparticles may be related 
with its process of preparation. Recently, the importance of controlling the pH of the 
formulation during chitosan nanoparticles preparation was demonstrated [14]. Other 
parameters, such as deacetylation degree and molecular weight of the polymer also has 
an impact on the properties of the final nanoparticles [33]. Nevertheless, it should be 
emphasised that a correct procedure during the release studies must be followed, 
including the rigorous verification of the temperature of the release medium, 37ºC, before 
the start of the experiment. 
3.3.2.2 Ovalbumin release profiles from alginate coated chitosan nanoparticles 
In contrast to uncoated chitosan nanoparticles, the release profile of ovalbumin from 
nanoparticles was significantly modified after coating with sodium alginate (figure 2a). In 
a pH 7.4 (phosphate buffer) more than 40% of the ovalbumin was released within the 
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first 60 minutes and during the following 16 hours not more than an additional 25% was 
released. On the other hand, when using HEPES buffer of the same pH or plain water, 
not more than 5.8 % of the ovalbumin was released within the first 3 hours and only 4% 
of ovalbumin was released in water after 17.5 hours from the alginate-coated particles. 
The observed differences at the same pH, are believed to be related, not only to the ionic 
strength of the buffers used, but also to the composition of the buffer. The high affinity of 
phosphate ions to the calcium ions is well known. Therefore, when pH phosphate buffers 
are used, the destabilizing of calcium-crosslinked alginate matrix has to be taken into 
account. This effect may cause a faster opening or breakdown of crosslinking compared 
to the results in HEPES buffer or to plain water where this reaction does not occur. The 
loss of the calcium ions from the alginate coating, has as a consequence, the increase of 
the permeability of the coating and consequently an increased diffusion of the ovalbumin 
into the release medium. Furthermore, the highest ionic strength of the phosphate buffer, 
compared with HEPES buffer and water should have an important impact on the 
weakening of the interactions, between the chitosan core and the alginate coating. This 
dependence on the ionic strength (pH 7.4) is typical of electrostatic interaction, and 
consequently these observations reinforce our previous considerations about the 
electrostatic nature of the interactions between the alginate coating and the chitosan 
core [5] 
Finally, when the ovalbumin release study was conducted using a pH 5.5 
phosphate buffer, the differences observed when compared to the same phosphate 
buffer of pH 7.4, should be attributed to the pH of the buffer. The pH (5.5) seemed to be 
favourable to maintain strong interactions between alginate and chitosan and this was 
probably the cause for the maintenance of the entrapment of ovalbumin at an elevated 
percentage. A comparable result was observed (figure 2a) at pH 6.8 in SIF.  
As evident from what was referred before, the release of ovalbumin from the 
coated particles is actually a result of a combination of different processes which made 
the application of a kinetic model a difficult task [38]. In particular, the electrostatic 
interactions between the chitosan core and the ovalbumin should have a determinant 
role in the release mechanism and should be impeditive to observe a good fit with a 
diffusion-controlled release mechanism. In fact among several models referred, including 
the ones of Higuchi, Korsmeyer-Peppas, Hopfenberg and Weibull [29], the Mt/M0 versus 
time graph, from the release studies performed in the phosphate buffers at different pH’s 
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(5.5, 6.8 and 7.4), showed to have the best fit for the first order model (figure 2b,c,d), 
described by following equation: 
Eq. 4      Mt/M0   = a*[1- exp(-bt)] 
Where Mt/M0 is the fraction of drug released at time t. The two parameters of eq. 
4, the pre-exponential term a and the first-order constant b were estimated by this fitting 
process and their values are shown in figure 2b, c and d. The first-order model release 
mechanism has been associated with particular characteristics of the delivery system, 
they reflected to some extent a reservoir-type delivery system [44]. Moreover, it was 
suggested that the first order kinetics could describe the release profile, from the 
pharmaceutical dosage forms such as those containing water-soluble drugs (that is the 
case of ovalbumin in the present study), where drugs would be released at the rates 
proportional to the amounts of drug remaining inside the dosage form [45].  
Similar to our results, it was demonstrated in a recent study [46], that the 5-Flu 
release data, from both lipossomes and PLGA or PLA microspheres, were modelled as a 
first-order process, with excellent reproducibility of the release kinetics. 
The alginate coating of the nanoparticles not only improved the stability of the 
chitosan particles at 37ºC in 6.8 and 7.4 pH buffers, but also allowed a significant 
reduction of the ovalbumin burst release observed for the uncoated particles with the 
different buffers, with an exception at pH 1.2 (SGF). The release characteristics of the 
present nanoparticles may be altered by the increase in complexity (presence of 
surfactants, enzymes, salts) of the selected release buffer. Thus in order to obtain a 
better knowledge of the situation in vivo, more complete in vitro models would be 
required. 
3.3.3 In vitro cell viability studies 
Splenocytes have been used for the evaluation of the toxicological profiles of several 
compounds and delivery systems. For example, in a recent study, the evaluation of the 
cytotoxicity of tetanus toxoid loaded poly(lactide-co-glycolide) nanospheres was done 
with splenocytes [47]. The principal reason for the choice of spleen cells in this study, 
was related to the fact that they are obtained and cultured easier, compared to other 
lymphoid organs, like Peyer’s patches, and represent a very good and sensitive 
representative of the different cells of mucosal immune system. The spleen is a lymphoid 
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organ, bridging the innate and adaptive immune system in a uniquely organized way 
(reviewed in ref. [48]). A primary culture of mixed spleen cells normally contains (FACS 
analysis performed in our own lab) more than 50% of B lymphocytes, about 30% of T 
lymphocytes (18% CD4+; 12% CD8+) and less than 20% erythrocytes, fibroblast, 
macrophages, dendritic cells, and granulocytes. Similar to the spleen, Peyer’s patches 
also contain a large number of B cells, T cells, macrophages and dendritic cells [15]. 
Thus, a primary culture of spleen cells should have the requisites to mimic possible toxic 
effects of the nanoparticles, when the nanoparticles, internalized by Peyer’s patches, 
remain in a close contact with those immune cells during a certain period of time. 
In this study, the viability of primary culture of splenocytes in the presence of the 
polymers sodium alginate and chitosan, at two different concentrations, was evaluated 
by different methods, and in order to estimate whether the preparation process of the 
particles would introduce any cytotoxicity, uncoated and alginate coated chitosan 
particles were also studied. 
The MTT test was used to evaluate the effects of the polymers and the particles 
on the metabolic activity of mice spleen cells. No evidence of cytotoxicity was observed 
for the polymer solutions (figure 3) or the particle suspensions (figure 4) and a cell 
viability of around 100% was observed in all test groups. Moreover, the statistical 
analysis of the results underlined the higher mean values of cell viability (% of control) in 
the groups treated with higher concentrations of polymers, chitosan or alginate and with 
particles coated or uncoated (in both concentrations) when compared with the control 
group. Considering that proliferating cells are metabolically more active than non-
proliferating (resting) cells, these results can also be interpreted as the possible impact 
of polymers and particles on cell proliferation. This is probably an indication that the 
polymers may favourably influence lysosomal and mitochondrial activity of the cells [22], 
nevertheless, this observation needs to be confirmed by specific experiments. 
On the other hand, the cytotoxicity results as measured by the reduction of the 
MTT substrate could, in theory, be “masked” by cellular proliferation. Therefore, it was 
decided to conduct cytoxicity studies with a different methodology using trypan blue or 
propidium Iodide (PI) dyes for staining the cells whose membrane integrity may have 
been compromised. The results of this study are summarized in figures 5, 6 and 7.  
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Figure 3 - Viability of splenocytes measured by the reduction of MTT. The cells were incubated 
for 20 hours in the presence of two different concentrations of the polymers, chitosan and 
sodium alginate. The control group corresponds to the assay just with cells in culture medium. 
Results represent the mean ± standard error of the mean for 3 different mice, each performed in 
triplicate (n=9). Statistical differences between control group and formulations are reported as: ∗ 
p<0.05, ∗∗ p<0.01. Cell viability (% of the control) = [A] test/ [A] control x 100 
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Figure 4 – Viability of splenocytes measured by the reduction of MTT. The cells were incubated 
for 20 hours in the presence of two different concentrations of the nanoparticles, alginate coated 
chitosan particles and uncoated chitosan particles. The control group corresponds to the assay 
just with cells in culture medium. Results represent the mean ± standard error of the mean for 3 
different mice, each performed in triplicate (n=9). Statistical differences between control group 
and formulations are reported as: ∗ p<0.05, ∗∗ p<0.01. ll viability (% of the control) = [A] test/ [A] 
control x 100 
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The count of non-viable splenocytes stained with trypan blue (figure 5) in 
comparison with the non-stained cells revealed that the presence of the polymers during 
15 hours did not decrease the percentage of viable cells and are in close agreement with 
the results obtained from the MTT assay. FACS sorting and analysis (figure 6) of 
lymphocytes previously treated with PI strengthened these observations and the 
proportion of dead (M1) cells in all the samples was always lower than 3%. The 
statistical analysis of these results showed that the values obtained in each treatment 
group were not different from the control group. However, a more pronounced difference 
between the location of FL3 histograms from control groups (figure 7, left and right 
picture) and groups treated with a solution of the polymers chitosan or sodium alginate 
(figure 7, right picture) was observed. These results possibly indicate that in the 
presence of the polymers, a slight perturbation of the plasma membrane occurred and 
these lymphocytes are more permeable to the fluorescent nuclear probe, PI. 
Nevertheless, this event did not induce cell death, as was demonstrated by trypan blue 
dye exclusion and MTT assays. The present results correlate with those found in the 
literature [21] where it was demonstrated that chitosan increased the Caco-2 cell 
permeability in a reversible and dose-dependent way and was not accompanied by cell 
extrusion.  
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Figure 5 – Viability of splenocytes measured by counting trypan blue stained and unstained 
cells with a hemocytometer. The cells were incubated for 15 hours in the presence of two 
different concentrations of the polymers, chitosan and sodium alginate. The control group 
corresponds to the assay just with cells in culture medium. Results represent the mean ± 
standard error of the mean for 3 mice (n=3) and each count was the resulted of pooled samples 
from the same mice. No statistical significant differences were found between the control and 
the polymer groups.  
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Figure 6 - Flow-cytometric analysis of mice splenocytes previously incubated in the presence of 
two different concentrations of the polymers chitosan and sodium alginate during 15 hours. The 
FL3 histograms show the proportion of PI stained non-viable (M1) and viable cells from pooled 
samples of one mouse. Each histogram is representative of three animals studied individually. 
No statistical significant differences were found when the control group was compared with the 
others treatment groups.  
The combination of these three different methods adds reliability to the final 
evaluation of the cytotoxicity profiles of these polymers and nanoparticulate formulations. 
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Figure 7 - Flow-cytometric FL3 histogram overlay of control groups on left picture and control 
plus polymer treatment groups (sodium alginate and chitosan) on right picture. 
3.3.4 Uptake studies of alginate coated chitosan nanoparticles into rat Peyer’s 
patches after intra-duodenal administration. 
The uptake of alginate coated chitosan nanoparticles into the rat Peyer’s patches 
through M-cells was investigated. Chitosan particles were loaded with ovalbumin labelled 
with fluorescein as a model vaccine and then coated with sodium alginate. To better 
visualise the contour of the cells, the Peyer’s patches were stained with Bodipy, which 
is a nonpolar lipophilic dye used to stain the cell membrane. The same methodology was 
recently used successfully to visualise the uptake of N-trimethyl chitosan nanoparticles 
by nasal epithelia and NALT cells [49] or to visualize chitosan nanoparticles within 
Peyer’s patches [8]. In the present work, CLSM images of Peyer’s patches from the rats 
treated with the suspension of fluorescent coated nanoparticles, showed the presence of 
fluorescent nanoparticles (green spots) inside the Peyer’s patch (upper pictures in figure 
8). The nanoparticles were visualized, not only in the region underneath (0.5 µm) the 
follicle-associated epithelium (FAE) (right upper picture in figure 8), the subepithelial 
dome region (SED), but also in deeper regions of the secondary lymphoid organ (left 
upper picture in figure 8). Z-scan images (21 images), in successive steps (0.5 µm 
distance between steps) and starting 6 µm deep from the surface of the Peyer patches, 
also indicated that the nanoparticles were also transported to deeper regions (data not 
shown). On the contrary, the photos from the control group (lower pictures in figure 8), 
treated with a solution of ovalbumin-FITC did not show any green fluorescence except a 
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slight shade green (lower left picture) that could mean that a small amount of ovalbumin-
FITC could be absorbed by the tissue. 
 
Figure 8 - CLSM visualization of rat Peyer’s patches. Upper images belong to two different 
animals fed with FITC-ovalbumin loaded alginate coated chitosan nanoparticles. Left image was 
taken from the transversal cross section of the intestinal epithelial barrier and the right image 
was taken from the villi side of the intestinal epithelial barrier. In all the four rats fed with the 
nanoparticles similar CLSM images could be made. ower images belong to two different 
animals fed with FITC-ovalbumin in PBS solution. Right and left images were taken from the villi 
side of the intestinal epithelial barrier.  
Some of the green dots visualized in the Peyer’s patches seemed not to be 
individual particles, but agglomerates of the nanoparticles taken up into lysosomal 
compartments. Focusing of sections at high power suggested that microparticle clusters 
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were localised intracellularly (left upper picture in figure 8), an observation consistent 
with a recently published study [50] in which CLSM images were presented, showing 
clusters of polystyrene nanoparticles present in the subepithelial dome region underlying 
the Peyer’s patch. Moreover, in the same study, dendritic cells labelled by 
immunostaining were shown to efficiently phagocytose microparticles and when the 
microparticles were associated to enterotoxin adjuvants, they were transported from the 
SED region into underlying B-cell follicles and adjacent parafollicular T-cell zones. 
The SED region underlying the FAE are rich in phagocytic cells (dendritic cells 
and macrophages) [50]. Recent published studies, showed that alginate nanoparticles 
are able to be taken up not only in vivo by Peyer’s patches [18-20], but also in vitro by 
phagocytic cells [19, 51]. Following this idea, alginate coated chitosan nanoparticles 
were most likely internalized by phagocytic cells, most probably dendritic cells, present in 
Peyer patches. In future work it will be important to determine the phenotype and 
maturation state of the microparticle-loaded cells as it can be important to follow and to 
know the mechanism of phagocytic cells migration. 
As an important finding, this study, provided an answer to our initial question 
related to the capability of this new delivery system, formed by hydrophilic negatively 
charged particles, to be internalized by Peyer´s patches. In spite of the argument that 
positive or a more hydrophobic surface increases cellular uptake due to its better 
interaction with lipophilic cell membranes, this study showed that also negatively charged 
hydrophilic particles are being internalised. Moreover in a recent study [51], the increase 
of the hydrophobicity of alginate particle surface did not improve its uptake by mouse 
macrophages and consequently, cellular uptake seems to be the result of a complex 
combination of size, hydrophobicity, as well as specific interactions between surface 
functional groups of alginate microspheres and the cell membrane. 
3.4 CONCLUSIONS 
The adsorption of therapeutic proteins and model antigens onto chitosan nanoparticles 
has proven to be a very mild process resulting in a very high loading efficacy. In this 
study, it was shown that coating of this delivery system with sodium alginate yielded 
coated particles, in the nanosize range, with a much better stability and controlled 
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release properties for vaccine delivery, than the chitosan loaded cores themselves. It 
was also demonstrated that the preparation process of the nanoparticles did not 
introduce any toxic compound on the particles. On the contrary, a slight stimulation of the 
splenocytes co-cultured with the nanoparticles was observed. Finally it was shown that 
these hydrophilic coated nanoparticles even with a negative surface charge were taken 
up by rat Peyer’s patches, which made them promising carriers for mucosal vaccination. 
In vivo studies with a real vaccine are underway to investigate the efficacy of this new 
mucosal delivery system. 
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ABSTRACT 
CD69 is a very early cell activation antigen expressed on the surface of activated 
immune cells. It can appear within 1 to 2 hours of activation and exhibits maximal 
expression levels between 18 and 24 hours after stimulation. In this work, the expression 
profile of CD69 in mice splenocytes was evaluated following exposure to the 
biopolymers, chitosan or alginate and the immunostimulatory factors, CpG ODN 1826 or 
concanavalin A. We have shown that both polymers are able to upregulate expression of 
CD69 on B cells and CD4+ T-lymphocytes, with alginate as the least potent stimulus. 
Moreover the expression of the CD69 molecule on CD8+ T-lymphocytes was observed 
only in splenocytes cultured with chitosan. However, activation of lymphocytes did not 
result in cell proliferation. On the other hand, CpG ODN proved to be a potent B cell 
stimulator, as evidenced by the upregulation of CD69, but had less effect on T-cells. 
These results, together with previous discoveries reported in scientific literature, may 
contribute to the clarification of the adjuvant effect, which has been attributed to chitosan 
and alginate formulations or to the biopolymers itself. 
 
4.1 INTRODUCTION 
The combination of biomaterials with proteins, DNA, vaccines, and cells has been a 
matter of study in several groups. Two well-known examples are the development of 
polymeric carriers of vaccines and tissue engineered constructs in which cells are 
delivered with a polymer component for the renovation or replacement of damaged 
tissue or organ function. In these two examples, different potential immune responses, 
due to the possible adjuvant effect of the biomaterial would be required. Clearly, from a 
tissue engineering point of view, immune responses are to be minimized or altogether 
avoided while an adjuvant effect of the polymeric vaccine delivery system would be 
desirable and even necessary, particularly for weak antigens [1]. Among the natural 
biomaterials, chitosan and alginate have been used for both of the previously stated 
purposes. In particularly the use of alginate [2-4] and chitosan [5-8] particles as an 
antigen delivery system were used with success in a number of vaccination studies. The 
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mechanism, by which particulates showing adjuvant effect is not completely understood. 
In general, are thought that particulate delivery systems promote trapping and retention 
of antigens in local lymph nodes and protecting them from degradation, which seems to 
be important in triggering protective T cell responses [9]. However in a recent study [7], a 
soluble derivative of the chitosan was administered in solution with influenza vaccine. An 
adjuvant effect of the chitosan was observed; therefore a different mechanism in this 
case may have to be considered and investigated.  
We also have been particularly interested in the use of chitosan and alginate for 
the design of vaccine carriers. In a recent publication [10], we described the 
development of a new vaccine delivery system of alginate coated chitosan nanoparticles, 
specially designed to deliver vaccines into mucosal surfaces. This delivery system is now 
being used in mucosal vaccination studies with the recombinant hepatitis B surface 
antigen associated with the adjuvant, the CpG ODN 1826. By this reason, the study of 
the effect of the polymers, used in our group for the preparation of the nanoparticles, on 
the cells from the immune system are of extreme importance.  
Both polymers are naturally occurring polysaccharides. Chitosan, a copolymer of 
D-glucosamine and N-acetyl-D-glucosamine is a derivative of chitin, one of the most 
abundant polysaccharides in nature. Alginate is composed of alternating blocks of 1-4 
linked -L-guluronic (G) and β-D mannuronic (M) acid residues. The sources of these 
polymers as well as their physical and chemical properties have been extensively 
reviewed in several publications [11-13].  
The immunostimulatory properties, found in certain alginates, in same cases have 
been associated with the presence of impurities, like endotoxins or mitogenic 
contaminants in alginate raw materials [14-16]. In a recent work, the production of the 
proinflammatory cytokine TNF-α was approximately 100 times higher in the case of non-
biomedical grade alginate in comparison to the purified one [14]. According to the same 
authors, this feature has implications on the utilization of impure alginates, for instance 
as carriers for cell immobilization. In fact, TNF-α is considered to be a potent cytokine 
that is known to activate leukocytes, stimulate fibroblast proliferation, promote migration 
of inflammatory cells into the intercellular matrix, and trigger local secretion of other 
proinflammatory cytokines. In addition to the considerations above, a vaccine 
nanocarrier should also be made with purified alginates given that stimulation of TNF-α 
would lead to an overgrowth of collagen-secreting fibroblasts and activated 
macrophages secreting growth regulatory cytokines over the nanocarrier and may have 
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as a consequence, an alteration of the vaccine release from the nanocarrier [14]. On 
other hand a highly purified alginate, with low polyphenol and protein content, prepared 
from Laminaria pallida, was evaluated in vitro using mice lymphocytes and no evidence 
of significant mitogenic activity was observed [16]. However there are also some studies 
that showed that the mannuronic acid rich alginates, have itself immunostimulating 
properties, stimulating monocytes to cytokine production [17] in where the TLR2 and 
TLR4 seemed to be involved [18]. In a more recent study [1], the effect of biomaterials 
on dendritic cell maturation was evaluated and it was demonstrated that the expression 
levels of CD86, CD40 and HLA-DQ (MHC class II) molecules, indicative of dendritic cell 
maturation, were decreased in the presence of alginate. On the contrary, the presence of 
chitosan in the same in vitro study caused a high expression level of the same co-
stimulatory molecules.  
The expression of CD69 was never investigated in lymphocytes cultured with 
chitosan; however the activation of lymphocytes following the administration of chitosan 
has been reported in some recent publications. For instance it was shown that rats fed 
orally with a purified low molecular weight chitosan triggered the release of IL-10 as well 
as the expression of IL-4 and TGF-β mRNA at the gut mucosa local microenvironment 
and stimulated CD3+ T-lymphocytes in the spleen [19]. The presence of chitosan also 
caused the enhancement of the natural killer (NK) cell activity in intestinal intraepithelial 
lymphocytes and splenic lymphocytes [20]. Furthermore, it has been demonstrated that 
chitosan [21, 22], and chitosan microparticles [23, 24] are able to up-regulate, to some 
extent, a number of macrophage functions. For instance, a low molecular weight water 
soluble chitosan induced the activation of macrophages through the production of 
cytokines such as IFN-γ, IL-12, and IL-18 from the intestinal intraepithelial lymphocytes 
[20]. Another example found in Scientific literature based on in vitro studies, shown that 
chitosan nanoparticles (1 a 10 µm) that can be phagocytised, stimulated alveolar 
macrophages, but at a significantly lower level than that elicited by oxidative responses 
observed with phagocytized chitin [24].  In a more recent study [21], using peritoneal 
macrophages, different results among the biomaterials chitosan, low molecular weight 
chitosan (LMW), and chitin were obtained. Therefore chitosan treatment induced 
activation markers, such as the major histocompatibility complex (MHC) class I, class II, 
Fc receptors, transferrin receptor, mannose receptor, Fas, and macrophage 
inflammatory protein (MIP)-2, whereas chitin and LMW chitosan induced only the 
expression of MHC class I and II molecules. Thus, small variations in molecular weight 
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or degree of deacetylation on chitosan molecule might lead to different degrees of 
activation in cells from the immune system [25, 26]. 
The adjuvant effects of CpG ODN have been studied intensively in the last few 
years. Briefly, CpG ODN directly stimulates immune cell types that express Toll-like 
receptor 9 (TLR9), with human B cells and plasmocytoid dendritic cells (pDCs) being the 
dominant cell types expressing TLR9 [27]. Activation of these cells promotes the 
production of T helper 1 (Th1) and pro-inflammatory cytokines and the 
maturation/activation of professional antigen-presenting cells (APC) [27]. These actions 
enable CpG ODNs to act as immune adjuvants which can accelerate and boost antigen-
specific immune responses. The maintenance of close physical contact between the 
CpG and the antigen has been reported to be the ideal situation for achieving optimal 
results [28]. This can be realized by encapsulating the CpG and the antigen together in 
the same delivery system. Moreover, if the polymers used to construct the delivery 
system, for instance chitosan and alginate, have themselves immune stimulating 
properties, then the formulation, may have optimized adjuvant properties.  
Therefore, the main goal of this work was to evaluate the capacity of each 
component of our coated nanoparticles, and compare them with the adjuvant, CpGODN 
1826, in order to determine which method resulted in the optimal activation of B and T-
lymphocytes. With this purpose, the CD69 receptor, which is considered a very early cell 
activation antigen, expressed on the surface of activated immune cells, was examined 
for the first time on splenocytes cultured with the raw materials chitosan or alginate, 
which are used in the preparation of the coated nanoparticles. This cell surface antigen 
can appear within 1 to 2 hours of activation and exhibits maximal expression levels 
between 18 and 24 hours after stimulation, making it a useful tool, albeit one that has not 
been fully investigated, for early evaluation of the effect of biomaterials in the stimulation 
of immune cells.  
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4.2 MATERIALS AND METHODS 
4.2.1 Materials 
4.2.1.1 Animals 
In this study, 6 to 7 week-old male BALB/c mice were used (Harlan Iberica, Barcelona, 
Spain). Animals were housed and cared for at the animal resource facilities of the 
Faculty of Pharmacy of the University of Porto, in accordance with institutional 
guidelines. 
4.2.1.2 Polymers 
Fine grade pure chitosan was purchased from Primex BioChemicals AS (Avaldsnes, 
Norway). According to the provider’s specifications, the degree of deacetylation is 95% 
(titration method) and the viscosity is 8 cP (measured in 1% solutions in 1% acetic acid) 
that corresponds to a low molecular weight chitosan. (According to the provider’s 
specifications a chitosan with a molecular of 40 kDa and another with 60 kDa have a 
viscosity of 25 cP and 35 cP respectively).  
A low molecular weight sodium alginate (MANUCOL LB) was kindly donated by 
ISP Technologies Inc. (Surrey, UK). According to the provider’s specifications, the typical 
values for the percentage of mannuronic and guluronic acid for Manucol LB is 61% and 
39%, respectively, and an estimated molecular weight of 18 kDa.  
Both polymers meet the requisites described in the European Pharmacopoeia for 
use in pharmaceutical formulations. In this work a 22 µm filtered solutions of the 
polymers were used. 
4.2.1.3 Reagents 
Class B, CpG ODN 1826 (5’-TCC ATG ACG TTC CTG ACG TT-3’) was purchased from 
Coley Pharmaceutical Group (Ottawa, Canada), concanavalin A (Con A) was purchased 
from Sigma Chemicals (St. Louis, USA), certified fetal bovine serum (FBS) and L-
glutamine (200 mM) were purchased from Gibco (Invitrogen Co, Paisley, Scotland, UK), 
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1M HEPES buffer (0.85% NaCl), RPMI 1640 medium without L-glutamine and Pen-Strep 
(10 000 U penicillin/ml; 10 000 µg streptomycin/ml) were purchased from Biowhitaker 
(Cambrex Bio Science, Verviers, Belgium). [methyl-3H] thymidine (1.0 mCi/ml) was 
obtained from Amersham Biosciences (UK), R-Phycoerythrin (PE)-conjugated hamster 
anti-mouse CD69, fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD4 and 
FITC-conjugated rat anti-mouse CD8 were obtained from BD Biosciences (Madrid, 
Spain). The FITC-conjugated goat anti-mouse IgM (anti-µ) was purchased from 
PharMingen (San Diego, CA, USA). All others reagents used were of analytical grade. 
All solutions were prepared in Millipore water. 
4.2.2 Methods 
4.2.2.1 Preparation of spleen cell suspensions. 
Three mice were euthanized by cervical dislocation and their spleens were aseptically 
removed. Individual spleen cell suspensions were prepared in a Petri dish using curved 
needles and washed twice with RPMI 1640. The final suspension was adjusted to a final 
concentration of 1x107 cells per ml in complete RPMI 1640 medium (supplemented with 
10% (v/v) fetal bovine serum, 1% (v/v) glutamine, 1% (v/v) Pen-Strep and 2% (v/v) 1M 
HEPES buffer). 
4.2.2.2 Polymer solutions 
The 0.25% (w/v), 0.125% (v/v), and 0.01% (v/v) chitosan solutions were prepared in 
complete RPMI medium acidified with acetic acid. Sodium alginate was first dissolved in 
HEPES buffer (0.5% w/v) and then diluted in complete RPMI (0.25% (v/v), 0.125% (v/v), 
and 0.01% (v/v)). Immediately following, the polymer solutions were aseptically filtered 
and incubated with the cells. The solvents used for the preparation of the polymer 
solutions (RPMI acidified with acetic acid and HEPES) were also used as controls for the 
experiment.  
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4.2.2.3 Cell culture in the presence of the polymers and mitogens 
Using sterile 96-well flat-bottomed tissue culture plates, 25 µl of splenocyte suspension 
(1x107 cells/ ml) from three individual mice were plated in triplicate along with 25 µl of 
complete RPMI solution with the mitogen [Con A (50 µg/ml) or CpG ODN (50 µg/ml) or 
without mitogen (control)] and 25 µl of a complete RPMI solution of the polymer 
[chitosan; or sodium alginate; or without polymer (control)]. Finally the volume of the well 
was diluted to 200 µl with complete RPMI and incubated at 37ºC with 95% relative 
humidity and in the presence of 5% CO2. 
4.2.2.4 Immunofluorescence labelling 
After 20 h of incubation, cells were washed and resuspended in cold phosphate buffered 
saline (PBS) supplemented with 2% FBS, resulting in a concentration of 0.5 x 106 cells/ 
well. The cells were then incubated in the dark for 30 minutes at 4ºC with saturating 
concentrations of PE-conjugated hamster anti-mouse CD69 and FITC-conjugated rat 
anti-mouse CD4 or FITC-conjugated rat anti-mouse CD8 or FITC-conjugated goat anti-
mouse IGM (anti-µ). After incubation, cells were washed three times with PBS-FBS and 
then resuspended with 500 µl of PBS-FBS. To exclude dead cells, 2.5 µl propidium 
iodide (50 µl/ml) was added just before data acquisition. At least 10,000 events were 
analysed by flow cytometric acquisition, performed in a fluorescent activated cell sorter 
(FACS Calibur) (BD Biosciences, Madrid, Spain). Data were analysed by CellQuest 
software (BD Biosciences, Madrid, Spain). Viable lymphocytes were selected on the 
basis of FSC/SSC values. 
The concentration of the polymers studied was kept at 0.156 mg/ml. Data were 
presented as the mean ± S.E.M. for three experiments and statistical significance was 
assessed using repeated measured one-way ANOVA followed by Dunnett’s post test 
using the GraphPad Prism 4 software. Differences were considered significant when 
p<0.05.  
4.2.2.5 Lymphocytes proliferation assay 
Splenocytes were obtained and cultured in a flat-bottomed 96-well plate with and without 
the mitogens and polymers as described above. The cells were cultured for 96 hours at 
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37ºC and on the last 8 h of incubation, each well was pulsed with 1µCi of [methyl-3H] 
thymidine. 96 well plates with the cells were frozen for further analysis. The cells were 
later thawed and harvested onto a Fiberglass filter (filter mats, molecular devices, 
Skatron, Lier, Norway) using a semiautomatic cell harvester (Scatron Instruments, USA) 
and thymidine incorporation was counted by standard liquid scintillation techniques with 
a Beckman LS 6500 scintillation counter (Beckman Coulter Inc, Fullerton, USA). 
Thymidine incorporation was expressed as counts per minute (cpm).  
The concentration in the well of the polymers studied were: conc1 = 0.312 mg/ml 
and conc2 = 0.0125 mg/ml. Data were presented as a mean ± S.E.M. for the three 
experiments and statistical significance was assessed using a nonparametric ANOVA 
with Kruskal-Wallis analysis using the GraphPad Prism 4 software. Differences were 
considered significant when p<0.05. 
4.3 RESULTS 
4.3.1 Effect of alginate or chitosan polymers or the immunostimulant CpG ODN 
on the size and granularity of spleen mouse lymphocytes 
The spleen is a lymphoid organ combining the innate and adaptive immune system in a 
unique and organized way [29]. The principal reason for the choice of spleen cells in this 
study was related to the fact that they are obtained and cultured easily and that they are 
a very sensitive representative of different lymphocytes. According to FACS analysis 
performed in our own laboratory, a primary culture of mixed spleen cells normally contain 
more than 50% of B lymphocytes, more than 30% of T lymphocytes (20% CD4+; 12% 
CD8+) and of the remaining cells, less than 10% were erythrocytes, fibroblasts, 
macrophages, dendritic cells, and granulocytes.  
Lymphocytic morphological alterations, as a consequence of the engorgement of 
the rough endoplasmic reticulum, which normally accompany cell activation, can be 
observed by flow cytometry analysis, combining forward light scatter (FSC) and side light 
scatter (SSC). In general, activated cells exhibited a dramatic increase in both forward 
and side scatter.  
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As a positive control, cells from the mouse spleen were cultured with 
concanavalin A (con A), a classical lymphocyte mitogen. As was expected and shown in 
figure 1, an increase of the forward scatter counts (FSC) of the stimulated lymphocytes 
was observed, suggesting augmentation of cell size. The size change was accompanied 
by an increase in cellular granularity (SSC) in all lymphocyte subtypes (CD4+, CD8+, 
and B cells) after 20 h culture (figure 2). 
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Figure 1 - Forward scatter counts–histograms (FSC-H) of B and T lymphocytes (CD4+ and 
CD8+) from Balb/c mice spleen stimulated with alginate or chitosan or CpG ODN for 20 h. The 
filled histograms represent the group control (splenocytes without stimulation) and the open 
histograms the stimulated (treatment) group. The results are representative of two separate 
experiments using three animals per experiment and each treatment.  
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Figure 2 – Side light scatter counts–histograms (SSC-H) of B and T lymphocytes (CD4+ and 
CD8+) from Balb/c mice spleen stimulated with alginate or chitosan or CpG ODN for 20 h. The 
filled histograms represent the group control (splenocytes without stimulation) and the open 
histograms the stimulated (treatment) group. The results are representative of two separate 
experiments using three animals per experiment and each treatment.  
In contrast, the presence of CpG ODN in the splenocytes culture, subjected to the 
same conditions did not induce a size (figure 1) and granularity (figure 2) augmentation 
in CD4+ and CD8+T-cells, however, a remarkable increase of these two parameters was 
observed in B cells. These results support the hypothesis that CpG ODN is 
predominately a B lymphocyte activator. 
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In the same way, to assess the differential effect of the alginate and chitosan 
biopolymer contact on spleen cell morphology, the cells were cultured with the polymers 
for 20 hours. Preliminary results [30] have shown cell viability near 100% with 
splenocytes cultured with 0.21 mg/ml of the polymers for 15 hours. In order to obtain 
non-toxic concentrations of polymers, we decided to decrease the concentration of 
polymers in the cell culture to 0.156mg/ml because we increased the incubation time to 
20 hours.  
As shown in figures 1 and 2, both polymers caused an increase in FSC and SSC 
of B cells. Chitosan was the polymer that showed a stronger effect, particularly on cell 
granularity (SSC). Moreover, CD4+ and CD8+ T-lymphocytes treated with chitosan also 
showed a strong modification of their morphology (SSC and FSC). T-lymphocytes 
treated with alginate did not show morphological differences (SSC and FSC) when 
compared to the appropriate control (filled overlap histogram in figures 1 and 2). 
4.3.2 Evaluation of the expression of CD69 by T and B mouse spleen 
lymphocytes 
As a positive control, we used Con A to induce the expression of CD69 in B and T 
lymphocytes and the results are shown in figures 3, 4, and 5. The CD69 expression 
results in spleen lymphocytes exposed to equal concentrations of polymers, alginate or 
chitosan (0,156mg/ml), or CpG ODN (6 µg/ml) are also shown in figures 3, 4, and 5. The 
percentage of CD4+ T-lymphocytes that naturally express CD69 is very low (3%). The 
addition of alginate to cell cultures result in a four fold increase (13%) of CD69+ T-
lymphocytes (figure 3). A similar result (18%) was obtained with CpG ODN 1826, which 
correlates well with the above results of size and granularity. In contrast, CD4+ T-
lymphocytes responded with elevated CD69 expression levels to the presence of 
chitosan (90%), similar to those observed with the positive control (Con A). The same 
robust effect of chitosan was also observed in CD8+ T lymphocytes (85%) (figure 4), 
contrasting with alginate, which has been shown not to induce CD69 expression on 
CD8+ cells. Therefore, these results are again, more closely related to the granularity 
and size results shown above. Following CpG ODN 1826 stimulation, we observed about 
50% of CD8+ T-lymphocytes that upregulated CD69; however there was considerable 
variation in expression (figure 4). 
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Figure 3 – Effect of the different compounds on the expression of the CD69 receptor on CD4+ 
splenocytes. The compounds used were the immunostimulators, CpGODN and Con A and the 
biopolymers chitosan and alginate. A combination between the biopolymers and the 
immunostimulators were also used. The filled histograms represent the group control 
(untreated) and the open histograms the stimulated (pretreated) group. The results are 
representative of two separate experiments using three animals per experiment and each 
treatment. The right picture corresponds to the entire data of one experiment. Similar 
histograms were obtained with the second experiment. The values are mean ± SEM of the 
percentage of the positive CD4 cells that express the CD69 antigen, obtained from three 
different mice.* p<0.01 
The effect of CpG ODN or the polymers chitosan or alginate on B lymphocyte 
CD69 activation was also studied. The results presented in figure 5 show a strong effect 
of all the assayed biopolymers, with alginate showing the smallest effect (about 40%) 
and chitosan the strongest effect (85%). More than 95% of the B cells expressed the 
CD69 antigen when cultured with CpG ODN, which is in close agreement with a recent 
published study [31]. This study was done with two sets of ODN with similar base 
compositions and it was demonstrated that ODN 1826 is a strong stimulator driving B 
cells to express CD69 in a dose-dependent fashion. Considering that our results were 
obtained with lower concentrations of the ODN’s and shorter culture times, these results 
may reflect saturation of the CD69 expression on B cells.  
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Figure 4 – Effect of the different compounds on the expression of the CD69 receptor on CD8+ 
splenocytes. The compounds experienced were the immunostimulators, CpGODN and Con A 
and the biopolymers chitosan and alginate. A combination of the biopolymers and the 
immunostimulators were also used. The filled histograms represent the group control 
(untreated) and the open histograms the stimulated (pretreated) group. The results are 
representative of two separate experiments using three animals per experiment and each 
treatment. The right picture corresponds to the entire data of one experiment and similar 
histograms were obtained with the second experiment. The values are mean ± SEM of the 
percentage of the positive CD8 cells that express the CD69 antigen, obtained from three 
different mice.*p<0.05; **p<0.01 
To examine possible synergistic effects using a combination of the polymers 
chitosan or alginate and the immunostimulator, CpG ODN 1826, the cells were incubated 
in the presence of both, CpG and polymers (chitosan or alginate). Chitosan, surprisingly, 
showed to be a strong CD69 expression inducer for both B and T-lymphocytes, such that 
CD69 expression could not further be upregulated by CpG. However, a statistically 
significant difference was observed for the CD8+ T-lymphocyte subpopulation incubated 
only with chitosan or only with the positive control, Con A. With respect to alginate (figure 
3 and 4), the results clearly showed that a synergy with CpG does not occur in T-
lymphocyte populations. Furthermore, the presence of alginate in the lymphocyte culture 
together with CpG dowregulated the expression of CD69 antigen on CD8+ lymphocytes 
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(figure 4) when compared to the cells incubated only with CpG. Potentially, as a result of 
the saturation of B-lymphocyte CD69 expression induced by CpG, the additional 
presence of alginate in cell culture did not produce any statistically significant results 
(figure 5). 
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Figure 5 – Effect of the different compounds on the expression of the CD69 receptor on B cells. 
The compounds used were the immunostimulators, CpGODN and Con A and the biopolymers 
chitosan and alginate. Experiments with the combination between the biopolymers and the 
immunostimulators were also performed. The filled histograms represent the group control 
(untreated) and the open histograms the stimulated (pretreated) group. The results are 
representative of two separate experiments using three animals per experiment and each 
treatment. The right picture corresponds to the entire data of one experiment and similar 
histograms were obtained with the second experiment. The values are mean ± SEM of the 
percentage of the positive B cells that express the CD69 antigen, obtained from three different 
mice.*p<0.05; **p<0.01 
4.3.3 Study of the effect of chitosan and alginate polymers on Lymphocyte 
proliferation 
To study whether the polymers, chitosan or alginate, or the CpG ODN have a 
proliferative effect on lymphocytes and whether CpG activates the lymphocytes in 
Chapter 4 
           
- 103 - 
synergy with the polymers, mouse spleen lymphocytes were cultured in the presence of 
the polymers during 96 hours. Cells from the spleen are normally resting cells and, when 
cultured in the absence of a mitogen, do not proliferate (figure 6c). In the presence of a 
mitogen, Con A, the activated cells exhibited the highest values of [3H] thymidine uptake. 
These values are used as the intended positive control (figure 6a). On the other hand, as 
shown in figure 6, while CpG ODN 1826 alone at concentrations of at least 6 µg/ ml 
stimulated splenocytes to proliferate, chitosan and alginate showed no significant 
stimulation in both concentrations used. However, with higher concentrations of alginate, 
a large variability of the results was observed (figure 6c).  
The concomitant presence of the polymers chitosan or alginate and the CpG or 
the Con A in the cell culture did not lead to an increase of [3H] thymidine uptake by the 
cells (figure 6a and b). These results may possibly indicate that no synergy between 
CpG or Con A and each of polymers occurred.  
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Figure 6 - [3H] Thymidine incorporation, expressed in cpm (counts per minute), by the 
proliferating splenocytes cultured with different compounds for 96 hours. The compounds 
experienced were the immunostimulators, CpGODN and Con A and two concentrations of the 
polymers chitosan and alginate. Conc. 1= 0.312 mg/ml and conc. 2= 0.0125 mg/ml. 
Experiments with the combinations between the biopolymers and the immunostimulators were 
also performed. Each bar is the mean ± SEM from three spleen mice cultured in triplicate (n=9). 
Similar histograms were obtained with the second experiment.  
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4.4 DISCUSSION  
Stimulation of lymphocytes leads to upregulation of various cell surface markers at 
various stages of cellular activation: CD69 (very early), CD71 (early), CD25 (late), and 
HLA-Dr (very late) [32]. Lymphocytes have little basal expression of CD69, but following 
activation, CD69 is rapidly expressed (2-3h) in all bone marrow-derived cells except 
erythrocytes, as reviewed in [33, 34]. The precise role of CD69 in immunity has not been 
elucidated owing to the absence of a known ligand and adequate in vivo models to study 
its physiological function [34]. It was recently suggested that a transient activation-
induced CD69 surface expression may be important for regulating T cell trafficking [35]. 
Moreover, CD69 might affect the immune response during T-cell differentiation, involving 
immunoregulatory cytokines that include, but might not be limited to, TGF-β, which 
controls T-cell differentiation. Recent in vivo results indicate that this receptor acts as a 
regulatory molecule, modulating the inflammatory response [34]. Based on several 
studies, it was reported [36] that CD69 functions as a signal-generating receptor, 
possibly regulating the activity of the transcription factor AP-1 and IL-2 gene expression 
through both AP-1 and NF-AT complexes. The results presented by [36] also suggested 
that CD69 participates in a variety of processes within the overall activation cascade.  
Therefore, in vitro manipulation of early activation marker CD69 is an approach 
used in many laboratories to explore potential pathways of cellular activation and can be 
used to measure the immunomodulatory effects of pharmaceutical agents and vaccine 
antigens [32].  
Synthetic oligodeoxynucleotides (CpG ODNs) and bacterial DNA containing 
unmethylated CpG dinucleotides in the context of particular base sequences (CpG 
motifs) are known to mediate several immune responses. In the present study it was 
shown that CpG ODN 1826 is a potent in vitro CD69 stimulator. Its presence in a culture 
of mice splenocytes was shown to increase the size and granularity of B lymphocytes, 
which was accompanied by a strong expression of the CD69 receptor. Furthermore, a 
mild but statistically significant increase of the expression of CD69 in T-lymphocytes was 
also observed and was accompanied by high lymphocyte proliferation. These 
conclusions, however, can not be generalized to include other CpG ODN, even if the 
concept of the immunostimulatory CpG motif has become widely accepted. Recently, it 
was demonstrated that not all DNA/ODN containing CpG motifs were equally stimulatory 
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[31] and CpG 1982 showed itself to be weaker than CpG 1826 in promoting cell 
activation. CpG ODN 1826 at concentrations of at least 0.3 µg/ml stimulated Ig-Tg B 
cells to proliferate and drove the same cells to express CD69 in a dose dependent 
fashion [31]. Related to T-cell CD69 activation caused by CpG, the data are relatively 
scarce and in a recent publication [37], using human T cells, the addition of CpG ODN 
2006 to peripheral blood mononuclear cells (PBMC) had only a small variable effect on 
the CD69 expression by CD4+ or CD8+ T cells. In contrast, the same CpG ODN 
sequence specifically caused increased expression of CD69 on CD4+ and CD8+ T cells 
when PBMC were stimulated via α-CD3 [37]. The study of possible synergistic effects 
between the CpG and other compounds, which could possibly explain some unexpected 
in vivo results, like broadening of the spectrum of CpG that primarily stimulate B cells 
with potential implications for the initiation and regulation of normal and pathologic 
immune responses, is an important aspect for a better understanding of the mechanisms 
involved [31]. Following this idea, the present study failed to show any synergistic effects 
between CpG and the polymers chitosan and alginate, respectively, in stimulating 
lymphocytes to proliferate or to express CD69 antigen. On the other hand, an 
unexpected result, to our knowledge described for the first time, was obtained with the 
polymers alone. The polymers proved to be potent CD69 activators, not only for B cells 
but in case of chitosan, also for T-cells. 
In fact, concluding from comparable studies described in the literature with other 
compounds [36], it is not known whether the expression was stress-induced or rather 
activation-induced because the observed CD69 expression was not followed by 
lymphocyte proliferation. On the other hand, it is not known whether CD69 activation is 
always linked with T-lymphocyte proliferation and incomplete activation might be 
indicative of anergy [34]. Recently we have reported [30] an increase in cell permeability 
for propidium iodide, observed in lymphocytes treated with polymers chitosan and 
alginate, and in the present study the same effect was confirmed (data not shown). 
Moreover, in an in vitro study, chitosan was indicated as the cause of a slightly reversible 
plasma membrane perturbation in Caco-2 cell monolayers [38]. This feature is most 
likely an indication of cellular stress. Nonetheless, chitosan and alginate, in the 
concentrations studied, did not show a suppressive effect on the lymphocyte 
proliferation, induced by the mitogens, Con A or CpG nor had any cytotoxic effects on 
the cells. These observations are important and point out that the presence of these 
polymers, for instance in an antigen nanocarrier delivery system, might not be able to 
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induce a suppressive lymphocyte proliferative effect, when internalized by a lymphoid 
organ. On the contrary, and giving as example a recent study [39], where it was shown 
that chitosan based formulation administered intraperitoneally, together with a weak 
antigen, elicited antibody responses that were 100 times higher than those observed for 
the antigen in the absence of the adjuvant. 
The second biopolymer in the present work investigated was a low molecular 
weight alginate, appropriate for pharmaceutical applications, like tissue engineering and 
vaccine delivery. Unexpectedly, lymphocytes upregulated CD69 expression when the 
immune cells were maintained in contact with the polymer. Similar to chitosan, our 
results showed for the first time that alginate can upregulate CD69 expression on B cells 
and to a lesser extent on CD4+ T cells and had no effect on CD8+ T lymphocytes. 
Moreover, alginate did not stimulate lymphocytes to proliferate, which is in accordance 
with other studies found in literature, and the highest individual variability observed has 
been attributed to their possible content in polyphenolic-like compounds [14].  
In the present study, chitosan and alginate were shown to activate lymphocytes 
and induce expression of the CD69, being the chitosan the one that showed the 
strongest effect. This feature together with the immune properties mentioned above in 
the introduction section, led us to hypothesize that the adjuvant properties, suggested 
several times for both polymers, could not only be related to their capacity for transport 
and delivery of the antigen to the lymphoid tissues, but perhaps may be related to their 
capacity to stimulate immune cells to initiate or simply amplify an immune response 
specific to the antigen.  
4.5 CONCLUSIONS 
In this study lymphocytes underwent strong activation and rapid CD69 upregulation upon 
contact with the biopolymers chitosan or alginate. More controlled studies are needed to 
understand this activation mechanism and the possible consequences for the initiation of 
an immune response. Moreover, as these are in vitro studies employing mice spleen 
cells it remains unknown whether the same effects would be observed with human cells 
or other peripheral lymphoid organs, such as Peyer’s patches, following in vivo oral 
administration. 
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ABSTRACT 
The purpose of this work was to assess the ability of recombinant hepatitis B vaccine, 
encapsulated in alginate coated chitosan nanoparticles, to induce local and systemic 
immune responses following oral vaccination. The antigen was administered either alone 
or in combination with the synthetic oligodeoxynucleotide containing immunostimulatory 
CpG motif (CpG ODN) as adjuvant, associated or not with the alginate coated chitosan 
nanoparticles. After two immunizations only the group I (HBsAg associated with 
nanoparticles) and the group VI (HBsAg and CpG, both associated with nanoparticles) 
induced an immune response. Both groups showed significant higher values of the CD69 
expression in CD4+ and CD8+ T-lymphocytes and lower values of this marker in B 
lymphocytes. Moreover, the strongest proliferative response of the splenocytes, ex vivo 
stimulated with concanavalin A, was observed in the same groups. Once more, only 
mice of the groups I and VI elicit the generation of anti-HBsAg antibodies. Both IgA 
obtained from intestine washings and IgG from serum, (with IgG2a being the 
predominant isotype in the case of group VI), corresponded to a humoral Th1 profile of 
response. These data demonstrate some potential of the coated chitosan nanoparticles 
for their use as a carrier adjuvant for oral vaccination with the recombinant hepatitis B 
surface antigen. 
5.1 INTRODUCTION 
According to a report of the World Health Organization (WHO/UNICEF, 2005) [1], the 
estimated number of deaths in the world in all age groups from diseases preventable by 
vaccines in 2002 was 2.1 million, 600 000 deaths being due to hepatitis B. The global 
coverage of infants with three doses of hepatitis B vaccine in 2004 was 48%, contrasting 
with 3% in 1992 [1]. In the last few years, the majority of industrialized countries have 
introduced hepatitis B vaccination campaigns. Therefore, the above statistics of deaths 
due hepatitis B are representative predominantly for developing countries, where mass 
vaccination has not been implemented yet (18% of the 192 WHO member states). Its 
implementation is highly dependent on the development of more stable and cheaper 
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vaccines for which the intervention of specialised human resources for the administration 
would not be required.  
Oral administration has been appointed as the only economically feasible 
approach to mass vaccination. Impressive logistical advantages of orally administered 
vaccines were exemplified by two national vaccination days in 1996, when 121 million 
Indian children were vaccinated against polio at 650,000 centres [2]. However, it has 
been shown that is very difficult to obtain a protective immune response following oral 
vaccination, the live-attenuated polio vaccines are being one of the few exceptions [3]. 
For this reason, only few vaccines currently approved for human use are being 
administered orally. 
Unfortunately, a simple oral formulation is not easily achieved for the new 
generation of subunit vaccines, which hold the greatest promise for disease prevention in 
the 21st century [4]. Several explanations have been appointed to justify the 
disappointing results found for oral administration of subunit vaccines, being almost 
exclusively biotechnological products. One of the most important reasons is related with 
the adverse environment of the gastrointestinal tract (GIT), rich in acids and enzymes, 
which are able to destroy the antigen. Equally important is the mechanism of oral 
tolerance, the vital physiological role for dietary antigens in preventing hypersensitivity 
reactions to food or to commensal bacteria [5, 6]. This hyporesponsivity to antigens 
orally administered is not yet fully understood, but it is thought that the mucosal immune 
system has involved a variety of mechanisms to achieve and maintain tolerance against 
self-antigens and against the overabundance of environmental antigens present in the 
microflora and food. Among them, activation-induced cell death, anergy and especially 
the induction of regulatory T cells are frequently reported in the literature [3]. In a recent 
study [7] the induction of oral tolerance to hepatitis B virus proteins was achieved by the 
administration of five low oral doses of hepatitis B virus proteins, followed by two 
inoculations with a commercial vaccine. 
In the case of the development of an oral hepatitis B vaccine, this mechanism has 
to be circumvented and the antigen must be protected from physical degradation and 
enzymatic digestion [3]. For this purpose, several strategies have been described in 
literature. Those approaches include the encapsulation of immunogenic peptide 
representing residues 127-145 of the immunodominant B-cell epitope of hepatitis B 
surface antigen (HBsAg) in poly(D,L-lactide co-glycolide) [8]. Another strategies are the 
encapsulation of the plasmid DNA encoding hepatitis B virus protein in poly(DL-lactide-
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co-glycolic acid) (PLGA) [9] or in Salmonella typhimurium [10-13] or the genetic 
modification of edible plants for the production and delivery of the hepatitis B vaccine, 
within e.g. potato tubers [4, 14], cherry tomatillo [13] and lettuce [15, 16]. A very recent 
clinical study [4] with previously vaccinated volunteers showed that the ingestion of 
doses of 100 g of uncooked potato tubes (8.5 µg/g) induced the increase of the serum 
anti-HBsAg titers in about 60% of the volunteers, who ate three doses of the potatoes. 
Approximately 40% of the volunteers were non-responders to the HBsAg. The necessity 
of finding a good mucosal adjuvant in order to elicit an increase of the number of 
responders was emphasised by the authors of this study [4]. 
Chitosan, a copolymer of D-glucosamine and N-acetyl-D-glucosamine is a 
derivative of chitin, one of the polysaccharides most abundant in nature. In the last few 
years, the properties of this biodegradable biopolymer have been intensively 
investigated. In particular, its ability to stimulate cells from the immune system has been 
shown in several studies. For instance, the presence of chitosan in a dendritic cell 
culture induced the expression levels of the co-stimulatory molecules CD86, CD40 and 
HLA-DQ [17], indicative of dendritic cell maturation. Likewise, chitosan has also shown to 
be able to up-regulate, in some extent, a number of macrophage functions [18, 19].  
The polymer has also been used in the nanoparticle formulation for loading and 
delivering different vaccines, like meningococcal C conjugate [20], diphtheria [21] and 
tetanus toxoid [22, 23] or used without any modification, suspending the bulk powder in a 
solution of the meningococcal C conjugate vaccine [24] or using a soluble chitosan 
derivative with the influenza vaccine [25, 26] or finally using chitosan to surface-modified 
PLGA microspheres containing hepatitis B vaccine for intranasal immunization [27]. 
In a previous study, we have formulated and characterised alginate coated 
chitosan nanoparticles [28]. They consist of a chitosan core (chitosan nanoparticles) to 
which the hepatitis B vaccine was adsorbed and in a second step, the sodium alginate. 
The alginate coating is afterwards cross linked with calcium ions. This delivery system 
has the particular advantage of being constructed under very mild conditions, which is a 
great benefit for the encapsulation of proteins, peptides and antigens. Moreover, in a 
very recent publication [29] we have demonstrated that these coated nanoparticles were 
able to be taken up by rat Peyer’s patches which is one of the essential features to 
internalise, deliver and target the intact antigen to specialised immune cells from the 
GALT (gut associated lymphoid tissue) [30]. This property makes these new 
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nanoparticles a promising delivery system especially for oral vaccination in combination 
with a suitable potent adjuvant.  
In the present study the feasibility of using the recombinant surface hepatitis B 
protein (HBsAg) encapsulated into the above mentioned alginate coated chitosan 
nanoparticles for the induction of local and systemic immune responses after oral 
vaccination was evaluated. Moreover, to improve the immune response, synthetic 
oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG ODN), were also 
incorporated into the delivery system. CpG ODN acts as a potent adjuvant and has 
shown in a number of studies to induce a Th1 type immune response, not only when 
administered parenterally [31, 32] but also for mucosal vaccination [33-35].  
5.2 MATERIAL AND METHODS 
5.2.1 Materials 
5.2.1.1  Polymers 
Ultra pure chitosan was purchased from Primex BioChemicals AS (Avaldsnes, Norway). 
According to the provider’s specifications, the degree of deacetylation is 95% (titration 
method) and the viscosity is 8 cP (measured in 1% solutions in 1% acetic acid). A low 
molecular weight pharmaceutical grade sodium alginate (MANUCOL LB) was kindly 
donated by ISP Technologies Inc. (Surrey, UK). According to the provider’s 
specifications, the typical values for the percentage of mannuronic and guluronic acid for 
Manucol LB are 61% and 39%, respectively, with an estimated molecular weight of 18 
kDa . 
5.2.1.2 Antigen, adjuvant and reagents 
The hepatitis B surface antigen (HBsAg), (subtype ADW2) was kindly offered by GSK 
Biologicals (Rixensart, Belgium). Class B, CpG ODN (1826) (5’-TCC ATG ACG TTC 
CTG ACG TT-3’) was purchased from Coley Pharmaceutical Group (Ottawa, Canada).  
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Concanavalin A (Con A), phenylmethanesulfonyl fluoride (PMSF), avidin 
peroxidise conjugate and the BCIP/NBT- purple liquid substrate system for membrane 
were from Sigma Chemicals (St. Louis, USA). Certified fetal bovine serum (FBS) and L-
glutamine (200 mM) were from Gibco (Invitrogen Co, Paisley, Scotland, UK), 1M HEPES 
buffer (0.85% NaCl), RPMI 1640 without L-glutamine and Pen-Strep (10 000 U 
penicillin/ml; 10 000 µg streptomycin/ml) were from Biowhitaker (Cambrex Bio Science, 
Verviers, Belgium). [methyl-3H] thymidine (1.0 mCi/ml) was obtained from Amersham 
Biosciences (UK), R-Phycoerythrin (PE)-conjugated hamster anti-mouse CD69, 
fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD4 and FITC-conjugated 
rat anti-mouse CD8 were obtained from BD Biosciences (Madrid, Spain). The FITC-
conjugated goat anti-mouse IgM (anti-µ), the anti-mouse IFN-γ and biotin rat anti-mouse 
IFN-γ  was purchased from PharMingen (San Diego, CA, USA). The mouse IgA ELISA 
quantitation kit was obtained from Bethyl Laboratories, (Montgomery, USA). All others 
reagents used were analytic grade. All solutions were prepared in ultrapure water. 
5.2.2 Methods 
5.2.2.1 Preparation of the coated nanoparticles 
The preparation of the alginate coated chitosan nanoparticles was performed according 
to the method previously described by us [28]. In brief, chitosan was dissolved at a 
concentration of 0.25% (w/v) in diluted acetic acid solution. The formation of the particles 
was achieved after the addition of 3.5 ml of sodium sulfate solution (10% w/v) to 200 ml 
of the chitosan solution. The resulting suspension was centrifuged for 30 minutes at 
3500 rpm (2800 x g) and the supernatant was discarded. The particles were re-
suspended in Millipore water and centrifuged twice. Finally they were frozen in liquid 
nitrogen and freeze-dried overnight using a Labconco freeze dry system (Labconco 
Corporation, Kansas, USA). The dry powder was kept frozen until further use. 
The loading of the nanoparticles with HBsAg or with CpG ODN was performed by 
incubating a solution of HBsAg or the solution of CpG with a suspension of chitosan 
particles at pH 7.4 (phosphate buffer) under mild agitation at room temperature during 
120 minutes. The resulting suspensions with the composition of 0.015% (w/v) HBsAg 
and 0.5% (w/v) nanoparticles and the second with 0.015% (w/v) CpG and 0.5% (w/v) 
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nanoparticles were used in the subsequent coating step. Alginate coated nanoparticles 
were obtained by mixing equal volumes of nanoparticles suspension and a buffer 
phosphate solution of sodium alginate (1% w/v) under magnetic stirring. The agitation 
was maintained for 20 min. The suspension was then centrifuged for 10 min at 1600 rpm 
and the supernatant was discarded. The particles were re-suspended in 0.524 mM CaCl2 
in 50 mM HEPES buffer solution, kept under agitation for another 10 minutes and 
immediately administered to the mice. 
5.2.2.2 Evaluation of the loading efficacy of HBsAg and CpG ODN in coated 
nanoparticles. 
The loading efficacy of the coated particles was calculated by an indirect way, 
quantifying the antigen that remained in solution as described before [29]. After the 
coating with alginate, an aliquot of the particle suspension was centrifuged at 14,000 rpm 
for 15 minutes and the protein in supernatant was quantified by micro-BCA-protein assay 
(PIERCE, Rockford, USA) using a microplate reader with a 570 nm filter.  
For the CpGODN the same procedure was followed and the 
oligodeoxynucleotides was quantified, measuring the OD of the supernatants at 260 nm. 
To eliminate background interference, the supernatant of unloaded particles were treated 
the same way. The results refer to the nanoparticle batches used in the vaccination 
studies (4 batches for each immunization). 
The loading efficacy (LE) and the loading capacity (LC) were calculated from the 
following equations: 
 
Eq. 1 - LE (%) = (Total amount of HBsAg or CpG – free HBsAg or CpG)/Total 
amount of HBsAg or CpG*100 
 
Eq.2 - LC (µg of HBsAg or CpG/mg chitosan nanoparticles dry weight) = (Total 
amount of HBsAg or CpG– free HBsAg or CpG)/ mg chitosan nanoparticles dry weight 
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5.2.2.3 Evaluation of the structural integrity of the vaccine 
The integrity of hepatitis B antigen was confirmed using SDS-Polyacrylamide gel 
electrophoretic (SDS-PAGE) analysis of the hepatitis B vaccine released overnight from 
the nanoparticles (7.4 pH buffer phosphate; 37ºC; 50 rpm). The samples were 
centrifuged at 14000 rpm in order to separate the released antigen from the particles and 
an aliquot was then solubilised with the loading buffer and treated (5 minutes at 100ºC). 
The SDS-PAGE was performed in accordance with standard protocols [36] with 12% 
resolving gel, cast and run in tris-glycine buffer at 25 mA and finally stained with silver 
nitrate.  
The antigenicity of the entrapped hepatitis B vaccine was assessed by Western 
blotting using a mouse antiserum raised against the native antigen. The hepatitis B 
vaccine samples were transferred from the unstained gel onto a nitrocellulose 
membrane, using semi-dry electroblotting system (115 mA; 1hour) and the membrane 
was blocked overnight at 4ºC with PBS-T (containing 0.05% of Tween 20 and 5% of 
milk). After washing with PBS-T, the membrane was incubated for 2 hours at room 
temperature with the positive anti-HBsAg IgG mouse antiserum, diluted 1:500 in PBS-T 
with 5% of low fat milk. After washing with PBS-T, the membrane was incubated with 
anti-mouse IgG conjugated to alkaline phosphatase, diluted 1:750. The ability of the 
mouse antiserum to recognize hepatitis B vaccine released from the nanoparticles was 
demonstrated colorimetrically using 5 ml of phosphatase buffer with 33 µl NBT (50 
µg/ml) and 16.7 µl BCIP (50 µg/ml). The reaction was stopped by washing the 
membrane with water. 
5.2.2.4 Immunization studies 
5.2.2.4.1 Animals: 
Six week-old female BALB/c AnNHsd mice were used (Harlan Iberica, Barcelona, Spain) 
with four or six mice per group. Animals were housed for acclimatization one week 
before the experiments at the animal resource facilities of the Faculty in accordance with 
institutional ethical guidelines. They had free access to food and water, with 12h 
light/dark cycle. Two hours before the oral vaccination and overnight before the end of 
the experiment, the mice were starved allowing only free access to water. 
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5.2.2.4.2 Treatment groups 
Group I - suspension of alginate coated chitosan nanoparticles loaded with 10 µg HBsAg  
Group II - suspension of alginate coated chitosan nanoparticles loaded with 10 µg 
HBsAg plus 10 µg of the adjuvant (CpG ODN) in solution. 
Group III - untreated - control 
Group IV - solution with 10 µg HBsAg 
Group V - solution with 10 µg HBsAg and 10 µg CpG ODN 
Group VI - suspension of the mixture of alginate coated chitosan nanoparticles loaded 
with 10 µg HBsAg and the same particles loaded with 10 µg CpG ODN  
5.2.2.4.3 Immunization schedule 
Each animal received immediately before immunization 100 µl of a 7.5 % sodium 
bicarbonate solution in order to neutralise the acid environment of the stomach. The 
different formulations, corresponding to each treatment group (see 2.2.4.2.) were 
administered orally with a gavage-feeding needle. The primary immunization was 
followed by one boost three weeks later with 150 µl volume containing 10 µg of the 
vaccine. The animals were sacrificed 10 days post boost and a collection of blood from 
the heart, vaginal secretions, small intestinal washes and the spleen was carried out for 
analysis as described in the following sections. 
5.2.2.4.4 Collection of samples 
Blood samples were taken from the orbital sinus before the boost and by cardiac 
puncture at the end of the experiment and the sera were prepared by centrifugation and 
stored at -20ºC until analysis. 
Vaginal and gut washes were obtained by rinsing with (75 µl x 3) 225 µl and 600 
µl cold PBS (containing 0.1% sodium azide, 0.1% bovine serum albumin (BSA) and 1 
mM PMSF) through the vagina or the intestine, respectively. The extract was vortexed, 
allowed to stay at room temperature for 15 minutes and then centrifuged (6000 rpm/15 
min/4ºC). The clear supernatants were stored at –80ºC until analysis. 
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5.2.2.4.5 Enzyme-linked immunosorbent assays (ELISA) for HBsAg specific 
immunoglobulins 
Ninety-six-well flat-bottomed microtiter plates (Nunc immunoplate maxisorb) were 
previously coated (incubated overnight at 4ºC) with the recombinant HBsAg (1 µg/well) in 
coating buffer (50 mM sodium carbonate, pH 9.6). The plates were washed 5 times with 
PBS-T (PBS containing 0.05% Tween-20) and blocked with 3% BSA in PBS-T 
(200µl/well) during 1 hour at 37ºC. The plates were then washed 5 times with PBS-T and 
the serial dilutions of each serum (100 µl/well) from the individual mice were tested in 
triplicate, starting from a dilution 1:100 in PBS-T. The serum was incubated during 2 
hours at 37ºC and after washing the plates with PBS-T, the plates were incubated for 
additional 30 min at 37ºC with peroxidase-labeled goat anti-mouse immunoglobulin G 
and isotypes (anti-IgG1, anti-IgG2a, anti-IgG2b and anti-IgG3). The bound antibodies 
were revealed adding 100 µl/well of 0.5 mg/ml of o-phenylenediamine dihydrochloride 
(OPD) (Sigma, Spain) in 10 ml of citrate buffer with 10 µl of H2O2. The reaction was 
stopped after 10 minutes with 50 µl of 3M HCl to each well. The absorbance was read 
out at 492 nm in an automatic ELISA reader (Easy Reader 400, SLT-
LABINSTRUMENTS). Elisa titers were expressed as mIU/ml and 1 mIU is the OD mean 
of the pre-immune serum plus 2 times the standard deviation.  
The measurement of IgA was carried out using a mouse IgA ELISA quantification 
kit (Bethyl Laboratories, Montgomery, Texas, U.S.) as described by the manufacturer. In 
order to make a correct evaluation of the sIgA in the gut and vaginal extracts, total sIgA 
and the specific anti-HBs sIgA were determined in the extracts. The results are 
presented as the anti-HBsAg IgA/total IgA. By this way differences between samples 
related with the extraction process or stability of the sIgA were minimized.  
The IgA standard was diluted to appropriate concentrations in PBS with 1% BSA 
to create a calibration curve. The gut washes were diluted in PBS-T with 1% BSA and 
added to the plates in series of twofold dilutions. The concentrations of the total and 
specific IgA were determined from the calibration curve generated for each set of 
samples using a four parameter logistic curve-fit generated by SigmaPlot software 
(version 8.0, SPSS Inc). 
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5.2.2.4.6 Preparation of spleen cell suspensions. 
The mice were euthanized by cervical dislocation and their spleens were aseptically 
removed. Individual spleen cell suspensions were prepared in a Petri dish using curved 
needles and washed twice with RPMI 1640. The final suspension was adjusted to a final 
concentration of 1x107 cells /ml in complete RPMI 1640 medium [supplemented with 
10% (v/v) fetal bovine serum (FBS), 1% (v/v) glutamine, 1% (v/v) Pen-Strep and 2% (v/v) 
1M HEPES buffer]. 
5.2.2.4.7 Cell population of the spleen 
The cells (0.025 x 107 cells) were washed twice with cold PBS-supplemented with 2% 
FBS and then incubated in the dark for 30 minutes at 4ºC with saturated concentrations 
of FITC-conjugated rat anti-mouse CD4 or FITC-conjugated rat anti-mouse CD8 or FITC-
conjugated goat anti-mouse IGM (anti-µ). After incubation, cells were washed three 
times with PBS-2% FBS and then re-suspended in 500 µl PBS-2% FBS. To exclude 
dead cells, 2.5 µl propidium iodide (50 µg/ml) were added just before data acquisition. At 
least 10,000 events were analysed by flow cytometric acquisition, performed in a 
fluorescent activated cell sorter (FACS Calibur) (BD, Biosciences, Madrid, Spain). Data 
were analysed by CellQuest software (BD, Biosciences, Madrid, Spain).  
5.2.2.4.8 Splenocyte cell culture in the presence of the mitogens 
Using sterile 96-well flat-bottomed tissue culture plates, 25 µl of splenocyte suspension 
(1x107 cells/ ml) from each mice were plated in triplicate along with 25 µl of a complete 
RPMI solution of the mitogen [con A (50 µg/ml), CpG ODN (50 µg/ml) plus HBsAg (25 
µg/ml), HBsAg (25 µg/ml) alone or without mitogen (control)]. Finally the volume of the 
well was completed to 200 µl with complete RPMI and incubated at 37ºC with 95% 
relative humidity and in the presence of 5% CO2.  
5.2.2.4.9 Cytokine production by splenocytes 
Spleen cell suspensions were plated with the mitogens (see 2.2.4.8) and incubated in a 
humidified 5% CO2 incubator for 24 h (IL-2) and 86 h (INF-γ) at 37ºC. The plates were 
centrifuged and the supernatants stored at –80ºC until analysis.  
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IL-2 and IFN-γ cytokines produced by splenocytes were determined by ELISA, 
following a technique described elsewhere [37].  
5.2.2.4.10 Evaluation of the CD69 expression on lymphocytes 
After 20 h of incubation in the presence of different mitogens (see 2.2.4.8), cells were 
washed and re-suspended in cold phosphate buffered saline (PBS) supplemented with 
2% fbs (PBS-2% FBS), resulting in a concentration of 0.5 x 106 cells/ well. The cells were 
then incubated in the dark for 30 minutes at 4ºC with saturated concentrations of PE-
conjugated hamster anti-mouse CD69 and FITC-conjugated rat anti-mouse CD4 or 
FITC-conjugated rat anti-mouse CD8 or FITC-conjugated goat anti-mouse IGM (anti-µ). 
After incubation, cells were washed three times with PBS-2% FBS and then re-
suspended in 500 µl of PBS-2% FBS. To exclude dead cells, 2.5 µl propidium iodide (50 
µg/ml) was added just before data acquisition. The flow cytometry determinations were 
done according to the description given above (see 2.2.4.7) 
5.2.2.4.11  Lymphoproliferation assay 
Splenocytes were obtained and cultured together with the mitogens in a flat-bottomed 
96-well plate as described before (see 2.2.4.8). The cells were cultured for 96 hours at 
37ºC and on the last 8 h of incubation; each well was pulsed with 1µCi of [methyl-3H] 
thymidine. 96 well plates with the cells were stored at -20ºC until further analysis. The 
cells were later thawed and harvested onto a fiberglass filter (filter mats, molecular 
devices, Skatron, Lier, Norway) using a semiautomatic cell harvester (Scatron 
Instruments, USA) and DNA thymidine incorporation was counted by standard liquid 
scintillation techniques with a Beckman LS 6500 scintillation counter (Beckman Coulter 
Inc, Fullerton, USA). Thymidine incorporation was expressed as counts per minute 
(cpm).  
5.2.3 Statistical analysis 
Data were presented as the mean ± S.E.M. for at least three experiments and statistical 
significance was assessed using one-way ANOVA followed by Dunnett’s post test using 
the GraphPad Prism 4 software. Differences were considered significant when p<0.05.  
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5.3 RESULTS  
5.3.1 Characterization of the alginate coated nanoparticles 
In a recent publication of our group [28], the development of alginate coated chitosan 
nanoparticles and the characterization of this new delivery system were reported. Briefly, 
before coating with sodium alginate, the chitosan nanoparticles have a mean diameter of 
643 nm (dynamic light scattering technique) and are positively charged (+37 mV). 
Scanning electron microscopy (SEM) images of uncoated particles also revealed the 
presence of small nanoparticles (around 100 nm) and demonstrated that the majority of 
the coated particles were in a range between 300 and 600 nm. The presence of the 
alginate coating layer was confirmed both by FTIR and DSC studies and by the 
observation of the inversion of the zeta potential to -34 mV. 
In another study we recently have shown [29] results of the particle uptake by 
Peyer’s patches and the ovalbumin release from alginate coated chitosan nanoparticles. 
In these studies, ovalbumin was chosen as a model vaccine. Ovalbumin release studies 
from coated and uncoated chitosan nanoparticles, performed with several pH buffers, 
allowed us to conclude that the coating with sodium alginate of the ovoalbumin loaded 
chitosan nanoparticles avoided an ovalbumin burst release observed in the first 30 
minutes compared to uncoated chitosan nanoparticles at pH 5.5; 6.8 and 7.4 (phosphate 
buffer). However at pH 1.2, a burst release was observed for both coated and uncoated 
nanoparticles. For this reason in the present study a 7% sodium bicarbonate solution 
was administered immediately before feeding the mice with the nanoparticles with the 
purpose to increase the pH of the stomach fluids. 
5.3.2 CpG ODN and hepatitis B antigen entrapment in coated nanoparticles 
Different ratios of Hepatitis B vaccine to chitosan nanoparticles and CpG ODN to 
chitosan nanoparticles were investigated (data not shown) and the systems with the 
highest loading efficacy were used for the further studies. It could be shown that hepatitis 
B antigen and CpG ODN were efficiently associated with alginate coated chitosan 
nanoparticles. The loading efficacy of Hepatitis B vaccine in the coated nanoparticles 
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was 85.9 ± 4.7 % (mean ± STDEV) and the mean of the loading capacity was 25.7 µg of 
HBsAg/ mg of dry chitosan nanoparticles ± 1.42 (STDEV). The loading efficacy of CpG 
was even better, 98.8 ± 1.29% and the loading capacity 29.85 ± 0.0364 (µg of CpG 
ODN/ mg of dry chitosan nanoparticles) since the existence of a strong interaction 
between DNA or oligodeoxynucleotides and the oppositely charged cationic chitosan has 
already been demonstrated [38, 39]. 
5.3.3 Confirmation of the structural integrity of hepatitis B antigen 
The adsorption of hepatitis B antigen (HBsAg) to chitosan nanoparticles occurred at 
room temperature, under mild agitation using a phosphate buffer as the external medium 
of the suspension. The coating with alginate was done under similar conditions, being 
considered as non aggressive for the entrapment of ODN’s, proteins, peptides and 
vaccines. Nevertheless, a SDS-PAGE analysis followed by a Western blotting was 
performed in order to confirm the integrity of hepatitis B antigen and the results are 
shown in figure 1. SDS-PAGE analysis of the bulk vaccine showed the presence of a 
dominant band with a molecular weight below 30 KD (fig. 1b lane 1) that, according to 
the literature, was identified to be the 24 kDa polypeptide described by Stephenne [40] 
and a second protein with a molecular weight between 35 and 55 kD. The same gel 
revealed identical bands for the entrapped HBsAg (lanes 2, 3 and 4) and there were no 
additional bands to indicate the presence of fragments. Therefore the integrity of the 
antigen was not affected by the entrapment procedure. Moreover the Western blot 
membrane shown in figure 1a demonstrated that the HBs specific antibodies from a 
serum of a vaccinated mouse recognized the antigen epitopes (fig. 1a; lanes 3, 4 and 5) 
in a similar way as for the bulk vaccine (fig. 1a; lanes 1 and 2), confirming that the 
antigenicity of the hepatitis B antigen was not altered after the entrapment into 
nanoparticles. 
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Figure 1 – Western blot and SDS-Page analysis of the released hepatitis B antigen from 
alginate coated chitosan nanoparticles a). Western blot. Lane1: molecular weight markers, 
lane2: HBsAg before association with particles in PBS, lane 3, 4 and 5: HBsAg after association 
with coated nanoparticles and subsequently released overnight in PBS at 37ºC. b) SDS-PAGE 
silver stained. Lane 1: HBsAg before association with the particles, lane 2, 3 and 4: HBsAg after 
association with coated nanoparticles and subsequently released overnight in PBS at 37ºC. 
5.3.4 Evaluation of cellular immune responses 
5.3.4.1  Lymphoproliferative response 
The cellular immune response of individual mice was evaluated measuring in vitro 
proliferation of splenocytes, incubated in the presence of HBsAg or in the presence of 
HBsAg plus CpG or in the presence of Con A (positive control), respectively. Cells 
cultured without mitogens were used as a negative control of the experiment and 
showed as expected only low counts per minute (cpm) values (data not shown). Similar 
to the negative control were the results obtained with cells incubated only with the 
antigen (data not shown). The lymphoproliferation in vitro induced by the mixture of the 
hepatitis B antigen and the immunopotentiator CpG ODN were evaluated in all the 
groups and are shown in figure 2A. The cellular proliferation observed in all the groups 
was probably caused by the presence of CpG, since it was previously demonstrated that 
the HBsAg alone in the concentration used did not induce any proliferative effect. The 
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same figure (2A) showed that the groups I (HBsAg associated with nanoparticles) and VI 
(HBsAg and CpG associated with nanoparticles) presented a lower splenocyte 
proliferative capability when compared with the control group. Nevertheless, due to the 
large variability of the results, the values are not statistically different from the control 
group. Even less or no proliferation was observed in groups IV (HBsAg in solution) and V 
(HBsAg and CpG in solution).  
Lymphoproliferation assay
 (HBsAg + CpG ODN)
0
5000
10000
15000
20000
25000
30000
Groups
cp
m
I II III IV VIV
cp
m
       
Lymphoproliferation assays 
(con A)
0
20000
40000
60000
80000
100000
120000
140000
160000
180000
200000
Groups
cp
m
I II III IV V VI
cp
m
 
Figure 2 – Lymphoproliferative response after oral administration of the different hepatitis B 
vaccine formulations. In vitro proliferation of individual mouse spleenocytes during a 96 hour 
period stimulated with: A) HBsAg + CpG ODN, B) Con A. Each circle represents the result of 
individual samples and the horizontal bar the mean of the group. The results corresponded to 
Thymidine incorporation and are expressed as counts per minute (cpm).  
Finally, figure 2B shows the lymphoproliferative results observed in the presence 
Con A, a classical mitogen, which served as a positive recall antigen. The groups II, IV 
and V presented cpm values between 20 000 and 60 000, similar to the control group 
(group III). These results contrasted with those found for the groups I and VI, where a 
much stronger proliferative response was observed, showing values between 100 000 
and 180 000 cpm. 
5.3.4.2  Cell populations 
The evaluation of spleen cell populations was done immediately after sacrificing the 
mice. Each individual value and the means for each group are shown in figure 3. The 
percentage of CD4+ T-lymphocytes showed to be similar in all groups. On the other 
hand, slight but statistically differences were found in the CD8+ T-lymphocyte 
A 
B 
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populations in some treated groups when compared with the control group. In particularly 
the percentage of CD8+ T-lymphocytes appeared slightly increased in groups IV and V 
and decreased in groups I and VI. 
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Figure 3 – Percentage of T-lymphocytes CD4+, CD8+ and B+ Lymphocytes in the spleens of 
mice from the treatment groups (I, II, IV, V and VI) and the control (naïve mice) (group III) 
determined by FACS analysis. Each bar corresponds to the group geometric mean plus the 
standard error of the mean (n between 3 and 6). The comparison between the control group (III) 
and the different treatment groups (I, II, IV, V, VI) was made with a one-way analysis of variance 
(ANOVA) followed by Dunnett’s multiple comparison test (** p<0.01 and *p<0.05). 
The increase of the CD8+ T-lymphocytes with the decrease of the CD4+/CD8+ 
ratio as well as a significant decrease of the lymphocyte proliferative response to antigen 
stimulation, appear to be correlated with the immunological tolerance phenomena [41]. 
The groups IV and V, where antigen or the antigen plus the adjuvant were given in 
solution, were shown to fulfil these two conditions. On the other hand the association of 
the antigen with nanoparticles (groups I, II and VI) may have circumvented this 
undesirable mechanism. Additional studies have to be performed to test this hypothesis. 
5.3.4.3 Cytokines production 
IL-2 and IFN-γ were assayed in the supernatants from splenocytes cultured in the 
presence of different mitogens (HBsAg, Con A and the mixture of HBsAg+CpG ODN) 
and the results are shown in figure 4. The highest IL-2 mean levels were found in Groups 
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I and VI. Nevertheless these results are not statistically significant due to the high 
variability within the groups. The production of IFN-γ by the splenocytes was detected in 
all the groups in the presence of different mitogens. However the highest mean value 
was detected in the group VI, where CpG and the antigen were administered associated 
to the coated nanoparticles, with CpG ODN as the main responsible factor for the high 
IFN-γ production. Therefore, the formulation given to the group VI seemed to be the most 
effective in the generation of a Th1 profile of  immune response. 
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Figure 4 – Cytoquine production by splenocytes of individual mice from each treatment group: 
A) IL-2 secretion from splenocytes cultured for 24 hours in presence of con A; B) IFN-γ 
secretion from splenocytes cultured for 86 hours in the absence or in the presence of different 
mitogens ( HBsAg; Con A; HBsAg + CpG ODN). Each bar corresponds to the group geometric 
mean plus the standard error of the mean (n between 3 and 6). The comparison between 
control group (III) and the different treatment groups (I, II, IV, V, VI) was made using a one-way 
analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test (** p<0.01 and 
*p<0.05). 
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5.3.4.4 Expression of the early activation marker CD69 
CD69 is a type II membrane protein expressed as a homodimer of heavily glycosylated 
subunits. Both T and B cells begin to express CD69 within a few hours after stimulation, 
being recognized as an early activation marker antigen of lymphocytes. In the present 
study the expression of CD69 in splenocytes of individual mice was evaluated after 20 
hours incubation with different mitogens, being the assay with Con A as the positive 
control of the experiment (figure 5D).  
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Figure 5 – Expression of the CD69 antigen on B and T splenocytes from different mouse groups 
in response to different in vitro stimulation. The stimulus experienced were the 
immunostimulators, CpGODN (histogram C) and Con A (positive control; histogram D), the 
antigen, HBsAg (histograms B and C) or without in vitro stimuli (histogram A). The values are 
means ± SEM of the percentage of the positive CD4 cells that express the CD69 antigen, 
obtained from individual mice of each group (n between 3 and 6). The comparison between 
control group (III) and the different treatment groups (I, II, IV, V, VI) was made with the one-way 
analysis of variance (ANOVA) with Dunnett’s multiple comparison test (** p<0.01 and *p<0.05). 
Cells from the spleen without in vitro stimulation, normally exhibit low levels of 
CD69 expression as demonstrated in figure 5A. In spite of that, significant differences in 
the CD69 expression on CD4+ T-lymphocytes between groups I (p<0.01) or VI (p<0.01) 
and the control group were observed. The splenocytes were collected 10 days after the 
boost and cultured for 20 hours without stimulation, which is considered as a long period 
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between the antigen exposure and the CD69 expression. These significant higher values 
were also observed with HBsAg (fig.5B) and HBsAg+CpG (fig. 5C) in vitro stimulated 
splenocytes. Despite of the lower CD69 expression levels observed on cells, (without in 
vitro stimulation the values were around 5% and 13-18%) the concordance of the three 
assays (figure 5A, B and C) gave consistency to the results observed for the groups I 
and VI. Moreover, in the same groups lower percentages of B lymphocytes CD69+ (8.4 
and 7.1% for the groups I and VI respectively) were observed when compared with the 
control group (17%) (figure-5A and -5B). This result correlates well with the above 
described lymphoproliferative assay (see 3.4.1.), where the B lymphocytes showed lower 
capability to proliferate. 
Finally, in the same in vitro study it was observed that the CD8+ T-lymphocytes 
from the groups I and VI, incubated in the presence of the HBsAg and CpG ODN, 
expressed significant higher percentage of CD69 molecule (9.7% and 12.9 % for the 
groups I and VI respectively) when compared with the control group (3.6%). 
5.3.5 Humoral immune response 
5.3.5.1  Systemic antibody response 
Serum from the mice was collected before the first immunization and before and after the 
boost and analysed for the anti-HBsAg IgG. The results are shown in figure 6. With only 
one boost, two of three groups orally vaccinated with the antigen associated with coated 
nanoparticles were able to show seroconversion. In fact, the group I vaccinated with the 
HBsAg associated with coated nanoparticles showed a very low responder number (1/6) 
whereas the group VI, with the antigen and the adjuvant associated with the 
nanoparticles showed a better result (2/5). This last result was most probably related 
with the presence of the also encapsulated adjuvant.  
IgG subclass titres were measured in responder mice before and after the boost 
(data not shown). Oral immunization with HBsAg loaded nanoparticles (group I) induced 
a Th2 humoral immune response profile (Ig1>Ig2a+Ig2b), however after the boost, the 
titres of Ig2a+Ig2b (Th1) were stronger, nevertheless lower than Ig1 (Th2). This mixed 
Th1/Th2 profile of response has been attributed to the HBsAg on its own [42]. On the 
other side, the oral immunization with the antigen plus the adjuvant loaded nanoparticles 
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(group VI) induced a Th1 profile humoral immune response, attributed to the presence of 
the CpG ODN [31]. This kind of immune response, normally associated with a strong 
immune cell response, has been claimed for the control of intracellular infections. This 
include viral infections, similar to infections with the hepatitis B virus [43]. 
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Figure 6 – Serum anti-HBsAg IgG titres of mice immunized with different oral formulations of 
hepatitis B vaccine. Values are expressed as antibody titres of individual mice taken before the 
boost and after the boost. Titres were defined as the highest plasma dilution resulting in an 
absorbance value twice that of nonimmune plasma (1 mlU/ml = mean + 2 SD of the control 
group). 
5.3.5.2 Mucosal anti-HBsAg sIgA  
The results of the determination of the IgA in gut washes are shown in figure 7. These 
results are presented as ratio between the amount of the specific IgA and the total IgA 
present in the washes of the gut of each mouse. No significant anti-HBsAg IgA was 
detected in the gut of mice immunized with the solutions of the antigen (groups IV and 
V). In contrast, detectable anti-HBsAg IgA was quantified in gut washes of some mice 
from groups I and VI (fig. 7). 
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Figure 7 – Secretory anti-HBsAg sIgA profile detected in individual intestine washing samples of 
mice immunized with different hepatitis B vaccine oral formulations. Each circle represents the 
result of individual samples and the horizontal bar the mean of the group. Samples with the 
value equivalent to mean plus twice the SD of the control group (group III), were considered 
anti-HBsAg sIgA positive. The values were expressed as the ratio between the anti-HBsAg sIgA 
(ng/ml) and total sIgA (µg/ml) 
5.4 DISCUSSION 
It has been suggested that the response to orally administered antigens is initiated 
locally in the gut and then disseminated to the secondary lymph nodes and spleen, while 
other groups suggest a simultaneous activation of antigen-specific T cells throughout the 
animal after feeding the antigen [44]. Following these thoughts, it was investigated if a 
short time oral vaccination scheme with different formulations of hepatitis B antigen was 
able to induce not only mucosal but also a systemic (cellular and humoral) immune 
response. One of the parameters studied was the CD69 expression on the B and T-
lymphocytes from the spleen. CD69 is a cell membrane receptor and has not been very 
often used in vaccination experiments. On the other hand, in a short time study, where 
an extended immune response is not expected, the investigation of an early activation 
marker may be useful to quickly evaluate different antigen formulations. 
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In the present study, the administration of the hepatitis B vaccine entrapped in 
alginate coated chitosan nanoparticles was investigated. In some cases (groups I and 
VI), those formulations were able to induce a cellular immune response, translated by 
the highest percentage of CD4+ T-lymphocytes expressing the CD69 and the lowest 
percentage of CD69+B cells. Moreover, in the same groups, the CD8+ T-lymphocytes 
have shown to be the most susceptible to CD69 induction when cultured in the presence 
of the antigen plus the adjuvant. Furthermore, the lymphocytes from those groups (I and 
VI) also have shown the highest capacity to proliferate and in some cases to produce IL-
2 and IFN-γ. This cellular immune response was accompanied by the presence of IgG 
and IgA HBsAg specific in the serum and on the intestinal mucosa, respectively, 
however with the presence of non responder mice within the groups (I and VI). In the 
recent literature, the presence of non responder orally vaccinated mice is frequently 
reported, especially when the evaluation of the specific antibodies was performed after a 
single immunization. Moreover, to have a high percentage of seroconverted mice within 
the groups orally vaccinated, it has been always necessary to administer higher antigen 
concentrations with successive administration of the vaccine. Commercial injectable 
hepatitis B vaccines also have this drawback in humans [45]. It was estimated that the 
priming doses only induce detectable levels of antibodies in 70 to 90% of healthy infants, 
adolescents and adults. The final boost of the vaccine induces protective levels of anti-
HBs antibodies in more than 95% [45] of infants and adolescents. In our study, the 
vaccination with a solution with 10 µg of the antigen (groups IV and V) did not induce 
cellular or humoral immune response and the results shown in this work allowed us to 
hypothesize that immunological tolerance might have been induced. In fact, oral 
tolerance has been one of the principal obstacles to different strategies designed for the 
oral administration of the vaccines and its induction seems to be related with the antigen 
dose [7, 46] and also most probably with the intrinsic properties of the antigen. Identical 
to our results obtained with a solution of the antigen were found in literature [33]. Even 
when the dose was increased to 100 µg, the vaccine given orally did not induce at all or 
in some cases only low anti-HBsAg IgG titers [34]. However, the association of CpG 
ODN [34] or of PLG microparticles [8] to the same high dose of the vaccine induced a 
systemic and mucosal immune response. 
In order to obtain an immune response, the increase of the antigen dose used 
may not be sufficient to produce immunological acceptable results. Moreover, those high 
concentrations may not be economically attractive and hence different solutions have to 
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be explored. The development of efficient adjuvants for the mucosal route is one of the 
more promising approaches. One of the examples was recently described in the 
literature, the CpG ODN. A number of studies has shown that the CpG ODN is an 
effective immunomodulator molecule for parenteral [31, 47] and mucosal routes [34, 35, 
48, 49]. CpG ODN has been shown to induce Th1 profile immune responses with a 
number of different antigens [31, 50]. The mechanism of adjuvant action of CpG ODN is 
not completely understood, but it is known that CpG ODN binds to the Toll-like receptor 9 
(TLR-9) [51]. Therefore the immunostimulator effect is mediated only after its cell 
internalization [50]. On the other hand, the entrapment of CpG into nanoparticles with a 
size larger than a cell, may fail to stimulate immune cells, most probably because the 
nanoparticles cannot be internalised.  
The physical proximity of the antigen and the adjuvant seems to be a requirement 
for an effective adjuvant effect [52]. This hypothesis could be the key, at least in part, of 
the lack of an early immune response observed in our study with the group of mice 
treated with the antigen associated with the nanoparticles and the adjuvant in solution 
(group II). The hepatitis B antigen antigen associated to the nanoparticles and the 
adjuvant in solution may have been taken up in different regions of the intestine. 
According to our own previous studies [29], alginate coated chitosan nanoparticles are 
able to be taken up by Peyer’s patches and the CpG ODN in solution was most probably 
internalized by the enterocytes. On the contrary in the group VI, antigen and adjuvant, 
both associated to the nanoparticles, were most probably internalized simultaneously by 
M-cells of the Peyer’s patches and this fact may explain the better results observed in 
this treatment group. 
5.5 CONCLUSION 
Alginate coated chitosan nanoparticles are able to entrap efficiently the hepatitis B 
recombinant vaccine and the CpG ODN used as an adjuvant. 
Humoral and cellular immune response were better induced in mice vaccinated 
with the formulation where the antigen and the adjuvant appeared associated with the 
nanoparticles. The Th1 profile immune response induced by this formulation is crucial in 
preventing or overcoming hepatitis B infections, thus making this delivery system a 
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promising one. However further studies and in time prolonged with additional boosts 
have to be done in order to evaluate the appearance of desirable new responder mice. 
Also it has to be demonstrated whether a long lasting cellular and humoral immune 
response can be induced with this formulation using this challenging oral administration 
route.  
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ABSTRACT 
Alginate coated chitosan nanoparticles were previously developed with the aim of 
protecting the antigen, adsorbed on the surface of those chitosan nanoparticles, from 
enzymatic degradation at mucosal surfaces. In this work, this new delivery system was 
loaded with the recombinant hepatitis B surface antigen (HBsAg) and applied to mice by 
the intranasal route. Adjuvant effect of the delivery system were studied by measuring 
anti-HBsAg IgG in serum, anti-HBsAg sIgA in feces extracts or nasal and vaginal 
secretions and interferon-γ production in supernatants of the spleen cells. The mice were 
primed with 10 µg of the vaccine associated or not with nanoparticles and associated or 
not with 10 µg CpG oligodeoxynucleotide (ODN) followed by two sequential boosts at 
three week intervals. The association of HBsAg with the alginate coated chitosan 
nanoparticles, administered intranasally to the mice, gave rise to the humoral mucosal 
immune response. Humoral systemic immune response was not induced by the HBsAg 
loaded nanoparticles alone. The generation of Th1-biased antigen-specific systemic 
antibodies, however, was observed when HBsAg loaded nanoparticles were applied 
together with a second adjuvant, the immunopotentiator, CpG ODN. Moreover, all 
intranasally vaccinated groups showed higher interferon-γ production when compared to 
naïve mice.  
6.1 INTRODUCTION 
A safe and effective vaccine to prevent infection with hepatitis B virus (HBV) has been 
available since 1982, and is recommended by the World Health Organization (WHO) for 
administration to all infants [1]. Therefore, it is not understandable that the number of 
chronically infected people continues to be a problem in many parts of the World, 
including Asia, Africa and the western Pacific region [2]. Some progress in the control of 
the disease in the western Pacific area were recently reported [1] after the  inclusion of  
hepatitis B vaccine in every national immunization programme. Even though the price of 
the vaccine had dropped significantly in the last years, there were still some countries 
that could not afford these immunization programmes. Futhermore, the control of the 
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spread of the disease through vaccination of infants would undoubtedly prevent a large 
number of infections among adults, but it will take several decades to be achieved. The 
implementation of vaccination programmes, at least for the vaccination of high risk 
adults, like drug users, sex workers and health professionals, would certainly prevent a 
large number of infections [3]. 
Recently some questions have been raised concerning the hepatitis B vaccine 
currently on the market [4]. A significant proportion of healthy individuals (between 2% 
and 10%) have failed to respond to the currently licensed vaccine [5, 6]. Additionally, 
rare but serious pathological events have been described during the weeks following a 
hepatitis B vaccine injection campaign [7], nevertheless no relation between vaccination 
and the occurrence of the majority of these events has been shown. Moreover, some of 
these secondary effects have been correlated to the aluminium compounds, used as 
adjuvant. For example, these adjuvants are know to stimulate IgE antibody formation, 
which is not desirable in a normal process of immunization (reviewed in [8]). On the other 
hand, the intramuscular administration of the vaccine currently on the market, is not able 
to induce mucosal antibodies. The presence of antigen-specific sIgA at mucosal surfaces 
has been shown to help, when the transmission of the disease is through one of the 
mucosal routes, which is the case of the sexual transmission of HBV. To note that sexual 
transmission (either homosexual or heterosexual) in high-risk adults is the main mode of 
transmission in Europe and North America (regions of low HBV prevalence) [2]. On the 
other side, the induction of mucosal antibodies seemed to be facilitated if the antigens 
were administered by a mucosal route together with an appropriate adjuvant. 
Furthermore, the development of efficient mucosal adjuvants, which allow an easy and 
inexpensive mass vaccination, with more stable vaccines are urgently required.  
Among the mucosal administration routes the nasal mucosa is the most attractive 
site for the delivery of vaccines. Compared with the more challenging oral vaccination, 
the nasal vaccination is more efficient at inducing secretory and systemic antibody 
responses (reviewed in [9]). For this reason, several attempts have been made regarding 
the intranasal vaccination with hepatitis B, in order to identify an effective mucosal 
adjuvant that elicits specific mucosal and systemic hepatitis B antibodies. Adjuvants such 
as recombinant cholera toxin B subunit [10], genetically modified adenovirus [11] 
expressing the hepatitis B surface antigen, attenuated Salmonella typhimurium [12] 
expressing the hepatitis B nucleocapsid, or Escherichia coli expressing the hepatitis B 
nucleoprotein antigen [13] have all been shown to be efficient as intranasal adjuvants. 
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However, safety concerns have predominantly been the cause for restricting the 
development and the use of these adjuvants in clinical studies. Synthetic 
oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG ODN) are 
considered to be potent immunopotentiator adjuvants. It was demonstrated in mice that 
the intranasal delivery of HBsAg, which alone has no effect, elicits good immune 
responses when given in combination with CpG ODN [14-16]. Moreover, CpG is superior 
to cholera toxin (CT) for the induction of humoral and cell-mediated systemic immunity 
as well as mucosal immune responses (IgA) at local (lung) and distant (intestine) sites 
[14]. 
Particulate vaccine delivery systems loaded with HBsAg have also been 
evaluated by the intranasal route. Some examples already published include polymeric 
biodegradable poly(lactide-co-glycolide) (PLGA) microparticles [17], cationic particles 
(SMBV™) [18], cationic lipid emulsion carrying a DNA vaccine [19] and lipid 
microparticles [20]. 
Great attention has been paid to the cationic biodegradable polysaccharide 
chitosan. It is of low toxicity, has mucoadhesive [21] and immunostimulating properties, 
therefore showing great potential for being used in mucosal vaccines. In a previous 
study, we have characterized alginate coated chitosan nanoparticles as a novel delivery 
system [22, 23] designed for the application at mucosal surfaces. The evaluation of the 
immune response by the oral route has been performed, as well (in process of 
publication). The present work describes the evaluation of the immune response induced 
by the intranasal administration of the recombinant hepatitis B vaccine associated with 
the nanoparticulate delivery system. Additionally, the adjuvant effect of CpG ODN, 
dissolved in the suspension of the antigen or associated with the coated nanoparticles, 
was investigated.  
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6.2 MATERIALS AND METHODS 
6.2.1 Materials 
6.2.1.1 Polymers 
Chitosan was purchased from Primex BioChemicals AS (Avaldsnes, Norway). According 
to the provider’s specifications, the degree of deacetylation was 95% (titration method) 
and the viscosity was 8 cP (measured in 1% solution in 1% acetic acid). A low molecular 
weight, pharmaceutical grade, sodium alginate (MANUCOL LB) was kindly donated by 
ISP Technologies Inc. (Surrey, UK). According to the provider’s specifications, the typical 
values for the percentage of mannuronic and guluronic acid for Manucol LB were 61% 
and 39%, respectively, with an estimated molecular weight of 18 kDa. Both polymers 
meet the requirements described in the European Pharmacopoeia for use in 
pharmaceutical formulations. 
6.2.1.2 Antigen, adjuvant and reagents 
The hepatitis B surface antigen (HBsAg), (subtype ADW2) was kindly offered by GSK 
Biologicals (Rixensart, Belgium), Engerix B was from GlaxoSmithKline Biologicals 
(Rixensart, Belgium), Class B CpG ODN (1826) (5’-TCC ATG ACG TTC CTG ACG TT-
3’) was purchased from Coley Pharmaceutical Group (Ottawa, Canada). Concanavalin A 
(Con A), phenylmethanesulfonyl fluoride (PMSF) and avidin peroxidase conjugate were 
from Sigma Chemicals (St. Louis, USA). Certified fetal bovine serum (FBS) and L-
glutamine (200 mM) were from Gibco (Invitrogen Co, Paisley, Scotland, UK), 1M HEPES 
buffer (0.85% NaCl), RPMI 1640 without L-glutamine and Pen-Strep (10,000 U 
penicillin/ml; 10,000 µg streptomycin/ml) were from Biowhitaker (Cambrex Bio Science, 
Verviers, Belgium). [Methyl-3H] thymidine (1.0 mCi/ml) was obtained from Amersham 
Biosciences (UK), R-phycoerythrin (PE)-conjugated hamster anti-mouse CD69, 
fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD4 and FITC-conjugated 
rat anti-mouse CD8 were obtained from BD Biosciences (Madrid, Spain). The FITC-
conjugated goat anti-mouse IgM (anti-µ), the anti-mouse IFN-γ and biotin rat anti-mouse 
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IFN-γ  was purchased from PharMingen (San Diego, CA, USA). The mouse IgA ELISA 
quantification kit was obtained from Bethyl Laboratories, (Montgomery, USA). All 
reagents used were of analytic grade. All solutions were prepared in ultrapure water. 
6.2.2 Methods 
6.2.2.1 Preparation of the coated nanoparticles 
The preparation of the alginate coated chitosan nanoparticles was performed according 
to the method previously described [23]. Briefly, chitosan was dissolved at a 
concentration of 0.25% (w/v) in diluted acetic acid solution. The formation of the particles 
was achieved after the addition of 3.5 ml of sodium sulfate solution (10% w/v) to 200 ml 
of the chitosan solution. The resulting suspension was centrifuged for 30 minutes at 
3500 rpm (2800 x g) and the supernatant was discarded. The particles were re-
suspended in ultrapure water and centrifuged twice. Finally, they were frozen in liquid 
nitrogen and freeze-dried overnight using a Labconco freeze dry system (Labconco 
Corporation, Kansas, USA). The dry powder was kept frozen until further use. 
The loading of the nanoparticles with HBsAg or with CpG ODN was performed by 
incubating a solution of HBsAg or the solution of CpG with a suspension of chitosan 
particles in phosphate buffer at pH 7.4, under mild agitation at room temperature for 120 
minutes. The resulting suspensions with the composition of 0.05% (w/v) HBsAg and 
0.5% (w/v) nanoparticles and the second with 0.05% (w/v) CpG and 0.5% (w/v) 
nanoparticles were used in the subsequent coating step. Alginate coated nanoparticles 
were obtained by mixing equal volumes of the loaded nanoparticles suspension and a 
buffer phosphate solution of sodium alginate (1% w/v) under magnetic stirring. The 
agitation was maintained for 20 min. The suspension was then centrifuged for 10 min at 
1600 rpm and the supernatant was discarded. The particles were re-suspended in 0.262 
mM CaCl2 in 50 mM HEPES buffer solution, kept under agitation for another 10 minutes 
and immediately administered to the mice. 
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6.2.2.2 Evaluation of the loading efficacy of HBsAg and CpG ODN in coated 
nanoparticles. 
The loading efficacy of the coated particles was calculated in an indirect way, quantifying 
the antigen that remained in solution as described before [22]. After the coating with 
alginate, an aliquot of the particle suspension was centrifuged at 14,000 rpm for 15 
minutes and the protein concentration in the supernatant was quantified by micro-BCA-
protein assay (PIERCE, Rockford, USA) using a microplate reader with a 570 nm filter.  
For the CpGODN the same procedure was followed and the oligodeoxynucleotide 
concentration quantified by measuring the OD of the supernatants at 260 nm. To 
eliminate background interference, the supernatant of unloaded particles was processed 
by the same way. The results refer to the nanoparticle batches used in the vaccination 
studies. 
The loading efficacy (LE) and the loading capacity (LC) were calculated from the 
following equations: 
 
Eq. 1 - LE (%) = (Total amount of HBsAg or CpG – free HBsAg or CpG)/Total amount of 
HBsAg or CpG*100 
 
Eq.2 - LC (µg of HBsAg or CpG/mg chitosan nanoparticles dry weight) = (Total amount 
of HBsAg or CpG – free HBsAg or CpG)/ mg chitosan nanoparticles dry weight. 
6.2.2.3 Immunization studies 
6.2.2.3.1 Animals: 
Seven week-old female BALB/cAnNHsd mice were used (Harlan Iberica, Barcelona, 
Spain) with four or six mice per group. Animals were housed for acclimatization one 
week before the experiments at the animal resource facilities of the Faculty of Pharmacy 
at University of Porto. Animal care, handling and immunization protocols were in 
accordance with institutional ethical guidelines. They had free access to food and water, 
with 12h light/dark cycle.  
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6.2.2.3.2 Treatment groups 
Group I - suspension of alginate coated chitosan nanoparticles loaded with 10 µg HBsAg  
Group II - suspension of alginate coated chitosan nanoparticles loaded with 10 µg 
HBsAg plus 10 µg of the adjuvant (CpG ODN) in solution. 
Group III - suspension of the mixture of alginate coated chitosan nanoparticles loaded 
with 10 µg HBsAg and the same particles loaded with 10 µg CpG ODN  
Group IV - solution with 10 µg HBsAg 
Group V - solution with 10 µg HBsAg and 10 µg CpG ODN 
Group VI - untreated or negative control  
Group VII – subcutaneous administration of Engerix B (1 µg HBsAg) (positive control) 
6.2.2.3.3 Immunization schedule 
The primary immunization was followed by two boosts with three week interval, between 
each immunizations and the mice were sacrificed 4 weeks after the last boost. To evoke 
an immune response a total volume of 15 µl (7.5 µl in each nostril) of the formulations 
were administered. The non-anesthetized mice were maintained in supine position and 
the formulation was deposited in the nasal cavity with the aid of a micropipette with a 10 
µl tip. The mice were kept in this position for another 5 min to allow optimal spreading of 
the formulations on the nasal mucosa. 
6.2.2.3.4 Sample collection 
Blood samples were taken from the orbital sinus before each boost and by cardiac 
puncture at the end of the experiment. The sera were prepared by centrifugation and 
stored at -20ºC until analysis. 
Vaginal secretions were collected at the end and 4 days before the end of the 
experiment, by rinsing with 150 µl of a cold PBS (containing 0.1% bovine serum albumin 
(BSA)) through the vagina. The 1% BSA-PBS solution was introduced into the vaginal 
tract of non-anesthetized mice using a Gilson pipette. These 150 µl aliquots were 
withdrawn and reintroduced six times.  
Nasal secretions were collected just at the end of the experiment, by washing the 
nasal cavity with 200 µl of cold PBS (containing 1% BSA). The washing solution was 
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forced to pass throughout the trachea of the sacrificed mice and collected from the 
nostrils side. 
The extracts were vortexed and treated with sodium azide and phenylmethyl 
sulfonyl fluoride (PMSF), allowed to stay at room temperature for at least 15 minutes and 
then centrifuged (6,000 rpm/15 min/4ºC). The clear supernatants (containing 0.1% 
sodium azide, 0.1% BSA and 1 mM PMSF) were then stored at –80ºC until tested by 
ELISA for secretory antibody (sIgA) levels. 
Fecal pellets (4-8) were collected four days before the end of the experiment into 
Eppendorf tubes. The pellets (0.2g/ml) were suspended in PBS (containing 0.1% sodium 
azide, 0.1% BSA and 1 mM PMSF), vortexed and allowed to rest at room temperature 
for 1 hour. Solid matter was separated by centrifugation at 14,000 rpm for 15 minutes. 
The clear supernatants were frozen at -80ºC before being used in ELISA to determine 
antigen-specific and total IgA. 
6.2.2.3.5 Enzyme-linked immunosorbent assays (ELISA) for HBsAg specific 
immunoglobulins 
Ninety-six-well flat-bottomed microtiter plates (Nunc immunoplate maxisorb) were 
previously coated with the recombinant HBsAg (1 µg/well) in coating buffer (50 mM 
sodium carbonate, pH 9.6) by overnight incubation at 4°C. The plates were washed 5 
times with PBS-T (PBS containing 0.05% Tween-20) and blocked with 3% BSA in PBS-T 
(200µl/well) for 1 hour at 37ºC. The plates were then washed 5 times with PBS-T and the 
serial dilutions of each serum (100 µl/well) from the individual mice were tested in 
triplicate, starting from a 1:100 dilution in PBS-T. The serum was incubated for 2 hours at 
37ºC and after washing the plates with PBS-T, they were incubated for an additional 30 
min at 37ºC with peroxidase-labeled goat anti-mouse immunoglobulin G and isotypes 
(anti-IgG1, anti-IgG2a). The bound antibodies were revealed by adding 100 µl/well of 0.5 
mg/ml of o-phenylenediamine dihydrochloride (OPD) (Sigma, Spain) in 10 ml of citrate 
buffer with 10 µl of 30% H2O2. The reaction was stopped after 10 minutes with 50 µl of 
3M HCl to each well. The absorbance was read out at 492 nm in an automatic ELISA 
reader (Easy Reader 400, SLT-LABINSTRUMENTS). Elisa titers were expressed as 
mIU/ml and 1 mIU is the OD mean of the pre-immune serum plus 2 times the standard 
deviation.  
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The measurement of IgA was carried out using a mouse IgA ELISA quantification 
kit (Bethyl Laboratories, Montgomery, Texas, USA) as described by the manufacturer. In 
order to measure the sIgA levels in the gut, nasal and vaginal secretions, total sIgA and 
the specific anti-HBs sIgA were determined in the extracts. The results are presented as 
the anti-HBsAg IgA/total IgA. By this way variations between samples related with the 
extraction process or stability of the sIgA were minimized.  
The standard IgA was diluted to appropriate concentrations in PBS with 1% BSA 
to create a calibration curve. The extracts were diluted in PBS-T with 1% BSA and added 
to the plates in series of two-fold dilutions. The concentrations of the total and specific 
IgA were determined from the calibration curve generated for each set of samples using 
a four parameter logistic curve-fit generated by SigmaPlot software (version 8.0, SPSS 
Inc). 
6.2.2.3.6 Preparation of spleen cell suspensions 
The mice were euthanized by cervical dislocation and their spleens were aseptically 
removed. Individual spleen cell suspensions were prepared in a Petri dish using curved 
needles and washed twice with RPMI 1640. The final suspension was adjusted to a final 
concentration of 1x107 cells /ml in complete RPMI 1640 medium supplemented with 10% 
(v/v) fetal bovine serum (FBS), 1% (v/v) glutamine, 1% (v/v) Pen-Strep and 2% (v/v) 1M 
HEPES buffer. 
6.2.2.3.7 Spleen cell populations 
The cells (106) were washed twice with cold PBS supplemented with 2% FBS and then 
incubated in the dark for 30 minutes at 4ºC with saturated concentrations of FITC-
conjugated rat anti-mouse CD4 or FITC-conjugated rat anti-mouse CD8 or FITC-
conjugated goat anti-mouse IgM (anti-µ). After incubation, cells were washed three times 
with PBS-2% FBS and then re-suspended in 500 µl PBS-2% FBS. To exclude dead 
cells, 2.5 µl propidium iodide (50 µg/ml) were added just before data acquisition. At least 
10,000 events were analysed by flow cytometric acquisition, performed in a fluorescent 
activated cell sorter (FACS Calibur) (BD, Biosciences, Madrid, Spain). Data were 
analysed by CellQuest software (BD, Biosciences, Madrid, Spain).  
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6.2.2.3.8 Splenocyte cell culture in the presence of the mitogens 
Using sterile 96-well flat-bottomed tissue culture plates, 25 µl of splenocyte suspension 
(1x107 cells/ ml) from each mouse were plated in triplicate along with 25 µl of a complete 
RPMI solution of the mitogen [Con A (50 µg/ml), CpG ODN (50 µg/ml) plus HBsAg (16 
µg/ml), HBsAg alone (16 µg/ml) or without mitogen (control)]. Finally the volume of the 
well was completed to 200 µl with complete RPMI and incubated at 37ºC with 95% 
relative humidity and in the presence of 5% CO2.  
6.2.2.3.9 Interferon-γ (IFN-γ) production by splenocytes 
Spleen cell suspensions were plated with the mitogens (see 2.2.3.8) and incubated in a 
humidified 5% CO2 incubator for 96 h at 37ºC. The plates were centrifuged and the clear 
supernatants stored at –80ºC until analysis of the IFN-γ by ELISA technique, following a 
procedure described elsewhere [24].  
6.2.2.3.10  Lymphoproliferation assay 
Splenocytes were obtained and cultured together with the mitogens in a flat-bottomed 
96-well plate as described before (see 2.2.3.8). The cells were cultured for 96 hours at 
37ºC and on the last 8 h of incubation each well was pulsed with 1µCi of [methyl-3H] 
thymidine. These 96 well plates with the cells were stored at -20ºC until further analysis.  
The cells were later thawed and harvested onto a fiberglass filter (filter mats, 
molecular devices, Skatron, Lier, Norway) using a semiautomatic cell harvester (Scatron 
Instruments, USA) and DNA thymidine incorporation was determined by standard liquid 
scintillation techniques with a Beckman LS 6500 scintillation counter (Beckman Coulter 
Inc, Fullerton, USA). Thymidine incorporation was expressed as counts per minute 
(cpm).  
6.2.3 Statistical analysis 
Data were presented as the mean ± S.E.M. for at least three experiments and statistical 
significance was assessed using one-way analysis of variance (ANOVA) followed by 
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Dunnett’s post test using the Prism 4 (GraphPad software, Ca, USA). Differences were 
considered significant when p<0.05.  
6.3 RESULTS  
6.3.1 Characterization of the vaccine delivery system 
In a recent publication of our group, the development of alginate coated chitosan 
nanoparticles and the characterization of this new delivery system were reported [23]. 
Briefly, before coating with sodium alginate, the chitosan nanoparticles with a mean 
diameter of 643 nm (dynamic light scattering technique) were positively charged (+37 
mV). Scanning electron microscopy (SEM) images of the uncoated particles also 
revealed the presence of small nanoparticles (around 100 nm) but demonstrated that the 
majority of the coated particles were in a range between 300 and 600 nm. More recently, 
we showed the results of the release studies, choosing ovalbumin as a model vaccine 
[22]. Ovalbumin release studies from coated and uncoated chitosan nanoparticles, 
performed in several buffers at different pH values, allowed us to conclude that the 
coating with sodium alginate of the ovalbumin loaded chitosan nanoparticles avoided an 
ovalbumin burst release observed with uncoated chitosan nanoparticles at pH 5.5; 6.8 
and 7.4 (phosphate buffer) within the first 30 minutes of incubation.  
6.3.2 CpG ODN and hepatitis B antigen entrapment in coated nanoparticles 
Different ratios of hepatitis B vaccine to chitosan nanoparticles and CpG ODN to 
chitosan nanoparticles were investigated (data not shown) and the systems with the 
highest loading efficacy were used for further studies. It was shown that hepatitis B 
antigen and CpG ODN were efficiently associated with alginate coated chitosan 
nanoparticles. The loading efficacy of hepatitis B vaccine in the coated nanoparticles 
was 84.1 ± 3.0 % (mean ± STDEV) and the mean of the loading capacity was 83.9 µg of 
HBsAg/ mg of dry chitosan nanoparticles ± 2.77 (STDEV). The loading efficacy of CpG 
Chapter 6 
           
- 154 - 
was 97.0 ± 1.3% and the loading capacity was 97.0 ± 0.03 (µg of CpG ODN/ mg of dry 
chitosan nanoparticles). 
6.3.3 Cellular immune responses after intranasal administration of HBsAg 
loaded nanoparticles. 
The percentage of T- and B-lymphocytes was determined in order to examine the 
possible influence of the HBsAg formulations on the cell populations of the mouse 
spleen. Figure 1A shows the results of the FACS analysis performed with freshly 
prepared spleen cell suspensions, using specific mAb against cell surface markers. The 
percentages of CD8+ and CD4+ T-lymphocytes subpopulations in different groups were 
shown not to have been significantly different from the control group (p>0.05). The group 
I vaccinated with the HBsAg associated with the coated nanoparticles was an exception 
and was shown to have a significantly lower percentage (p<0.05) of CD8+ T-cells (0.7-
fold decrease compared to the control mice), whereas no significant difference in the 
ratio of CD4+/CD8+ T-cells (Fig. 1B) was observed in the same group when compared 
with the control group. A slight, but statistically significant difference (p<0.01) in the 
decrease of B cells was observed in the groups vaccinated without nanoparticles (groups 
IV, V and VII).  
We also tested whether the spleen lymphocytes were susceptible to proliferation 
when cultured in the presence of the antigen or the antigen plus the adjuvant. The 
comparison between the results obtained with cells cultured without mitogens (negative 
control of the experiment) (Fig. 2A) and the results of cells incubated only with the 
HBsAg (Fig. 2B) allowed us to conclude that in general the presence of the antigen in the 
cell culture proved the ability to induce some division of the cells. However in the 
concentration used, the stimulation appeared to be non-specific and, in general, the 
results shown appeared just amplified, when compared with the results without any 
stimulus. In most cases, the different groups were shown not to be different from the 
control group. However, two exceptions with a higher mean value (p<0.01) were 
observed: the group vaccinated with the antigen in solution and the group vaccinated 
with a solution of the antigen in the presence of the adjuvant (groups IV and V). 
Nonetheless, due to high variability of the individual values within the groups, these 
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results should not be overestimated. A similar situation was observed for the cells 
cultured with antigen in the presence of CpG ODN (Fig. 2C). 
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Figure 1 – A) - Percentage of T-lymphocytes CD4+, CD8+ and B+ Lymphocytes in the spleens 
of mice from groups (I, II, III, IV, V, VI and VII) by FACS analysis. Each bar corresponds to the 
group geometric mean plus the standard error of the mean. The comparison between the 
control group (VI) and the different treatment groups (I, II, III, IV, V, VII) was made with a one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple comparison test (** p<0.01 
and *p<0.05). B) – T-lymphocytes quota between percentage of CD4+ cells and CD8+ cells 
from individual mouse spleen of each group. 
Finally, figure 2D shows the lymphoproliferative results observed in the presence 
of Con A, a classical mitogen, which served as a positive recall antigen. In this case all 
the groups vaccinated intranasally showed significantly (p< 0.01) lower values. In 
addition, the group vaccinated with a commercial formulation by subcutaneous injection 
showed a higher mean value (p< 0.01) when compared to the control (group VI). 
The quantification of the interferon-γ (IFN-γ) in the supernatants of the different 
group splenocytes, cultured under the same conditions is shown in figure 3. A direct 
observation of the results allowed us to conclude that the splenocytes of all the groups 
vaccinated produced IFN-γ. Moreover, the statistical analysis showed that the amount 
produced is significantly higher than the amount produced by the cells from the control 
group in all the groups. 
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Lymphoproliferative assay
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Figure 2 – Lymphoproliferative response after intranasal administration of the different hepatitis 
B vaccine formulations. In vitro proliferation of individual mouse splenocytes during a 96 hour 
period stimulated with: A) - without stimulus. B) – HBsAg. C) – HBsAg + CpG ODN, D) Con A. 
Each circle represents the result of individual samples and the horizontal bar the mean of the 
group. The results correspond to the thymidine incorporation and are expressed as counts per 
minute (cpm).  
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Figure 3- IFN-γ production by splenocytes of individual mice from each treatment group (Groups 
I-VII). Each bar corresponds to the group geometric mean plus the standard error of the mean 
(n between 3 and 6). The comparison between the control group (VI) and the different treatment 
groups (I, II, III, IV, V, VII) was made with a one-way analysis of variance (ANOVA) followed 
Bonferroni’s test.   
6.3.4 Humoral immune response to the intranasal administration of HBsAg 
nanoparticles. 
6.3.4.1 Systemic immune response 
The positive control group of the experiment received a subcutaneous injection with 1 µg 
of HBsAg in the presence of aluminium adjuvant (commercial formulation). The highest 
concentrations of the anti-HBsAg IgG were observed within this group (Fig. 4A). The 
presence of HBs specific IgG was also observed in some mice within the groups nasally 
vaccinated with the antigen and in the presence of CpG ODN. The groups I and IV 
(absence of CpG ODN) did not induce detectable anti-HBs IgG antibodies in the plasma 
of any mice. Therefore the presence of a strong mucosal adjuvant seemed to be 
necessary to induce a systemic humoral immune response in mice vaccinated with 10 µg 
of the HBsAg. On the other hand, the results also showed that within the nasally 
vaccinated groups the highest IgG titers were found in the groups where the adjuvant 
was not associated with the nanoparticles (groups II and V).  
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The anti-HBsAg IgG subclasses present in the responder mice were also 
evaluated in order to examine the induced Th profile as shown in figure 4B. In the 
seroconverted nasally vaccinated mice the detected antibodies were predominantly type 
IgG2 (Th1–like), whereas with the commercial formulation administered subcutaneously, 
the responses were predominantly Th2 (IgG1>IgG2a).  
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Figure 4 – A) - Serum anti-HBsAg IgG titers of mice nasally immunized with different 
formulations of hepatitis B vaccine. Values are expressed as antibody titers of individual mice 
taken at the end of the experiment. The horizontal bar is the mean of the group. B) - Serum anti-
HBsAg IgG1 and IgG2a titers of mice nasally immunized with different formulations of hepatitis 
B vaccine. The bar corresponds to mean titer of responder mice in each group. Titers were 
defined as the highest plasma dilution resulting in an absorbance value twice that of 
nonimmune plasma (1 mlU/ml = mean + 2 SD of the control group). 
6.3.4.2 Mucosal immune response 
Nasal and vaginal washings and the collection of fresh feces were performed at the end 
of the experiment in order to evaluate the presence of HBsAg specific antibodies (sIgA) 
on the mucosal surfaces. Detection of sIgA in the nasal washings was possible in almost 
all the groups nasally vaccinated (Fig. 5A). The exception was group IV vaccinated with 
a solution of the antigen for which no specific sIgA could be detected. Similarly, it was 
not possible within this group to detect antibodies in the vaginal washings (Fig. 5B) or in 
the feces (Fig. 5C), where only one mouse presented a very small amount of the HBsAg- 
specific sIgA. The entrapment of the hepatitis B antigen into the coated nanoparticles 
(group I) showed to improved the vaccine inducer ability for the generation of specific 
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mucosal antibodies. This formulation induced the generation of anti-HBsAg sIgA not only 
at the nasal mucosa (4/6) (Fig. 5A) but also in vaginal secretions (3/6) (Fig. 5B). The 
application of the suspension of the nanoparticles associated with both the antigen and 
the adjuvant (group III) yielded similar results to group I. Group II differs from the group 
III because in this group the CpG is not associated with the coated nanoparticles. In this 
case not only the number of responder mice increased (4/5 nasal secretions, 4/5 vaginal 
secretions) but also the relative amount of the specific antibodies detected was much 
higher (Fig. 5A and B).  
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Figure 5 – Secretory anti-HBsAg sIgA profile detected in individual mice samples of immunized 
mice with different hepatitis B vaccine oral formulations. Each circle represents the result of 
individual samples and the horizontal bar the mean of the group. A) – nasal washings. B) – 
vaginal washings. C) – feces. Samples with the value equivalent to mean plus twice the SD of 
the control group (Group III), were considered anti-HBsAg sIgA positive. The values were 
expressed as the ratio between the anti-HBsAg sIgA (ng/ml) and total sIgA (mg/ml) 
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A similar and anticipated result was obtained with the formulation in which the 
antigen and the adjuvant were not associated with the coated nanoparticles (group VI). 
In a comparable study performed by McCluskie [25], the intranasal immunization of mice 
with the same doses of the HBsAg plus the CpG ODN in a solution, also induced the 
generation of both systemic and mucosal antibodies. Anti-HBsAg sIgA in the lung, gut, 
saliva, vaginal secretions and in feces could be determined by the same researchers. 
Finally, as predictable, the subcutaneous injection of the commercial formulation 
did not produce any detectable mucosal antibodies in nasal washings extracts.  
6.4 DISCUSSION 
In several publications it has been convincingly demonstrated that the subcutaneous (sc) 
or the intramuscular (im) routes of vaccine application are not effective to induce antigen 
specific mucosal antibodies. In the present work, it was possible to confirm once more 
that the sc vaccination with a commercial formulation of the hepatitis B (group VII), was 
unable to induce the generation of detectable sIgA in both, vaginal and nasal secretorial 
fluids. The induction of mucosal antibodies, with few exceptions described elsewhere for 
hormonally induced immunomodulation after intramuscular administration of HBsAg [26], 
seems to be only feasible when a mucosal route of vaccination was chosen and the HBs 
antigen was associated with an appropriate adjuvant. On the other hand, the importance 
of inducing mucosal antibodies after a  immunization process has been well emphasized 
in the last few years [27-29]. This aspect is even more relevant for those infections that 
start their deleterious effects on the mucosal surfaces. In these cases, the infection can 
be resolved before the causative agent enters the blood. The main protective 
mechanism is the generation of a local secretory immune response, with secretory IgA 
(sIgA) antibodies as the primary effectors molecules, but additional humoral and cell-
mediated mucosal protective mechanism have also been identified [27, 30].   
It is well known that one of the more important modes of hepatitis B virus 
transmission is the sexual contact with an infected person [31]. Therefore, the induction 
of the anti-HBsAg sIgA at the urogenital surface  would be of great benefit. In the present 
work, the intranasal administration of a saline solution with 10 µg of HBsAg without any 
adjuvant (group IV)  was not able to induce the generation of mucosal or systemic 
Chapter 6 
           
- 161 - 
antibodies. Similar results were also observed by other groups [10, 14, 18]. Therefore, all 
the evidences show that an adjuvant is required for the intranasal route, in order to 
obtain a HBV protective immune response. It has been reported that alum (insoluble 
aluminium salts), the unique adjuvant approved by the US Food and Drug 
Administration, is ineffective for the induction of mucosal immunity [32]. Consequently, 
the investigation of novel, non- toxic adjuvants for the expression of suitable antigens at 
mucosal surfaces is necessary. In this work, the evaluation of the immune response 
followed by the intranasal vaccination with the HBs antigen associated to the alginate 
coated chitosan nanoparticles was evaluated for the first time. This delivery system 
proved to efficiently encapsulate the HBs antigen and in preliminary studies [22] also 
showed the capability for internalization by intestinal Peyer’s patches through specialized 
M-cells. We did not study the uptake of the alginate coated chitosan nanoparticles into 
the epithelium of nasopharyngeal lymphoid tissue (NALT). However, it was 
demonstrated by Y. Fujimura [33, 34] in an  electron microscopic study that the M cells of 
human NALT are ultrastructurally similar to those in Peyer’s paches and colonic 
lymphoid follicules. On the basis of these facts, we assumed that an identical alginate 
coated chitosan particle uptake in the NALT would occur. Moreover, to support this 
hypothesis, the uptake of chitosan nanoparticles into the epithelium of human [35] and 
trimethyl-chitosan nanoparticles into mice NALT [36] has already been demonstrated. 
Equally important, in a study performed by Tafaghodi [37], alginate microspheres 
showed to have a clearance rate in the human nose similar to PLGA microspheres and 
lower than sephadex microspheres, and were therefore considered as a suitable nasal  
delivery system. The alginate coating of the chitosan nanoparticles described here, may 
show a similar behaviour as solid alginate particles on mucosal surfaces, at least during 
the initial contact with mucosal surfaces.          
In the present work, the HBV antigen associated to the chitosan core in alginate 
coated chitosan nanoparticles was able to induce the generation of mucosal antibodies 
with strong relevance for nasal secretions. This formulation also induced to some extent 
a cellular immune response; however the highly required systemic immune response 
was not induced. The difference between these results and the ones with the solution of 
the antigen, proved in an indirect way the superior capacity of the chitosan particles in 
retaining the antigen in the nose cavity. On the other hand, the systemic non-
responsiveness in this group could be also explained by a mucosally induced tolerance 
[9]. This is merely a hypothesis since cellular and molecular contributions of the 
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immunocompetent cells present in NALT to the generation of tolerance are unknown [9]. 
However, if this kind of immune response (only mucosal antibodies) would suffice to 
protect human recipients from a HB infection, especially against transmission by the 
urogenital tract, it should be further investigated.   
Anti-HBsAg IgG antibodies were detected only in the serum of mice immunized 
with formulations containing a class B CpG ODN (1826). It has been proven that this 
adjuvant is a potent immunopotentiator and can not be compared with an antigen 
delivery system the mechanism of which seems to be only related with its capacity of 
slow release the antigen or to facilitate the antigen internalisation into antigen-presenting 
cells (APCs) [32]. Conversely, there are strong indications that responses to CpG are 
dependent on the presence of TLR9 in the cells [38-40]. After interaction with this 
receptor, the activation of cell signalling pathways occurs, which results in a cascade of 
immune events [41, 42]. In the present study, the best results were found within the 
groups vaccinated with the antigen associated with the nanoparticles plus the adjuvant in 
solution (group II) and in group V, vaccinated with a solution of the antigen plus the 
adjuvant, being group V with the higher titers. One of the hypothesis to explain this result 
could be related with the uptake mechanism of the antigen and the adjuvant in the NALT. 
In the group II, the HBsAg associated with nanoparticles may probably have been 
retained in the NALT during a period that was probably more prolonged than the time 
period of retention of the adjuvant or the free antigen. This fact may cause a lower 
amount of the free antigen in close proximity of the adjuvant when compared with the 
situation observed in the group V, vaccinated with a solution of the antigen and the 
adjuvant not associated with the nanoparticles. The proximity between the HBV antigen 
and the CpG ODN has been demonstrated to be an important condition for the intensity 
of the antigen specific immune response [43-45]. Some examples were reported in the 
literature, e.g., the adjuvant activity of a non-coding plasmid was demonstrated  only 
when the plasmid and the HBsAg were co-entrapped in the same liposomes, but not in 
separate vesicles [45]. Interestingly enough, we have observed the same effect: in fact 
with group III, where both antigen and adjuvant were associated with separate 
nanoparticles and the result obtained was similar to the result obtained with group I (i.e. 
the group without CpG ODN). The results indicated that the association of the CpG ODN 
to separate chitosan nanoparticles was not a good strategy for the intranasal 
administration. Further studies are needed to evaluate if the co-encapsulation of the 
antigen and the adjuvant in the same nanoparticle would produce a better immune 
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response. On the other hand, the CpG ODN used in this vaccination study is synthesized 
with a phosphorothioate (PS) backbone and hence is resistant to nuclease degradation. 
Consequently, the use of this CpG for intranasal vaccination may need no protection. 
However, the second mechanism by which the nanoparticles may improve the efficacy of 
the CpG ODN is by a depot effect, which may result in an extended period during which, 
both, antigen and CpG ODN are available in the application site, therefore increasing 
their probability for being internalized by the NALT cells [39]. Therefore in this case the 
encapsulation may be useful, however the poor immunogenic response observed in the 
group III, led us to hypothesise that the free amount of the CpG ODN was not high 
enough to stimulate the immune system to respond to the HBV antigen. Therefore, the in 
vivo CpG ODN amount released from the coated nanoparticles was most probably, 
inadequate. This phenomenon could be associated with a strong affinity of the CpG 
ODN’s to the cationic chitosan [46, 47]. This hypothesis was addressed in different 
studies where a poor transfection by chitosan-DNA nanoparticles was observed [48, 49] 
and dependent on several factors, including the degree of deacetylation and molecular 
weight of the chitosan, and the chitosan/plasmid charge ratio conferred, essentially by  
amino amino groups (chitosan) and phosphate groups (DNA) [50, 51].  
Nevertheless, these results are still not fully conclusive with regard to the 
advantages of the association of the CpG ODN to nanoparticles. As referred above, 
theoretically, suitable nanoparticles may increase the residence time in the NALT tissue 
and facilitate the internalization of the CpG into the mucosal lymphoid tissues. This 
would decrease the amount of the immunopotentiator needed for eliciting the desirable 
adjuvant effect. Once inside the target tissue, the ideal delivery system should release 
the CpG ODN, while most cell types have the capacity to take up CpG ODN via 
endocytosis [52] or the CpG ODN internalization in cells would be facilitated by the use 
of CpG associated to suitable nanoparticles. 
Several studies in the literature have shown that chitosan is a biopolymer with 
characteristics for high loading efficacy of macromolecules like, peptides, plasmid 
vectors, DNA and vaccines. Promising results of intranasal vaccination using Bordetella 
bronchiseptica [53], meningococal C conjugate vaccine with mucosal adjuvant LTK63 
mutant [54], diphtheria [55, 56] and influenza antigens [57] all associated with chitosan 
particles or just with chitosan powder have been demonstrated in animal models. More 
recently, the nasal vaccination in human volunteers by simple syringe insufflations of 
Menjugate-C associated with chitosan produced geometric mean titers of serum 
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bactericidal antibody comparable to parenteral immunization. More importantly, the sIgA 
antibodies were detected in nasal washings [58]. Compared with the above cited 
vaccines, recombinant hepatitis B surface antigen is considered to be a weaker antigen. 
Therefore, chitosan based formulations need to be improved, in terms of a delivery 
system for the simultaneous intranasal administration of the vaccine and an 
immunopotentiator yielding synergistic effects.  
6.5 CONCLUSION 
The association of the HBsAg with alginate coated chitosan nanoparticles, administered 
nasally to mice, gave rise to humoral mucosal immune responses, which was not 
induced by the HBsAg alone. The generation of systemic, predominantly Th1-type 
antibodies was observed when the HBV antigen entrapped in the particles was 
administered simultaneously with the adjuvant, CpG ODN, in solution. Future work will 
focus in the improvement of the chitosan nanoparticles in order to better control the in 
vivo CpG ODN release from the particles and the co-entrapment of the antigen and the 
adjuvant, in order to elicit not only mucosal antibodies but also, if possible, systemic 
humoral immune response. 
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ABSTRACT 
We recently described a delivery system that is composed of a chitosan core to which 
the hepatitis B surface antigen (HBsAg) was adsorbed and then coated with sodium 
alginate as the second polymer. In this work, the alginate coated chitosan nanoparticles 
were evaluated as a subcutaneous adjuvant for HBsAg. A high anti-HBsAg IgG titer 
(2271 ± 120 mIU/ml), with the majority of antibodies being of Th2 type, was observed 4 
weeks after the boost. The specific antigen immune response was 5.3-fold higher than 
the mean value found for the control group immunized with the saline solution of the 
antigen. However, regarding the cellular immune response, no important differences 
were observed for the antigen-specific splenocyte proliferation or for the secretion of Th1 
(IFN-γ) and Th2 type cytokines (IL-4). Additionally, the co-delivery of antigen-loaded 
nanoparticles and the adjuvant, CpG ODN 1826, was investigated. The increase in anti-
HBsAg IgG titers was not statistically different from the first group; however, an increase 
of the IgG2a/IgG1 ratio from 0.1 to 1.0 and an increase (p<0.01) of the IFN-γ production 
by the splenocytes stimulated with the HBV antigen was observed. Finally, a third 
formulation, designed as antigen and adjuvant co-adsorption in the same uncoated 
chitosan nanoparticles was also evaluated, but no additional benefits were found in 
comparison to the other formulations.  
The enhancement of the immune response, observed with the antigen-loaded 
nanoparticles demonstrated that chitosan is a promising platform for parenteral HBsAg 
delivery and when co-administered with the CpG ODN, results in a mixed Th1/Th2 type 
immune response.  
7.1 INTRODUCTION 
Chitosan, a biodegradable and biocompatible polysaccharide with immunological activity 
[1, 2], which acts both as a bioadhesive [3] and an efficient absorption enhancer material 
[4], has also been regarded as a promising polymer for the formulation of vaccine 
delivery systems, especially for the application to mucosal surfaces [5]. Recently, we 
have designed a delivery system composed of a chitosan core to which the hepatitis B 
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surface antigen (HBsAg) was adsorbed and then coated with sodium alginate. This 
delivery system was recently evaluated for the mucosal routes of immunization. 
On the other hand, the evaluation of chitosan as an adjuvant for parenteral 
vaccination has been less studied and, in most cases, the results of the vaccination were 
reported together with the results of intranasal or oral vaccination studies, making the 
possible value of chitosan as an adjuvant for parenteral routes less perceptible in the 
scientific literature. Generally speaking, the development of safe novel adjuvants is 
necessary not only for the more challenging environment of the mucosal surfaces, but 
also for parenteral vaccination, to maximize the efficacy of new or already available 
vaccines. In the last few years this idea became even more urgent since the newer 
generation of antigens are predominantly purified recombinant proteins, which are often 
poorly immunogenic. Additionally, new generation of adjuvants may also allow 
vaccination strategies to be applied to novel areas, including “therapeutic” vaccines 
designed to control allergies, auto-immune diseases, malignancies, drug dependencies, 
neural diseases, or fertility [6]. 
Despite the efficacy of hepatitis B virus vaccines, immunization failure may occur 
and can sometimes be explained by several factors such as improper storage or 
administration of the vaccines, advanced age, chronic liver disease, and 
immunosuppression. Another important factor causing a non-responder rate of up to 
10%, seems to be a genetically determined resistance [7, 8]. Moreover, all the 
conventional licensed hepatitis B vaccines in use contain alum as adjuvant. Although 
being a potent B cell stimulator, alum is less effective in inducing a Th1 response by the 
intramuscular route [9]. The Th1 type immune responses, characterized by secretion of 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), opsonizing antibodies such as the 
IgG2a isotype, and strong cytotoxic T-lymphocyte (CTL) induction, are necessary for the 
control of intracellular infections, such as viral infections [10-12]. In contrast, the 
development of a strong Th2 response, which is characterized by the secretion of IL-4 
and IL-5 cytokines and antibodies such as IgG1 and IgE, is more useful in combating 
extracellular infections [12].  
The viral clearance in acute, self-limited hepatitis B virus infection correlates with 
increasing CTL and T-helper cell activities and the occurrence of anti-HBs antibodies 
[13]. In contrast, patients suffering from chronic hepatitis B have insufficient or absent 
immune responses [9, 13]. On the other hand, experimental data support the hypothesis 
that the enhancement of HBV- specific immune reactions could have some beneficial 
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effects in the therapy of chronic hepatitis B [13]. Therefore, it has been suggested [9] that 
the administration of the hepatitis B vaccine alone, or in combination with diverse 
cytokines, should be evaluated in future studies for treatment of chronic hepatitis B virus 
infection. The usefulness of this therapeutic vaccination may be further improved if the 
vaccine was able to induce a stronger Th1 immune response. 
The differentiation of an antigen specific CD4 T helper subset (Th1 or Th2) takes 
place at the time of priming, and the type of stimulated CD4 subset will depend on a 
number of factors, including the cytokine environment [10]. The adjuvant used can alter 
the cytokine environment at the site of the primary immune response [10]. Therefore the 
selection of an appropriate adjuvant is the first step for a successful induction of an 
appropriate immune response. 
In the present study, the above mentioned alginate coated chitosan nanoparticles 
were investigated for the first time as adjuvants for the subcutaneous vaccination with 
the recombinant hepatitis B surface antigen. Moreover, this paper investigates the co-
administration of CpG ODN 1826, a potent adjuvant in mice that was shown to induce 
Th1 type immune response in combination with a number of different antigens, such as 
e.g. influenza virus [14], hepatitis B antigen [15-17], and tetanus toxoid [18], with the 
nanoparticles. 
7.2 MATERIALS AND METHODS 
7.2.1 Materials 
7.2.1.1 Polymers 
Chitosan was purchased from Primex BioChemicals AS (Avaldsnes, Norway). According 
to the provider’s specifications, the degree of deacetylation was 95% (titration method) 
and the viscosity 8 cP (measured in 1% solutions in 1% acetic acid). A low molecular 
weight pharmaceutical grade sodium alginate (MANUCOL LB) was kindly donated by 
ISP Technologies Inc. (Surrey, UK). According to the provider’s specifications, the typical 
values for the percentage of mannuronic and guluronic acid for Manucol LB were 61% 
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and 39%, respectively, with an estimated molecular weight of 18 kDa. Both polymers 
meet the requirements described in the European Pharmacopoeia for use in 
pharmaceutical formulations. 
7.2.1.2 Antigen, adjuvant and reagents 
The hepatitis B surface antigen (HBsAg), (subtype ADW2) was kindly offered by GSK 
Biologicals (Rixensart, Belgium), Engerix B was from GlaxoSmithKline Biologicals 
(Rixensart, Belgium), Class B, CpG ODN (1826) (5’-TCC ATG ACG TTC CTG ACG TT-
3’) was purchased from Coley Pharmaceutical Group (Ottawa, Canada).  
Concanavalin A (Con A), phenylmethanesulfonyl fluoride (PMSF), avidin 
peroxidase conjugate and the BCIP/NBT- purple liquid substrate system for membrane 
were from Sigma Chemicals (St. Louis, USA). Certified fetal bovine serum (FBS) and L-
glutamine (200 mM) were from Gibco (Invitrogen Co, Paisley, Scotland, UK), 1M HEPES 
buffer (0.85% NaCl), RPMI 1640 without L-glutamine and Pen-Strep (10 000 U 
penicillin/ml; 10 000 µg streptomycin/ml) were from Biowhitaker (Cambrex Bio Science, 
Verviers, Belgium). [methyl-3H] thymidine (1.0 mCi/ml) was obtained from Amersham 
Biosciences (UK), R-Phycoerythrin (PE)-conjugated hamster anti-mouse CD69, 
fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD4 and FITC-conjugated 
rat anti-mouse CD8 were obtained from BD Biosciences (Madrid, Spain). The FITC-
conjugated goat anti-mouse IgM (anti-µ), the anti-mouse IFN-γ and biotin rat anti-mouse 
IFN-γ was purchased from PharMingen (San Diego, CA, USA). The mouse IgA ELISA 
quantification kit was obtained from Bethyl Laboratories, (Montgomery, USA). All others 
reagents used were of analytic grade. All solutions were prepared in ultrapure water. 
7.2.2 Methods 
7.2.2.1 Preparation of the coated nanoparticles 
The preparation of the alginate coated chitosan nanoparticles was performed according 
to the method previously described [19]. In brief, chitosan was dissolved at a 
concentration of 0.25% (w/v) in diluted acetic acid solution. The formation of the particles 
was achieved by the addition of 3.5 ml of sodium sulfate solution (10% w/v) to 200 ml of 
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the chitosan solution. The resulting suspension was centrifuged for 30 minutes at 3500 
rpm (2800 x g) and the supernatant was discarded. The particles were re-suspended in 
Millipore water and centrifuged twice. Finally they were frozen in liquid nitrogen and 
freeze-dried overnight using a Labconco freeze dry system (Labconco Corporation, 
Kansas, USA). The dry powder was kept frozen until further use. 
The loading of the chitosan nanoparticles with HBsAg was performed by 
incubating a solution of HBsAg with a suspension of chitosan particles in phosphate 
buffer of pH 7.4 under mild agitation at room temperature during 120 minutes. The 
resulting suspension with the composition of 0.015% (w/v) HBsAg and 0.5% (w/v) 
nanoparticles was used in the subsequent coating step. Alginate coated nanoparticles 
were obtained by mixing equal volumes of the HBsAg loaded nanoparticle suspension 
and a solution of sodium alginate in phosphate buffer (1% w/v) under magnetic stirring. 
The agitation was maintained for 20 min. The suspension was then centrifuged for 10 
min at 1600 rpm and the supernatant was discarded. The particles were re-suspended in 
0.262 mM CaCl2 in 50 mM HEPES buffer solution, kept under agitation for another 10 
minutes and immediately administered to mouse group I. Group II received the same 1% 
particle suspension to which previously CpG ODN was added. Finally, a 1% chitosan 
nanoparticle suspension, which contained CpG and the antigen but was not coated with 
alginate, was administered to mouse group III. 
7.2.2.2 Evaluation of the loading efficacy of HBsAg in coated and uncoated 
nanoparticles. 
The loading efficacy of the coated and uncoated nanoparticles was calculated by an 
indirect way, quantifying the antigen that remained in solution as described before [20]. 
After the coating with alginate, an aliquot of the particle suspension was centrifuged at 
14,000 rpm for 15 minutes and the protein concentration in the supernatant was 
quantified by micro-BCA-protein assay (PIERCE, Rockford, USA) using a microplate 
reader with a 570 nm filter. 
The loading efficacy (LE) and the loading capacity (LC) were calculated from the 
following equations: 
 
Eq. 1 - LE (%) = (Total amount of HBsAg – free HBsAg)/Total amount of HBsAg *100 
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Eq.2 – LC (µg of HBsAg /mg nanoparticles dry weight) = (Total amount of HBsAg – free HBsAg)/ 
mg chitosan nanoparticles dry weight. 
7.2.2.3 Immunization studies 
7.2.2.3.1 Animals: 
Seven week-old female BALB/cAnNHsd mice were used (Harlan Iberica, Barcelona, 
Spain) with four mice per group. Animals were housed for acclimatization one week 
before the experiments at the animal resource facilities of the Faculty. Animal care, 
handling, and immunization protocols were in accordance with institutional ethical 
guidelines. The mice had free access to food and water, with a 12h light/dark cycle.  
7.2.2.3.2 Treatment of groups (see also table 1) 
Group I - suspension of alginate coated chitosan nanoparticles loaded with 10 µg HBsAg  
Group II - suspension of alginate coated chitosan nanoparticles loaded with 10 µg 
HBsAg plus 20 µg of CpG ODN in solution. 
Group III - suspension of the chitosan nanoparticles loaded with 10 µg HBsAg and 20 µg 
CpG ODN  
Group IV – Phosphate buffer saline (PBS; pH 7.4) solution with 10 µg HBsAg (reference 
group) 
Group V - untreated or control  
 
Table1 – Resume of the formulations 
 Group I Group II Group III Group IV 
Chitosan NP X X X - 
Alginate coating X X - - 
HBsAg loaded on NP X X X - 
HBsAg solution - - - X 
CpG ODN loaded on NP - - X - 
CpG ODN in sol. - X - - 
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7.2.2.3.3 Immunization schedule 
The primary immunization was followed by one boost with three week intervals between 
the immunizations. The mice were sacrificed 4 weeks after the boost. To evoke an 
immune response, a total volume of 100 µl of the formulations was subcutaneously 
administered to non-anesthetized mice. 
7.2.2.3.4 Collection of samples 
Blood samples were taken from the orbital sinus before the boost and by cardiac 
puncture at the end of the experiment. The sera were prepared by centrifugation and 
stored at -20ºC until analysis. 
Fecal pellets (4-8) were collected in Eppendorf tubes four days before the end of the 
experiment. The pellets (0.2g/ml) were suspended in PBS (containing 0.1% sodium 
azide, 0.1% BSA, and 1 mM PMSF), vortexed, and allowed to rest at room temperature 
for 1 hour. Solid matter was separated by centrifugation at 14,000 rpm for 15 min. The 
clear supernatants were frozen at -80ºC until determination of antigen-specific and total 
secretory IgA by ELISA. 
7.2.2.3.5 Enzyme-linked immunosorbent assays (ELISA) for HBsAg specific 
immunoglobulins 
Ninety-six-well flat-bottomed microtiter plates (Nunc immunoplate maxisorb) were coated 
before use with the recombinant HBsAg (1 µg/well) in coating buffer (50 mM sodium 
carbonate, pH 9.6) by overnight incubation at 4ºC. The plates were washed 5 times with 
PBS-T (PBS containing 0.05% Tween-20) and blocked with 3% BSA in PBS-T 
(200µl/well) for 1 hour at 37ºC. The plates were then washed 5 times with PBS-T and the 
serial dilutions of each serum (100 µl/well) from the individual mice were tested in 
triplicate, starting from a 1:100 dilution in PBS-T. The serum was incubated for 2 hours at 
37ºC and after washing the plates with PBS-T, the plates were incubated for additional 
30 min at 37ºC with peroxidase-labeled goat anti-mouse immunoglobulin G and isotypes 
(anti-IgG1, anti-IgG2a, anti-IgG2b, and anti-IgG3). The bound antibodies were revealed 
by adding 100 µl/well of 0.5 mg/ml of o-phenylenediamine dihydrochloride (OPD) 
(Sigma, Spain) in 10 ml of citrate buffer with 10 µl of H2O2. The reaction was stopped 
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after 10 minutes with 50 µl of 3M HCl to each well. The absorbance was read at 492 nm 
in an automatic ELISA reader (Easy Reader 400, SLT-LABINSTRUMENTS). ELISA 
titers were expressed as mIU/ml, and 1 mIU is the mean OD of the pre-immune serum 
plus two times the standard deviation.  
The measurement of IgA was carried out using a mouse IgA ELISA quantification 
kit (Bethyl Laboratories, Montgomery, Texas, USA) as described by the manufacturer. In 
order to measure the sIgA levels in the feces, total sIgA and the specific anti-HBs sIgA 
were determined in the extracts. The results are presented as the anti-HBsAg IgA/total 
IgA. By this way, variations between samples related with the extraction process or 
stability of the sIgA were minimized.  
The IgA standard was diluted to appropriate concentrations in PBS with 1% BSA 
to create a calibration curve. The gut washes were diluted in PBS-T with 1% BSA and 
added to the plates in series of two-fold dilutions. The concentrations of the total and 
specific IgA were determined from the calibration curve generated for each set of 
samples using a four parameter logistic curve-fit generated by SigmaPlot software 
(version 8.0, SPSS Inc). 
7.2.2.3.6 Preparation of spleen cell suspensions 
The mice were euthanized by cervical dislocation and their spleens were aseptically 
removed. Individual spleen cell suspensions were prepared in a Petri dish using curved 
needles and washed twice with RPMI 1640. The final suspension was adjusted to a final 
concentration of 1x107 cells/ml in complete RPMI 1640 medium supplemented with 10% 
(v/v) fetal bovine serum (FBS), 1% (v/v) glutamine, 1% (v/v) Pen-Strep, and 2% (v/v) 1M 
HEPES buffer. 
7.2.2.3.7  Spleen cell populations 
The cells (106) were washed twice with cold PBS supplemented with 2% FBS and then 
incubated in the dark for 30 minutes at 4ºC with saturated concentrations of FITC-
conjugated rat anti-mouse CD4 or FITC-conjugated rat anti-mouse CD8 or FITC-
conjugated goat anti-mouse IGM (anti-µ). After incubation, cells were washed three 
times with PBS-2% FBS and then re-suspended in 500 µl PBS-2% FBS. To exclude 
dead cells, 2.5 µl propidium iodide (50 µg/ml) were added just before data acquisition. At 
least 10,000 events were analysed by flow cytometric acquisition, performed in a 
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fluorescent activated cell sorter (FACS Calibur) (BD, Biosciences, Madrid, Spain). Data 
were analysed with CellQuest software (BD, Biosciences, Madrid, Spain).  
7.2.2.3.8  Splenocyte cell culture in the presence of the mitogens 
Using sterile 96-well flat-bottomed tissue culture plates, 25 µl of splenocyte suspension 
(1x107 cells/ ml) from each mouse were plated in triplicate with 25 µl of complete RPMI 
solution of the mitogen [Con A (50 µg/ml), CpG ODN (50 µg/ml) plus HBsAg (16 µg/ml), 
HBsAg (16 µg/ml) alone, or without mitogen (control)]. Finally the volume of the well was 
filled up to 200 µl with complete RPMI and incubated according to the following 
conditions (see 2.2.3.9 and 2.2.3.10.). 
7.2.2.3.9 Cytokine production by splenocytes 
Spleen cell suspensions were plated with the mitogens (see 2.2.3.8) and incubated in a 
humidified 5% CO2 incubator for 48h (IL-4, IL-10) and 96h (IFN-γ) at 37ºC. The plates 
were centrifuged and the clear supernatants stored at –80ºC until analysis of the 
cytokines by ELISA technique described elsewhere [21].  
7.2.2.3.10 Lymphoproliferation assay 
Splenocytes were obtained and cultured together with the mitogens in flat-bottomed 96-
well plates as described before (see 2.2.3.8). The cells were cultured for 96 hours at 
37ºC and during the last 8 h of incubation, each well was pulsed with 1µCi of [methyl-3H] 
thymidine. The 96 well plates with the cells were stored at -20ºC until further analysis. 
The cells were later thawed and harvested onto a fiberglass filter (filter mats, molecular 
devices, Skatron, Lier, Norway) using a semiautomatic cell harvester (Scatron 
Instruments, USA) and DNA thymidine incorporation was counted by standard liquid 
scintillation techniques with a Beckman LS 6500 scintillation counter (Beckman Coulter 
Inc., Fullerton, USA). Thymidine incorporation was expressed as counts per minute 
(cpm).  
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7.2.3 Statistical analysis 
If not referred to another method, the data were presented as the mean ± S.E.M. for at 
least three experiments and statistical significance was assessed using one-way 
analysis of variance (ANOVA) followed by Dunnett’s post test for comparing the 
vaccinated groups with the control group. The Kruskal-Wallis test followed by Dunn’s 
multiple comparison test, was used for comparing the cytokine values between the 
groups using the Prism 4 (GraphPad software, CA USA). Differences were considered 
significant when p<0.05.  
7.3 RESULTS  
7.3.1 Characterization of the vaccine delivery systems 
Our group recently reported on the development of alginate coated chitosan 
nanoparticles and the characterization of this new delivery system [19]. Briefly, before 
coating with sodium alginate, the chitosan nanoparticles have a mean diameter of 643 
nm (dynamic light scattering technique) and are positively charged (+37 mV). Scanning 
electron microscopy (SEM) images of uncoated particles also revealed the presence of 
small nanoparticles (around 100 nm) and demonstrated that the majority of the coated 
particles were in a range between 300 and 600 nm. More recently [20], we published 
release studies with ovalbumin as a model vaccine. Ovalbumin release studies from 
coated and uncoated chitosan nanoparticles, performed in several buffers at different pH 
values, allowed us to conclude that the coating with sodium alginate of the ovalbumin 
loaded chitosan nanoparticles prevented an ovalbumin burst release observed in 
uncoated chitosan nanoparticles at pH 5.5; 6.8, and 7.4 (phosphate buffer) within the first 
30 minutes of incubation.  
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7.3.2 Hepatitis B antigen entrapment and CpG adsorption to nanoparticles 
Hepatitis B antigen was efficiently associated with alginate coated chitosan 
nanoparticles. The loading efficacy of hepatitis B vaccine in the coated nanoparticles 
was 77.1 ± 3.0 % (mean ± STDEV) and the mean of the loading capacity was 23.1 µg of 
HBsAg/mg of dry chitosan nanoparticles ± 2.1 (STDEV). The adsorption efficacy of CpG 
to the chitosan nanoparticles was 97.0 ± 1.3% and the loading capacity was 29.0 ± 0.03 
(µg of CpG ODN/mg of dry chitosan nanoparticles). 
7.3.3 Cellular immune response to SC administration of HBsAg associated with 
the chitosan nanoparticles 
The study of the spleen cell populations of the mice subcutaneously vaccinated 
with different chitosan based formulations was done immediately after sacrificing the 
mice. The freshly prepared spleen cell suspensions of each mouse were fluorescently 
labelled and analysed by FACS in order to evaluate the hypothetical influence of the 
HBV vaccine associated with chitosan formulations on the cell composition of the spleen. 
A significantly higher percentage of B lymphocytes was observed (Fig. 1) in group I 
(p<0.01), vaccinated with HBV antigen associated with coated nanoparticles than in 
group II (p<0.05), vaccinated with the antigen associated with the coated nanoparticles 
plus the CpG ODN in solution. The percentage of CD4+ and CD8+ T-lymphocytes in the 
spleen was shown not to be significantly different from the percentages found for the 
naïve mice group, 21% (CD4+) and 13% (CD8+), respectively.  
Furthermore, possible changes in the splenocyte function were also studied. One 
of the parameters observed was their ability to proliferate (figure 2) and to produce 
cytokines (figure 3) after being stimulated with HBsAg, HBsAg+CpGODN, and Con A 
(positive control). As expected, after 96 hours of culture without any external stimulation 
(negative control), the splenocytes did not exhibit significant proliferative activity. Group 
IV was an exception, with a mean value statistically higher (p<0.05) than the control 
group; however the variability was high (Fig. 2A). The same behaviour was observed 
when the splenocytes from the same group IV (vaccinated with a solution of the HBsAg) 
were stimulated in vitro with the antigen (Fig. 2B) or with the antigen + CpG ODN (Fig. 
2C), but not with Con A (Fig. 2D).  
Chapter 7 
           
- 182 - 
0
5
10
15
20
25
30
35
40
45
I II III IV V
Groups
(%
)
CD4+ CD8+ B+Cells
**
*
 
Figure 1 – A) - Percentage of T-lymphocytes CD4+, CD8+ and B+ Lymphocytes in the spleens 
of mice from groups (I, II, III, IV and V) by FACS analysis. Each bar corresponds to the group 
geometric mean plus the standard error of the mean. (** p<0.01 and *p<0.05).  
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Figure 2 – Lymphoproliferative response after sc administration of the different hepatitis B 
vaccine formulations. In vitro proliferation of individual mouse splenocytes for a 96 hour period 
stimulated with: A) - without stimulus. B) – HBsAg. C) – HBsAg + CpG ODN, D) - Con A. Each 
circle represents the result of individual samples and the horizontal bar the mean of the group. 
The results corresponded to the thymidine incorporation and are expressed as counts per 
minute (cpm).  
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Another group that showed a statistically higher (p<0.05) proliferative response 
was the group II, vaccinated with the HBsAg associated with the coated nanoparticles + 
the adjuvant in solution. This last result had a different significance. The higher 
proliferative response was selective to the presence of the antigen (p<0.01), HBsAg (Fig. 
2B) or the antigen plus the CpG ODN (p<0.05) (Fig. 2D). Moreover, after the incubation 
with the different compounds, the production of cytokines was analysed in the culture 
supernatants. It was not possible to observe detectable amounts of IL-10 in the 
supernatants of splenocytes cultured without mitogenic compounds or cultured in the 
presence of the HBsAg. Additionally, the concentration of IL-10 was only weakly 
increased (Fig. 3A) in the group IV cultures stimulated with Con A. 
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Figure 3- Cytokine production by splenocytes. The spleens were harvested at 4 week post 
boost and suspension of individual spleen cells were cultured with either medium alone or in the 
presence of different stimulus (HBsAg, Con A and HBsAg+CpGODN). Each bar corresponds to 
the group geometric mean plus the standard error of the mean (n=9). A) – Data are IL-10; B) 
and C) – Data are IL-4; D) – Data are IFN-γ 
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Next we wanted to examine the profile of the cell mediated immune response, 
specifically IFN-γ (Th1) and IL-4 (Th2) cytokines. The production of IL-4 was inhibited in 
the mouse groups vaccinated with the solution of HBsAg and in the group vaccinated 
with uncoated chitosan nanoparticles associated with the antigen and to the adjuvant, 
groups III and IV, respectively. This characteristic was observed in the cultures without 
mitogen, as well as in the cultures stimulated with the HBsAg. Groups I and II, 
vaccinated with the HBsAg associated with coated nanoparticles and in the second case 
with coated nanoparticles + adjuvant, did not show any change in IL-4 production, which 
may indicate that a Th2 immune response was not predominant. Nonetheless, following 
in vitro stimulation of the splenocytes with a solution containing HBsAg + CpG ODN, a 
small, but significant IL-4 enhancement was observed in almost all the vaccinated 
groups (Fig. 3C). On the other hand, this effect was not confirmed with the splenocytes 
cultured in the presence of Con A (positive control), except for the group IV, where a 
statistically higher mean value (p<0.05) was observed again. At the same time, low 
amounts of interferon-γ in the supernatants of the splenocytes, cultured for 96 hours 
without any mitogen, when compared with the non vaccinated mice (control group), were 
observed in all vaccinated groups while a simultaneous enhancement was observed in 
group IV, when the splenocytes were stimulated with the antigen HBsAg and with Con A. 
Furthermore, comparison within HBsAg vaccinated groups showed that an increase in 
the amount of IFN-γ, produced by splenocytes cultured in the presence of the HBsAg 
(p<0.01) or in the presence of con A (p<0.05), in group II (with CpG) occurred when this 
group was compared with group I (without CpG). This result was expected since the 
ability of CpG ODN adjuvant to induce Th1 type cytokines has been previously 
demonstrated [10]. Also of note, is the comparison between the two groups vaccinated 
with formulations containing the CpG ODN. In group II, the adjuvant was in solution and 
in group III the adjuvant was adsorbed together with the antigen to the surface of the 
chitosan nanoparticles. A statistical significant (p<0.01) decrease for the amount of the γ-
IFN produced in the second group referred (Group III) was observed for the cells in vitro 
stimulated with the antigen plus the adjuvant. 
According to these cytokine data, a clear Th1 cellular immune response, induced 
by each formulation, was not observed. On the contrary, a Th1/Th2 mixed response was 
observed in the group vaccinated with a saline solution of the antigen. This mixed 
Th1/Th2 response has been attributed to the HBsAg alone [22].  
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7.3.4 Humoral immune response following subcutaneous administration of 
HBsAg associated with nanoparticles. 
7.3.4.1 Systemic immune response 
The association of the HBV antigen (group I) to the alginate coated chitosan 
nanoparticles induced a strong immune response that was 5.3-fold higher than the mean 
titer found for group IV, vaccinated with the antigen without any adjuvant (Fig. 4A).  
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Figure 4 – A) - Serum anti-HBsAg IgG titers of mice immunized with different formulations of 
hepatitis B vaccine. Values are expressed as antibody titers of individual mice taken in the end 
of the experiment. The horizontal bar is the mean of the group. T-test was used for analysis of 
significance between each group and the group IV. B) - Serum anti-HBsAg IgG1 and IgG2a 
titers of mice immunized with different formulations of hepatitis B vaccine. The bar corresponds 
to mean titer in each group. Titers were defined as the highest plasma dilution resulting in an 
absorbance value twice that of nonimmune plasma (1 mlU/ml = mean + 2 SD of the control 
group). 
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In group I, both anti-HBsAg IgG1 and IgG2a were detected in the serum, however 
there was a clear predominance of IgG1 (Fig. 4B). The addition of the CpG ODN to the 
formulation of the group I, given to group II, resulted in an increase in anti-HBsAg IgG2a 
antibody titers and in a decrease of anti-HBsAg IgG1 antibody titers. Thus, the main 
impact was the breaking of the clear predominance of the Th2 immune response for the 
induction of a mixed Th2/Th1 response (Fig. 4C). Moreover, the mean IgG titers are not 
different between the groups I and II. Consequently it can be concluded that the immune 
response differences between the two groups are only qualitative. Finally, the group III 
was vaccinated with HBsAg + CpG ODN adsorbed to the uncoated chitosan 
nanoparticles. A strong HBsAg-specific IgG immune response was observed and was 
7.7-fold higher than the mean value found for the control group, immunized with the 
saline solution of the antigen. Moreover, comparing group I with group III, the values of 
the anti-HBsAg IgG are not significantly different. However, similar to group I, the group 
III showed a predominance of the IgG1 antibody subtype (Th2 profile immune response). 
The amount of CpG ODN administered to both groups II and III, was equal. In the group 
III, the CpG ODN, associated with the chitosan nanoparticles and therefore less 
available to interact with the immune cells, seemed to exert a smaller effect, resulting in 
the decreased ratio of IgG2a/IgG1 of 1.0 in the group II to 0.7 in the group III (Fig. 4C).   
7.3.4.2 Mucosal immune response 
In this study the evaluation of anti-HBsAg sIgA antibodies in the faeces extracts was 
done with fresh faeces, collected two days before the end of the experiment. As 
expected, since the induction of mucosal antibodies seemed to be complicated, after the 
subcutaneous route of administration of the vaccines, the ratio anti-HBsAg IgA/total IgA 
of the vaccinated groups was not different from the control group (Naïve mice) (Fig. 5). 
7.4 DISCUSSION 
We recently described a new delivery system that is composed of a chitosan core to 
which the antigen was adsorbed and thereafter coated with sodium alginate. One 
advantage of this delivery system is that the antigen is encapsulated under non-stressful 
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conditions, with a high probability that the biological properties of the antigen will remain 
intact, which has been confirmed in our own previous studies (results not shown). 
Coated chitosan nanoparticles were originally designed for targeting and transporting 
recombinant protein antigens to mucosal surfaces, in particular the oral mucosa. In this 
study, we evaluated for the first time the potential of the chitosan nanoparticles as an 
adjuvant for the hepatitis B surface antigen administered by a subcutaneous route. The 
adjuvant effect of the alginate coated chitosan nanoparticles for HBsAg (group I) could 
be clearly demonstrated, by the production of high anti-HBsAg IgG titers, with a clear 
dominance of Th2 type antibodies (IgG1>IgG2a). A similar situation (IgG1>IgG2a) was 
recently reported with a different type of nanoparticle and antigen. For example, 
nanoparticles of poly(D, L-lactic-co-glycolic acid) encapsulated tetanus toxoid, were used 
as a model protein vaccine [18] and also with liposomes encapsulated influenza subunit 
[23], both of which were administered intramuscularly. 
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Figure 5 – Secretory anti-HBsAg sIgA profile detected in individual mice samples of mice faeces 
colleted in the end of the experiment. Samples with the value equivalent to mean plus twice the 
SD of the control group (Group V), were considered anti-HBsAg sIgA positive. The values were 
expressed as the ratio between the anti-HBsAg sIgA (ng/ml) and total sIgA (mg/ml). 
Comparing the results of group I (HBsAg loaded nanoparticles) with the results 
observed with the group vaccinated with the solution of the antigen (Group IV) it can be 
concluded that even though nanoparticles had stimulated both Th1 and Th2 type 
antibodies, IgG2a antibodies was induced in a lower proportion, resulting in a decrease 
of the IgG2a/IgG1 ratio from 0.4 to 0.1. This means that the induced mixed Th1/Th2 
profile was shifted towards the Th2 profile, when the alginate coated chitosan 
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nanoparticles were used as an adjuvant. The enhancement of the Th2 response by a 
formulation with chitosan nanoparticles after intranasal immunization with genetically 
detoxified diphtheria toxin was also recently reported [24]. 
In a previous study (intranasal vaccination), we investigated the induction of an 
immune response to alginate coated chitosan nanoparticles loaded with HBsAg. In the 
same study, we also included a subcutaneous study with a commercially available 
hepatitis vaccine. For this reason, we did not include such a test with a commercially 
available vaccine in the present study. Although the set-up of the nasal study with the 
commercially available vaccine was slightly different compared with the study presented 
here, nevertheless a similar Th2 profile can be observed with both alum (commercial 
formulation) and coated chitosan nanoparticles. 
In addition, after the statistical analysis of the cellular immune responses, it was 
possible to draw attention to the higher percentage of B cells in the spleen and a higher 
proliferation capability of the spleen cells from group I stimulated with Con A, when 
compared with the control group (group V). In contrast, an up-regulation of Th2 type 
cytokines (i.e., IL-4) ex vivo produced by the splenocytes was not observed. On the other 
hand, downregulation of IFN-γ may indicate that natural killer T (NKT) and T cells (Th1 
type cells), which are both IFN-γ producers [13], were less activated in comparison to the 
same cells from the unvaccinated mouse group.  
It has been demonstrated that a cell-mediated immune response, and in 
particular a Th1 response, is important not only for preventing, but also for overcoming 
HBV infections [13, 25] and eliminating the virus from the infected cells [12]. At the same 
time, it has been suggested that the conventional vaccine is able to elicit a high humoral 
immune response, but failed to elicit a cell-mediated immune response, which makes it 
ineffective for treatment of chronic hepatitis B infection [26]. Therefore the study of new 
potential adjuvants with emphasis on their capacity to induce a cell-mediated immune 
response has been reported in the literature [26-28]. For this reason, we decided in this 
study to co-administer HBsAg loaded nanoparticles and CpG ODN 1826 (group II), 
which is recognized for its ability to re-direct the Th bias toward a Th2 type immune 
responses in mice [10, 16, 17, 29]. In fact, in group II an increase of the anti-HBsAg 
specific IgG2a antibodies and a slight decrease of the IgG1 was observed, but the total 
HBsAg specific IgG antibodies were not significantly different from the previous group 
(Group I). Therefore, in this study, the ability of the CpG ODN to induce a Th1 profile 
immune response was again confirmed; however, an additive effect with the 
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nanoparticles was not observed, most likely because chitosan nanoparticles appeared to 
be an already strong adjuvant. A similar situation was recently described with tetanus 
toxoid loaded PLGA microspheres and CpG ODN in solution [18].  
A more simple formulation was studied using mouse group III. In this case, we 
tested the effect of the co-adsorption of the antigen and the CpG ODN together in 
chitosan nanoparticles. This nanoparticle formulation was easily prepared by simple 
mixing of the chitosan nanoparticles with the adjuvant and the antigen, and was then 
immediately administered to the mice, avoiding the additional coating procedure with 
sodium alginate. Furthermore, as a second hypothetical advantage of this delivery 
system, it could present multiple copies of the antigen on its surface, an effect which has 
been shown to be optimal for B cell activation [30]. Moreover, the co-adsorption of the 
antigen and the CpG ODN to the same nanoparticles, has been indicated as the ideal 
formulation [31-34]. However, comparing the results with those of mouse group II, where 
the adjuvant was in particle formulation as a free suspension, this group (Group III) 
showed a lower IgG2a/IgG1 ratio. In addition and in comparison with a recent study [23] 
which showed comparable IgG2a/IgG1 ratios in mice containing the CpG ODN as 
adjuvant in their formulations, a mixed Th1/Th2 immune response can be consider for 
group III. Additionally, although the mean value of the total specific IgG has been higher 
in group III, the value was not statistically different when compared with group II, due to 
the high polydispersion of the values obtained. A decrease in IFN-γ production was also 
observed. Therefore, all the observations seemed to support the idea that the soluble 
CpG ODN was more accessible and could interact with the cells better, perhaps due to 
its increased availability in the formulation of the group II.  
In the present study, the evaluation of the cellular and humoral immune 
responses was done 4 weeks after the last boost. To better evaluate the effect of the 
CpG ODN released from the chitosan particles longer sampling might be useful. 
Other studies on particulate delivery of CpG, either surface adsorbed [35] or in 
liposomes [32] or in PLGA nanoparticles [18], found a stronger effect when CpG ODN  
was encapsulated in the delivery system in comparison with CpG ODN in solution. This 
feature was considered to be important since it would allow for a decrease in dosage of 
CpG ODN administered while obtaining the same effect. Two different mechanisms can 
be discussed to explain our results. The first is related with the frequently reported strong 
affinity between the CpG ODN and the cationic chitosan polymer [36, 37], that may 
cause a slow release of the CpG in vivo. Therefore, the amount of free CpG, ready to be 
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internalized by the target cells is lower when compared with the situation where the CpG 
ODN was given in solution. The second one is that the internalization of the CpG ODN 
into the cells is a prerequisite before it can bind to Toll-like receptor 9 (TLR9) present 
within a number of mouse immune cells and subsequently trigger the immune response 
[34, 38]. Supported by theory and also by some experimental evidence [39], the 
internalization of the CpG ODN would be facilitated, if it administered in associated with 
chitosan nanoparticles. Additionally a protective effect against the CpG ODN enzymatic 
degradation by the chitosan biopolymer, especially in the enzyme rich oral mucosa 
should also be considered as previously reported [39-41].  Moreover in this study, the 
size of the administered particles seemed to be adequate for their internalization, 
although hypothetically an in vivo aggregation of the particles may also take place, with a 
concomitant increase in size. This cannot be totally excluded and will be evaluated in 
future studies. Finally, even under the assumption that chitosan nanoparticles have been 
internalized to some extent, the release of the CpG ODN from the particles after 
intracellular uptake should also be considered as an important issue which can influence 
the efficacy of a vaccine formulation. 
Due to their unique and interesting properties, recently reviewed in several 
papers [3, 42-45], chitosan and chitosan nanoparticles have been used in mucosal 
delivery systems for vaccination using several antigens and mucosal routes [24, 46-49]. 
However their potential as adjuvants for parenteral vaccination has been less studied. In 
a very recent study, [50] a chitosan solution was explored as an adjuvant for 
subcutaneous vaccination of mice with a model antigen. It was found that chitosan 
enhanced the antigen-specific antibody titers over five-fold and antigen-specific CD4+ 
lymphocytes proliferation over six-fold. Mechanistic studies performed by the same 
authors revealed that the antigen depot and a transient cellular expansion in draining 
lymph nodes induced by chitosan may explain its adjuvant properties [50].  
7.5 CONCLUSION 
For the first time, in this present study, the adjuvant effect of alginate coated chitosan 
nanoparticles for the hepatitis B surface antigen was evaluated after subcutaneous 
application in mice. A potent enhancement of the humoral immune response was 
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observed with predominance of Th2 type antibodies. The Th profile immune response 
was re-directed to Th1 type when the antigen loaded chitosan nanoparticles were co-
delivered with the CpG ODN 1826 in solution. A third formulation, in which the antigen 
and the adjuvant were both adsorbed to chitosan nanoparticles was also evaluated. No 
additional benefits were observed with this formulation 4 weeks after the last boost. 
However, the manufacturing simplicity of this last formulation makes it a potential basis 
for future formulation improvements. All tested formulations have shown a potential for 
the improvement of the currently licensed HBV vaccines, in particular in rendering them 
useful for the treatment of chronic hepatitis B, where a strong Th-1 cellular immune 
response induction is required. However, the controlled delivery of the antigen and the 
CpG ODN from the chitosan nanoparticles should be further investigated with respect to 
enhanced longevity of the immune response, as well as their ability to produce and 
maintain the Th1-type cellular and humoral immune response. 
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The development of novel vaccine adjuvants together with an optimized delivery platform is 
becoming as important as the development of novel vaccines. This idea is especially true for the 
new generation of antigens, including those identified through genomic screening of 
microorganisms, which are predominantly recombinant purified proteins but often poorly 
immunogenic. Additionally, increasingly scientific evidences of the advantages, associated with the 
production of mucosal antibodies following oral, nasal and even pulmonary immunization, especially 
for the microorganisms that invade the body through mucosal surfaces, strongly supports the 
necessity to do more studies on efficient adjuvants.  
An even important argument is related with the dependence that exists between successful mass 
vaccination programmes, especially in underdeveloped countries, but also in situations of a 
bioterrorism, and the availability of novel adjuvants that allows the rapid production of more stable, 
cheaper and “needle free” vaccines. Having this in mind, our first ambition was the design of 
chitosan nanoparticles based delivery system for oral vaccination.  
Due to its unique properties, the use of chitosan in life science became and is being a research 
subject of considerable interest [1-8]). Several in vitro studies, showing the immune stimulating 
activity of the biopolymers with macrophages and dendritic cells, have been published in the 
scientific literature. A similar approach was also performed by us in vitro, using primary cultures of 
splenocytes incubated in the presence of the biopolymer. Stronger induction of the CD69 
expression, not only on B cells, but also in T-Lymphocytes was observed by us. However 
extrapolations to the in vivo situation should be made carefully. Therefore, it is of great interest and 
it is in our plans to further investigate the in vivo stimulation of the immune cells, not only in spleen 
but especially in the Peyer’s patches, following subcutaneous and oral administration of chitosan to 
mice.  
The use of chitosan based formulations for mucosal vaccination has been already widely used in 
several studies with different antigens. For example, in an oral vaccination study with diphtheria 
toxoid (DT) [9], adsorbed to chitosan nanoparticles, a strong enhancement, when compared with 
the delivery of the antigen alone, of both, systemic and local mucosal immune responses against 
DT were observed, after six applications in mice. In another study, the conjugated group C 
meningococcal vaccine, adsorbed to similar chitosan particles was also given orally (data not 
published), however an immune response could not be elicited. As a final example, in which 
Toxoplasma gondii GRA1 protein and the DNA vaccine loaded chitosan particles were used, the 
type of immune response seemed to be largely depend on the prime/boost regimen [10]. In all these 
studies, the chitosan particles had very similar properties; therefore the variations in the immune 
response obtained in these studies are certainly related with the characteristics of the antigen used 
and also with prime/boost regime. 
The interpretation of the different results found in the scientific literature stimulated us to think about 
the possibility to improve the properties of these chitosan nanoparticles. The antigen adsorption to 
the surface of the chitosan particles has been regarded as a convenient and safe loading method, 
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however for low porous nanoparticles, the antigen would be more exposed to the adverse 
environment of the gastrointestinal fluids. Hence it looked reasonable to us that a subsequent 
coating of the antigen, adsorbed onto chitosan nanoparticles might provide a better protection 
during their passage through the gastrointestinal tract. As a result of these considerations sodium 
alginate has been chosen as the second polymer layer because of its insolubility in the acid 
environment of the stomach and, like chitosan, of its mucoadhesive properties. 
In the second chapter of this thesis the development of chitosan nanoparticles, loaded with a model 
antigen and subsequently, coated with calcium chloride crosslinked alginate is described. According 
to our hypothesis, and verified by our experimental results, the use of the calcium, as alginate 
crosslinker, strengthened the coating, and so contributed for the delayed antigen release from the 
particles. Moreover, the neutralization of part of the negative charges of the alginate molecule, 
resulting in a less negative zeta potential of the coated nanoparticles and this aspect, together with 
the size of the coated nanoparticles, is believed to have been important for the success of the 
subsequent studies of the particle’s internalization by M-cells in gut. 
In contrast to what was found in literature, the methodology developed in this work allowed the 
obtainment of coated particles still in the nanosize range, which is one of the requisites for the 
uptake by M-cells (reviewed in several references [11, 12]). In fact, our uptake studies in rat Peyer’s 
patches of the coated chitosan nanoparticles (3rd chapter) clearly showed the internalisation of the 
particles. This promising result was important to support the decision to continue with vaccination 
studies in mice. However, and despite of being frequently found in the scientific literature, these 
uptake studies are in the most of the cases only qualitative. They do neither allow the access to 
information about the percentage of the nanoparticles internalized nor give details about the 
mechanism of internalization or about the residence time in the Peyer’s patches. Moreover, the type 
of immune cells that preferentially are attracted to the site of the vaccine entrance and subsequently 
facilitate the recognition of the vaccine by professional antigen-presenting cells is not known. The 
same hold for the total or partial uptake of the vaccine into these cells, which will dictate the type of 
immune response [13]. As future prospects based on this discussion, a better understanding of the 
interaction of the particles with the cells of mucosal surfaces, required for the optimization or 
development of more efficient vaccine delivery systems, is dependent on more detailed and 
quantitative uptake studies. 
 
The role of the alginate coated chitosan nanoparticles as adjuvant was evaluated for the hepatitis B 
vaccine. Following subcutaneous administration of the antigen associated with the nanoparticles, a 
100% seroconversion and 5.2 fold enhancement of the anti-HBsAg IgG was observed when 
compared with the solution of the antigen. The mechanism responsible for that result was not 
further investigated in detail and should be clarified in the future. However, we are aware about the 
difficulties that such mechanistic adjuvant studies can involve. For instance, the adjuvant effect of 
the widely used aluminium compounds is still not fully understood at the present time, and 
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continuous is an important research subject. In a recent review, Lindblad [14] has summarized as 
the most probable mechanisms the gradual release and delay clearing of the adsorbed antigen from 
the inoculated aluminium compound depot. However and also in accordance with the same author, 
over the last two decades the role of T cells and cytokine profiles following the application of 
aluminium adjuvants have been described as well. In the studies of this thesis, a similar gradual 
release of the adsorbed Hepatitis B antigen from the inoculated coated nanoparticles may have 
occurred. A little knot, observed on the site of the injection may indicate that a depot was formed, a 
fact which supports this hypothesis. But there is also the possibility that some of the coated 
nanoparticles have been internalized by local cells and therefore were originating different 
mechanisms.  
Finally, oral and nasal vaccination simply with the HBsAg entrapped into coated nanoparticles 
induced a low or no seroconversion rate. In the recent literature, the presence of non responder 
mice in the orally vaccinated groups is frequent reported, especially when the evaluation of the 
specific antibodies was performed after a single immunization. Moreover, to get a high percentage 
of seroconverted mice within the orally vaccinated groups it was always necessary to administer 
higher antigen concentrations (10-fold more from what was used in this work) together with a 
successive administration of the vaccine, especially when these results are compared with the 
intramuscular or subcutaneous route of administration [15]. Commercial injectable hepatitis B 
vaccines also have this drawback in humans. Therefore the recombinant hepatitis B vaccine will 
become a very challenge for vaccinations through mucosal routes. 
Regarding mucosal immune response we have found that for the subcutaneously vaccinated mice 
groups the concentration of anti-HBsAg sIgA in fecal extracts was below the detection limit of the 
ELISA method. In contrast, the detection of mucosal antibodies in gut washes after oral vaccination 
studies, was possible within mice groups vaccinated with the antigen entrapped into coated 
nanoparticles. The same holds for nasal and vaginal secretions within the nasal vaccination groups. 
Recently, Holmgren & Czerkinsky [16] reviewed some mucosal immunity concepts like the one of 
the “common mucosal immune system” whereby immunocytes activated at one site disseminate 
immunity to remote mucosal tissues rather than to systemic sites. However, the appearance of a 
higher or lower antigen specific sIgA concentration, in a specific mucosal tissue is dependent of the 
vaccination route. For instance, the oral immunization may induce substantial antibody responses in 
the small intestine, mammary and salivary glands and, according with the same authors, it is 
relatively inefficient in evoking an IgA antibody response in the distal segments of the large 
intestines, tonsils or female genital tract mucosa in humans [16]. On the other hand, the intranasal 
vaccination seems to be more efficient to evoke mucosal antibodies in the upper airway mucosa, 
regional secretions (saliva and nasal secretions) and cervicovaginal mucosae in humans, without 
evoking an immune response in the gut. Our observations in mice are in accordance with these 
findings (chapter 6).  
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The choice of the administration route is an important aspect and should be carefully taken into 
consideration to where we want the induction of a mucosal immune response.  
It was found that the sc vaccination with the hepatitis B vaccine entrapped into alginate coated 
chitosan nanoparticles elicited the enhancement of the humoral immune response with a 
predominance of the Th2 type antibodies. Similar observations were made after oral vaccination 
with the same nanoparticles associated with HBsAg. For all administration routes investigated (in, 
oral and sc) the immune response profile was re-directed to mixed Th2/Th1 profiles or towards Th-1 
profile, when the antigen entrapped into coated nanoparticles was co-delivery with the CpG ODN 
1826. These formulations have shown a great promising potential for the improvement of the 
currently licensed HBV vaccines, in particular to make them useful also for the treatment of chronic 
hepatitis B, where a strong Th-1 cellular immune response induction is required. Additionally, it 
would be worth examining if the controlled delivery of the antigen and the CpG ODN from the 
chitosan nanoparticles is also able to enhance the longevity of the immune response.  
Finally, regarding CpG ODN 1826, the importance of its entrapment into the alginate coated 
chitosan nanoparticles is related with the route of administration. For oral vaccination, the necessity 
of protecting the CpG oligodeoxynucleotides from the enzymatic and acidic adverse environment of 
the gastrointestinal tract is higher than for the intranasal or subcutaneous routes. Therefore in the 
oral vaccination study, the best result was obtained within the mice group vaccinated with HBsAg 
and CpG ODN encapsulated in alginate coated chitosan nanoparticles. On the contrary, intranasal 
and subcutaneous vaccination with both the HBsAg and the CpG ODN encapsulated into the same 
delivery system have induced a weaker immune response when compared with the group where 
the CpG ODN was administered free in phosphate buffer saline solution together with the HBsAg in 
the nanoparticles. A possible explanation for this unexpected observation is most probably related 
with the CpG ODN in vivo release profile from the chitosan nanoparticles which results in a lower 
available concentration of the CpG ODN for interaction with the Toll-like receptor 9 (TLR-9. A 
second concurrent hypothesis is related with the possibility of the nanoparticles for being 
internalized by the cells that express the TLR-9.  
 
In summary a new nano-sized chitosan based delivery system for mucosal vaccination of the 
hepatits antigen is described in this work. The delivery system is composed of a chitosan core, to 
which the antigen was adsorbed, and was subsequently coated with sodium alginate. The 
appropriateness of the methodology for a high efficiency encapsulation of the hepatitis B antigen 
and of the CpGODN was demonstrated. Alginate coated chitosan nanoparticles have shown to be 
non-cytotoxic and their ability to be taken up by the M-cells of the Peyer’s patches was 
demonstrated in rats. 
The study of the adjuvant effect of alginate coated chitosan nanoparticles was performed by 
subcutaneous, oral and intranasal vaccination routes (see table 1). The vaccination studies have 
shown that alginate coated chitosan nanoparticles have an adjuvant effect for the hepatitis B 
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antigen when administered subcutaneously, however for the mucosal routes the association of an 
immunopotentiator is required.  
As future prospects of my research the advantages of these nanoparticles over the currently used 
adjuvant (alum) in the commercial formulation of the hepatitis B vaccine will be assessed for the 
subcutaneous route. In these new studies the long-term protection should also be evaluated. 
Moreover, the association of the CpG ODN to the pre-formed suspension of the HBsAg loaded 
particles would allow a new application for the vaccine in treatment of chronic hepatitis B. To 
confirm this hypothesis additional studies have to be performed with a suitable animal model.  
Furthermore with adequate improvement of the delivery system and of the prime/boost regimens, 
the suspension of the nanoparticles containing the antigen and the CpG ODN will be investigated in 
order to have a higher seroconversion rate. Finally, the delivery system has shown promising 
capabilities for being evaluated in the future also with other vaccines.  
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